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 Abstract 
 
 
Tobacco addiction is a leading preventable cause of death worldwide and places a 
heavy social and financial burden on society.  There exists a substantial genetic 
variability in smoking behavior, the mechanisms of which are largely 
unknown.   Despite significant advances in sequencing power, progress in the 
identification of genetic variants affecting smoking behavior based on human genome 
wide association studies has been slow.  Thus this thesis investigates the utility of 
zebrafish as a model species in which to search for genetic variants affecting nicotine 
seeking.  The work is based on the premise that as zebrafish are vertebrate with 
conserved neurochemical pathways and circuitry with humans, and the pathways 
involved in drug mediated reward and addiction are evolutionarily ancient, 
homologues of genes affecting zebrafish nicotine-seeking behavior will likely affect 
human smoking behavior. Thus results in zebrafish can be used to direct human 
genetic studies. 
  The first result chapter addresses the hypothesis that zebrafish show conserved 
reward responses to common drugs of abuse.  A conditioned place preference assay is 
used to assess zebrafish reward responses to stimulants, opioids, benzodiazepines and 
alcohol. The results indicate that, with the exception of benzodiazepines, reward 
responses are conserved, supporting the use of this model in a screen for genetic 
variants affecting nicotine preference.  The second and third results chapters describe 
the findings of a pilot screen of ENU-mutagenized zebrafish provided by the Sanger 
Institute, Cambridge. I demonstrate that nicotine preference is heritable in fish as in 
Abstract 
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humans and identify 3 mutant lines that show increased or decreased nicotine place 
preference.  Genotyping indicated that one of the families showing increased nicotine 
preference carries a predicted loss of function mutation in the slit3 gene. The 
involvement of this gene in nicotine preference was confirmed in a separate line. 
Further characterization of this line using qPCR showed slit3 mutants to have altered 
developmental expression of key nicotinic and dopaminergic genes.  
Having identified the slit3 gene as a locus affecting nicotine seeking in fish, I 
then tested the hypothesis that results in fish could be used to predict loci that affect 
human smoking behavior. Cohorts of patients were genotyped for 20 SNPs within the 
slit3 locus.  Results of this analysis identified 1 novel SNP in the slit3 gene associated 
with smoking behavior in a cohort of individuals that were heavy smokers. This result 
was validated in cohorts of low and normal smoking prevalence.  These data 
demonstrate the utility of behavioral assays in zebrafish to identify genes affecting 
human behavior and pave the way for the use of zebrafish to inform human studies 
exploring the genetic basis of drug seeking and behavioral disease. 
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Chapter 1  
 
 
General Introduction 
 
The work described in this thesis uses fish to inform human research into novel alleles 
affecting smoking behavior. In the following section, background to smoking 
prevalence, the neurobiology of nicotine addiction as well as what is known of the 
genetic risk factors involved will be covered. In the latter sections the use of zebrafish 
as a model system for identifying genetic factors and molecular mechanisms of 
addictive disorders is described. 
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1.1 Worldwide smoking prevalence, health risks and 
associated costs 
 
Tobacco addiction is one of the leading preventable causes of death in the world and 
places a huge social and financial burden on society. There are currently over 1.4 
billion smokers worldwide and this figure is expected to rise to 1.9 billion in 2025 
(Guindon, de Beyer, & Galbraith, 2003; Shibuya et al., 2003a). Chronic diseases 
directly caused by smoking include cancers, chronic lung diseases, cardiovascular 
disease and asthma.   
Around 100 million deaths were caused by tobacco in the 20th century with 
the current annual global death toll from smoking being 5 million.  If current trends 
persist tobacco-related deaths will increase to more than eight million a year by 2030 
(Shafey O, Eriksen M, Ross H, & J, 2009), with 80% of those deaths predicted to 
occur in the developing world.  All this adds up to the distinct possibility of tobacco 
causing up to one billion deaths in the 21st century (Shibuya et al., 2003b). 
The act of quitting, even in middle age is remarkably effective in reducing the 
risk of illness and death.  Thus, whilst persistent smoking triples the risk of death in 
each decade of life, stopping smoking at age 50 years halves the risk, and a smoker 
who stops at age 30 years has the same life expectancy as someone who has never 
smoked at all (Peto et al., 2000).  It is therefore abundantly clear that public 
awareness of the dangers of smoking and the implementation of interventions to 
increase people’s chances of quitting has huge benefits on improving quality of life 
and alleviating the burden smoking exerts on health services. 
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1.2 The neuro-circuitry underlying addiction 
 
In recent years addiction has become recognized as a disease of memory and learning 
affecting evolutionarily ancient neural pathways. These pathways will have originally 
arisen as a means aiding rapid establishment of self-preserving patterns of motor 
behavior. With excessive exposure to drugs of abuse, these pathways can be hijacked 
and allow destructive, drug-associated behavior to gain pathological importance.  
Although the mechanisms are not fully understood, and other systems are 
undoubtedly involved, it is currently thought that coordinated signaling within 
dopaminergic and glutamatergic systems integrates the main neurological processes 
thought to be involved in addictive disorders like motivation, memory and learning 
(Bonci & Malenka, 1999; Nestler, 2001). Glutamatergic neurotransmission plays a 
fundamental role in regulating synaptic plasticity (the reconfiguring of neural 
networks) underlying memory and learning, and dopaminergic neurotransmission 
within the mesolimbic system underlies reward and motivational drive.  Co-ordinated 
activation of glutamatergic and dopaminergic neurotransmission integrates these two 
systems and enhances the motivational value of memories thus reinforcing associated 
patterns of behavior commonly seen in addicts. Repeated stimulation of the 
mesolimbic reward pathway by drugs of abuse (including nicotine) leads to adaptive 
changes in gene expression and synaptic organization in the central nervous system. 
These adaptive changes reinforce drug taking and underlie long-term changes in 
behavior and dependence (L. J. Kily et al., 2008; Le Foll, Gallo, Le Strat, Lu, & 
Gorwood, 2009). 
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The mesolimbic pathway transmits dopamine from the ventral tegmental area 
(VTA) to the nucleus accumbens. Since the mesolimbic pathway is shown to be 
associated with feelings of reward and desire, this pathway has been heavily 
implicated in most neurobiological theories of addiction.  Under normal 
circumstances the brain uses these dopaminergic and glutamate systems to optimize 
responses that enhance survival.  Drugs of abuse, act predominantly by either directly 
or indirectly increasing dopaminergic transmission in the mesolimbic system. By 
repeatedly activating these pathways, they are able to induce very long term, or even 
permanent, alterations in motivational networks, ultimately leading to changes in 
behavioral control (i.e. addiction) (Berke & Hyman, 2000; Hyman, Malenka, & 
Nestler, 2006; Kelley, 2004). 
Much of the recent progress in identifying lasting neuro-adaptations that are 
associated with such addiction-related behaviors have come in animal models 
(Kalivas, 2004; Shaham & Hope, 2005; Weiss et al., 2001). For instance, drug-
seeking phenotypes have predominantly been associated with altered basal levels or 
sensitivity of dopaminergic, serotonergic and glutamate neurotransmission (Kalivas, 
2004; Tupala & Tiihonen, 2004; Weiss et al., 2001).  Similarly, expression analysis 
has identified components of a number of other neurotransmitter pathways involved 
in drug addiction such as the mono-aminergic, glutamatergic and cannabinoid 
pathways. Several other pathways including 5-hydroxytyramine (5-HT), opioid, 
gamma-Aminobutyric acid (GABA) and benzodiazepine receptor pathways have also 
been implicated through altered levels of expression in the nucleus accumbens (NAc), 
pre-frontal cortex (PFC) or amygdala (Nestler, 2004; O'Brien & Gardner, 2005; 
Ohkuma, Katsura, & Tsujimura, 2001; Rhodes & Crabbe, 2005). Components of 
signal transduction pathways such as ERK (extracellularly regulated kinase) and PI3K 
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(phosphatidylinositol 3-kinase) have been shown to be altered in their expression 
levels in the brains of animals demonstrating drug dependency ((M. D. Li, Kane, 
Wang, & Ma, 2004; Lu, Koya, Zhai, Hope, & Shaham, 2006; Pollock, 2002; Rhodes 
& Crabbe, 2005; Yuferov, Nielsen, Butelman, & Kreek, 2005). Orexins are 
hypothalamic neuropeptides more traditionally implicated in behaviors like feeding, 
sleep and arousal. More recent evidence from animal models suggests a role for 
orexins in reward processing and drug addiction though their interaction with the 
mesocorticolimbic reward pathway (Sharf, Sarhan, & Dileone, 2010). 
All these changes in neurotransmission and gene expression have been 
proposed to contribute to altered sensitivity to the rewarding effects of drugs of abuse. 
For these changes to occur however, there needs to be exposure to the drugs that 
activate these pathways.  Nicotine is the active ingredient (although some other 
compounds involved) in tobacco responsible for its addictive quality. Activation of 
the mesolimbic pathway via nicotinic acetylcholine receptors underlies its reinforcing 
properties. Repeated stimulation leads to these permanent changes in neurocircuitry 
and is why people often persist with compulsive smoking behaviors despite the 
deleterious effects on health.    
 
 
1.3 Pharmacodynamics of nicotine & cessation treatments 
 
Nicotine from tobacco is rapidly absorbed through the lungs and buccal mucosa and 
then transported through the bloodstream and across the blood-brain barrier, reaching 
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the brain within 10–20 seconds after inhalation (Le Houezec, 2003).  The elimination 
half-life of nicotine in the body is around two hours (Le Houezec, 2003). Nicotine 
crosses the blood–brain barrier where a variety of neural substrates, especially 
nicotinic acetylcholine receptors, mediate the reinforcing effects of nicotine and the 
development of nicotine dependence (D'Souza & Markou, 2011). 
 
 
Figure 1.1: Summary of neurotransmitters (and related psychological effects) whose release are 
potentiated by the binding of nicotine to nAChRs in the brain accounting for the various psychoactive 
effects of smoking. Figure reproduced with permission (Quaak, van Schooten, & van Schayck, 2013) 
adapted from8 (Benowitz, 1999). 
 
Through binding to nicotinic acetylcholine receptors (nAChRs), nicotine 
potentiates the release of various neurotransmitters including dopamine, serotonin 
noradrenaline and acetylcholine (Pomerleau & Pomerleau, 1984; Pomerleau & 
Rosecrans, 1989). Nicotinic acetylcholine receptors are broadly distributed in the 
brain but are mainly concentrated in the cortex, thalamus, hippocampus and 
amygdale. Many subtypes of the nAchR are known, accounting for nicotine’s broad 
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effects, however the majority of neuronal nAchRs fall into two categories; α7-
homopentamers with a low affinity to nicotine and α4β2 heteropentamers which have 
a high affinity to nicotine. The α4β2 receptors account for over 90% of neuronal 
nAchRs (Singh & Budhiraja, 2008) with studies suggesting that their presence in the 
nucleus accumbens plays a major role in the reinforcing effects of nicotine 
(Mansvelder & McGehee, 2002; McCallum et al., 2006).  
NAchRs are present on the cell bodies of dopaminergic neurons in the VTA as 
well as on pre-synaptic terminals of excitatory glutamatergic neurons and inhibitory 
gabaergic neurons with which they form synapses, with different combinations of 
these nAchR receptor subunits being expressd on each of these cell types (Klink, de 
Kerchove d'Exaerde, Zoli, & Changeux, 2001). As the subunit composition influences 
the affinity and pharmacodynamics of channel opening and desensitization, the cells 
upon which the nAChR subunits reside, respond differently to nicotine depending on 
the particular combination of subunits. When nicotine levels increase in a smoker’s 
blood stream, nAChRs present on the DA and glutamatergic neurons are initially 
activated leading to an increase in firing of the DA neurons. On top of this, the 
subunit combination of nAchRs present on GABAergic neurons are more sensitive to 
desensitization than those on DA neurons leading to a gradual decrease in GABA-
ergic inhibition.  This leads to an additive effect of nicotine mediated increase in DA 
transmission within the mesolimbic system by a combination of enhanced excitation 
and decreased inhibition of the DA neurons in the VTA (P. B. Clarke & Pert, 1985; 
Corrigall, Franklin, Coen, & Clarke, 1992; Pidoplichko, DeBiasi, Williams, & Dani, 
1997).  
Chapter 1 
 28 
In addition to nicotine, tobacco smoke contains the monoaminoxidase 
inhibitors harman and norharman. Monoamine oxidase enzymes break down 
monoaminergic neurotransmitters like dopamine, serotonin and norepinephrine. It is 
thought that inhibition of this process in addition to dopamine mediated nicotine 
reinforcement are the key additive components contributing to the addictive 
properties of smoking tobacco. 
 
 
1.4 Types of smoking cessation treatment and their efficacy 
 
Through public awareness and better education, the risks involved in smoking and the 
health benefits of cessation are well known, and nearly 40 percent of current smokers 
try to quit each year. Despite this, only approximately 5 percent of quit attempts will 
still be successful after 6 to 12 months, with the majority failing within the first 8 days 
(J. R. Hughes, 2004). Professionally administered smoking-cessation therapy 
improves the odds of a successful quit attempt after 12 months marginally to 10.2% 
(Fiore & Jaen, 2008), however it is thought that the effectiveness of smoking 
cessation treatments is limited by the lack of effective medications.  
To date, the only smoking-cessation medications approved by the Food and 
Drug Administration (FDA) are nicotine replacement therapy (NRT), bupropion 
(Wellbutrin/Zyban) and varenicline (Chantix).  NRT is available in several 
formulations, including transdermal patch, gum, nasal spray, inhaler, and lozenge.  Of 
these FDA approved treatments, varenicline appears to be most effective, yielding 
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abstinence rates of approximately 22 percent at the end of 1 year (Gonzales et al., 
2006). The effectiveness of the three treatments according to the most recent 2013 
Cochrane Review on smoking cessation treatments is surmised in Table 1. 
 
 
Table 1.1: Odds ratios of abstinence compared to placebo for the three main smoking cessation 
treatments. Values derived from 2013 Cochrane Review on pharmacological interventions for smoking 
cessation treatment (Cahill, Stevens, Perera, & Lancaster, 2013). 
 
 
 
1.4.1 Nicotine replacement therapy (NRT) 
 
The principal mechanism of action of NRT is to partially replace the nicotine 
normally obtained through smoking tobacco, thus alleviating the severity of 
withdrawal symptoms and cravings, increasing the chances of successful cessation 
attempts (Gross & Stitzer, 1989). Differences in formulations may have an impact on 
the efficacy for some of these effects. For example, the more rapid delivery of 
nicotine obtained with the nasal spray appears to provide faster relief of withdrawal 
Treatment Odds Ratio* (95% CI)†
 NRT: All forms, pooled (meta-analysis of 123 studies with ≥6 mo follow-up) 1.84 (1.66–1.88)
  Gum 1.66 (1.52–1.81)
  Patch 1.81 (1.63–2.02)
  Inhaler 2.14 (1.44–3.18)
  Lozenge 2.05 (1.62–2.59)
  Nasal spray 2.35 (1.63–3.38)
 Bupropion (meta-analysis of 19 trials with ≥6 mo follow-up) 2.06 (1.77–2.40)
 Varenicline 2.88 (2.40-3.47) 
*	

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symptoms. Furthermore, the inhaler formulation provides an alternative coping 
mechanism for the behavioral aspects of smoking by imitating the hand-to-mouth 
motion. 
 
 
1.4.2 Bupropion 
 
Bupropion is a cessation aid generally marketed with the trade name Zyban by 
GlaxoSmithKline. It is a non-tricyclic antidepressant and affects multiple 
neurotransmitter systems. Primarily it acts as a dopamine reuptake inhibitor whilst 
also being a mild noradrenaline reuptake inhibitor and nicotinic acetylcholine receptor 
antagonist. It is hypothesized that smokers have artificially elevated dopamine levels 
due to the presence of monoamine oxidase inhibitors. On stopping smoking, MAO are 
removed and the dopamine levels fall, leading to feelings of depression as well as 
nicotine withdrawal (Ascher et al., 1995). Bupropion is thought to alleviate these 
symptoms of depression while also, through its nAChR antagonist action, reducing 
the reinforcing spike of dopamine after smoking a cigarette. 
 Bupropion is licensed for smoking cessation in both the UK and US and is 
recommended as a first line agent for smoking cessation. Patients themselves set a 
target quit date, typically 2 weeks hence, and are prescribed 150 mg daily for 6 days 
followed by 150 mg twice daily for 7 to 9 weeks. The first prescription for bupropion 
should last approximately 4 weeks and take the patient beyond the target quit date. 
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Those who return following successful cessation are given the remainder of the 
treatment course. 
Approximately 1 in 5 smokers successfully stop and remain non-smoking at 
one year with bupropion therapy. Trials reporting the efficacy of Bupropion as a 
cessation treatment have shown comparably significant one-year abstinence rates of 
23% vs 12% (Hurt et al., 1997) and 30% vs 16% (Jorenby et al., 1999) for bupropion 
therapy when compared with placebo. A recent Cochrane systematic review of 19 
randomized trials, showed that bupropion doubled the odds of smoking cessation 
when compared to placebo (Odds ratio 2.06, 95% confidence intervals 1.77 to 2.40 
(R. A. Hughes, Jewitt, & Swan, 2004)). 
 
 
1.4.3 Varenicline 
 
The most recent treatment to be approved by the FDA for the treatment of smoking 
cessation is varenicline. It is marketed by Pfizer under the trade name ‘Chantix’ in the 
USA and ‘Champix’ Europe, and usually comes in the form of varenicline tartrate. 
Varenicline has been approved by the FDA for a treatment course of up to twelve 
weeks.  In the event smoking cessation is not achieved, treatment can be continued for 
another twelve weeks (Reus et al., 2007). 
Varenicline is a partial agonist of the α4β2 subtype of the nicotinic 
acetylcholine receptor while a full agonism has been displayed on α7-receptors 
(Mihalak, Carroll, & Luetje, 2006). Acting as a partial agonist varenicline binds to, 
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and partially stimulates, the α4β2 receptor without producing a full effect like 
nicotine. Thus varenicline does not greatly increase the downstream release of 
dopamine. Due to its competitive binding on these receptors, varenicline blocks the 
ability of nicotine to bind and stimulate the mesolimbic dopamine system, akin to the 
action of buprenorphine in the treatment of opioid addiction (Rollema et al., 2007). 
A randomized controlled trial has demonstrated that after one year the rate of 
continuous abstinence was 10% for placebo, 15% for bupropion and 23% for 
varenicline (Jorenby et al., 2006). A meta-analysis of 101 studies found varenicline to 
be more effective than both bupropion (odds ratio 1.40) and NRTs (odds ratio 1.56) 
(Mills, Wu, Spurden, Ebbert, & Wilson, 2009). A Cochrane systematic review 
concluded that varenicline trebled the likelihood of successfully quitting smoking 
relative to pharmacologically unassisted attempts (Odds ratio 3.98, 95% confidence 
interval 2.01 to 7.87 (Cahill, Stead, & Lancaster, 2012)). 
 
 
1.5 Genetic factors that influence smoking behavior 
 
Both genetic and environmental factors contribute to smoking behavior.   What has 
become apparent is that genetic determinants account for more of this behavior than 
first thought.  Based on twin studies, genetic factors have been estimated to account 
for 40-70% of the variance in smoking maintenance, 50% of the variance in cessation 
success and 30-50% of the variance in withdrawal symptoms (Batra, Patkar, 
Chapter 1 
 33 
Berrettini, Weinstein, & Leone, 2003; Heath et al., 1993; Heath & Martin, 1993; 
Kendler et al., 1999; Sullivan & Kendler, 1999; True et al., 1997). 
Two broad classes of genes may contribute to the variation in nicotine 
dependence, the first being genes that influence the response to nicotine directly, such 
as genes involved in nicotine metabolism and the different subtypes of nicotinic 
receptors for which nicotine acts as a substrate. The other types of genes effect key 
neurotransmitter pathways, such as the dopamine pathway, and predispose addictive 
behavior. 
This is reflected in human genome-wide association studies (GWAS) that 
have identified genetic polymorphisms associated with smoking behaviors. Several 
genes involved in nicotine-related pathways have been identified in the recent GWAS 
and are summarized in table 2. The majority of the genes showing high statistical 
associations with smoking behaviors are those in the cholinergic receptor gene 
clusters, which seem to predominantly affect the level of tobacco consumption, albeit 
with a relatively small effect size. A closer examination of these clusters has led to the 
identification of specific independent loci responsible for these associations (Saccone, 
Saccone, et al., 2009; Saccone, Wang, et al., 2009) as well as haplotypes associated 
with the effects in Europeans (W. Berrettini et al., 2008). Further research has 
demonstrated that markers in acetylcholine synthetic pathways may also contribute to 
nicotine dependence (W. Berrettini et al., 2008). One gene involved in dopamine 
metabolism and noradrenalin synthesis (dopamine-b hydroxylase) has been linked to 
spontaneous cessation in GWAS studies and interestingly this gene has also 
demonstrated effects on response to treatment with NRT in one randomized 
controlled trial (Johnstone et al., 2004). Owing to the requirement for large numbers 
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in GWAS, only genes involved in nicotine dependence have been identified in studies 
to date. Thus, this technique has not been applied to date to identify genetic 
determinants of response to treatment. In general, randomized trials of smoking 
cessation have fewer than 1000 participants, half of whom will receive a placebo., 
Random trials, therefore, provide insufficient numbers of participants for genome-
wide analysis. As a consequence, conventional candidate gene studies undertaken 
within smoking cessation trials currently provide the best available evidence for 
pharmacogenetic effects on smoking cessation. 
 
 
Table 1.2: Summary of recent genome-wide association studies. Strongest associations are between 
level of tobacco consumption and markers in the cholinergic receptor gene cluster on chromosome 15. 
Replicated associations are also observed between the CYP450 gene that metabolizes nicotine and 
numbers of cigarettes smoked each day and also the dopamine-b hydroxylase gene and quitting. The 
lowest p-values have been highlighted in bold.  
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1.5.1 Nicotine metabolism 
 
The major genes responsible for nicotine metabolism are the cytochrome enzymes 
P450 2A6 (CYP2A6) and P450 2D6 (CYP2D6). It is well documented in the 
literature that polymorphisms at the CYP2A6 locus associated with reduced 
enzymatic activity are generally result in smoking fewer cigarettes per day and greater 
cessation success (Huang et al., 2005; Malaiyandi et al., 2006; Sellers, Tyndale, & 
Fernandes, 2003).  
 
 
Figure 1.2: Nicotine metabolism in the liver. Mechanisms by which nicotine is metabolised into 
cotinine in the liver by the cytochrome enzymes P450 2A6 (CYP2A6) and P450 2D6 (CYP2D6). 
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Altered nicotine metabolism displayed in CYP2A6 variants has also been shown to 
have an effect on smoking cessation. Individuals with a lower plasma 3’-
hydroxycotinine/cotinine ratio (an indicator of CYP2A6 activity) have been shown to 
be associated with more successful smoking cessation in transdermal nicotine therapy 
trials (Malaiyandi et al., 2006; Schnoll et al., 2009). This is due to the higher 
therapeutic doses of nicotine the slow metabolizer sub-group obtain from comparable 
levels of transdermal nicotine treatment when compared with individuals with normal 
CYP2A6 activity (Schnoll et al., 2010). It is clear that the effectiveness of a particular 
nicotine replacement therapy could be predetermined by an individuals CYP2A6 
activity. Treatments tailored specifically to an individual’s genotype could prove 
more cost effective and improve chances of successful cessation. 
There have been recent studies investigating the duration of nicotine 
replacement where it was found that smokers receiving an extended transdermal 
nicotine therapy of 6-months were more than twice as likely to be abstinent at the end 
of treatment than people on the normal, 8-week treatment (Lerman et al., 2010).  
However due to the high cost of administering this type of extended therapy, being 
able to identify biomarkers which can inform the best course of therapy to take on an 
individual basis, both saving on costs and improving the quality of treatment, would 
be invaluable. 
There has been work to this end, with studies looking into the effect of 
extended-duration transdermal nicotine therapy on participants displaying higher and 
lower metabolism phenotypes, characterized by their nicotine metabolite ratio (NMR) 
(Malaiyandi et al., 2006; Schnoll et al., 2010). Both reduced and normal metabolizers 
were subjected to extended (6-month) and normal (8-week) replacement therapy.  It 
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was found that smokers with reduced nicotine metabolism benefit more from the 6-
month extended therapy than normal metabolizers. This suggests individuals with the 
reduced CYP2A6 activity genotype would be strong candidates for extended 
transdermal nicotine therapy and an alternative approach may be needed for people 
with normal rates of nicotine metabolism (Lerman et al., 2010). 
 
 
1.5.2 Dopaminergic genes 
 
The mesolimbic pathway in the brain transmits dopamine from the ventral tegmental 
area to the nucleus accumbens. Since the mesolimbic pathway is associated with 
feelings of reward and pleasure, this pathway is heavily implicated in most 
neurobiological theories of addiction (Comings & Blum, 2000). Nicotine activates the 
dopamine reward pathway through nicotinic acetylcholine receptors (nAChRs) 
thereby increasing dopamine levels in the nucleus accumbens and generating the 
sense of ‘wellbeing’ experienced by smokers (Di Chiara et al., 2004). As a result, 
variants in genes involved in the dopaminergic pathway may have effects on smoking 
behavior and response to treatment. 
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1.5.2.1 Dopaminergic receptors 
 
 There are five known subtypes of dopamine receptors: DRD1, DRD5 
(members of the DRD1-like family) and the DRD2, DRD3 and DRD4 receptors (D2-
like family). Polymorphisms affecting the dopamine D2 receptor (DRD2) gene have 
been most studied in tobacco dependence and may have an effect on smoking 
behavior and response to treatment. Polymorphisms in DRD2 may confer reduced 
dopamine-receptor expression or function, and some studies have demonstrated that 
individuals with this genotype may have a higher chance of becoming addicted to 
nicotine (Quaak, van Schayck, Knaapen, & van Schooten, 2009b). There are two 
main DRD2 polymorphisms that have been extensively studied for their effect on 
smoking cessation treatments: Taq1A and -141C ins/del. The DRD2 Taq1A 
polymorphism is located approximately 10 kb downstream of the DRD2 coding 
sequence in the closely linked ankyrin repeat and kinase domain containing the 
ANKK1 gene (Neville, Johnstone, & Walton, 2004). Carriers of the A1 allele have a 
higher quit rate on NRT (Johnstone et al., 2004; Yudkin et al., 2004). Those 
homozygous for the A2 genotype demonstrate greater response to bupropion 
treatment and display fewer of the withdrawal symptoms normally associated with the 
drug (Lerman et al., 2003; Swan et al., 2005). The -141C ins/del variant affects 
transcription of the DRD2 gene. Individuals with at least one copy of delC have a 
better response to NRT than those without, and those with the InsC allele respond 
more favorably to bupropion (Lerman et al., 2006). A study investigating the effects 
of variants in DRD4 on NRT has also been conducted. The variants were variable 
number non-tandem repeats (VNTRs) which confer lower receptor activity in those 
with the long allele, and also a -521C/T polymorphism which confers lower 
Chapter 1 
 39 
transcription levels in those with the T allele. Alleles at the DRD4 locus had no effect 
on cessation in NRT trials (David et al., 2008; Quaak et al., 2009b). Typing people for 
ANKK1/DRD2 markers could therefore potentially lead to more effective bupropion 
treatment, and minimize the occurrence of side effects. The benefits of using DRD2 
gene variants to guide selection of nicotine replacement or bupropion therapy have 
not yet been examined in prospective trials. 
 
 
1.5.2.2 Dopamine metabolism and synthesis 
 
Variants in genes involved in dopamine synthesis also have an effect on response to 
drug therapy in smoking cessation. Dopamine beta hydroxylase (DBH) is the enzyme 
responsible for the metabolism of dopamine to noradrenaline. A polymorphism 
(1368A/G) in the promoter region of the DBH gene confers lower enzyme activity 
and is more frequent in heavy smokers (McKinney et al., 2000). In one NRT trial, 
individuals carrying at least one A allele demonstrated significantly higher quit rates 
(Johnstone et al., 2004). Catechol-O-methyltransferase (COMT) is responsible for 
degrading dopamine. A functional valine to methionine mutation at position 158 
(Val158Met) leads to a reduction in enzymatic activity (Lotta et al., 1995). 
Individuals homozygous at this locus have an increased likelihood of abstinence in 
NRT trials (Johnstone et al., 2007; M. R. Munafo, Johnstone, Guo, Murphy, & 
Aveyard, 2008). The same Val158Met polymorphism has been demonstrated not to 
influence the efficacy of bupropion treatment (W. H. Berrettini et al., 2007). 
However, the same study identified two additional COMT polymorphisms (rs165599 
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and rs737865), which demonstrated a significant association with abstinence (W. H. 
Berrettini et al., 2007). 
 
 
Figure 1.3: Genes involved in the dopamine pathway.  TH: tyrosine hydroxylase; L-DOPA: L-3,4-
di-hydroxy-phenyllalanine; DDC: 3,4-dihydroxyphenylacetic acid (DOPAC) decarboxylase; MAO: 
monoamine oxidase; DAT: dopamine transporter; DRD: dopamine receptor; COMT: catechol-O-
methyltransferase; HVA: homovanillic acid; 3-MT: 3-methoxytyramine. Circles: dopamine.  
 
 
1.5.3 Serotonergic and opioid genes 
 
In addition to dopamine, nicotine also causes both serotonin and opioid peptide 
release as a consequence of stimulating cholinergic receptors. Many symptoms of 
nicotine withdrawal can be associated with reduced serotonergic neurotransmission 
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(Quaak et al., 2009b). It therefore appears possible that variation in genes involved in 
the serotonin pathway could influence individual response to smoking cessation 
treatment. So far studies have centered on one variant in the serotonin transporter 
gene (5-HTT) and examined its effect on abstinence in NRT trials. The 5-HTTLPR 
variant regulates transcription of the serotonin transporter with the short form 
conferring higher transcriptional activity (David, Munafo, Murphy, Walton, & 
Johnstone, 2007). As a result, this might be expected to govern the availability of 
serotonin released by nicotine (Quaak et al., 2009b). A r ecent study has demonstrated 
individuals with the high-activity variant are more likely to quit in a bupropion trial 
(Quaak, van Schayck, Knaapen, & van Schooten, 2009a). Nicotine triggers the release 
of b-endorphin, which targets the μ-opioid receptor (OPRM1), evoking feelings of 
pleasure. The Asp40 variant of OPRM1 confers increased activity owing to an 
increased binding affinity for b-endorphin. Studies have demonstrated an association 
between the Asp40 genotype and increased quit rates when using transdermal nicotine 
patches (Lerman et al., 2004). Another study has investigated two further genes 
involved in the opioid pathway, the MOR-interacting proteins b-arrestin 2 (ARBB2) 
and histidine triad nucleotide binding protein 1 (HINT1). However at the end of NRT 
treatment, neither HINT1 nor ARRB2 were found to be significantly associated with 
abstinence (Ray et al., 2007). 
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1.5.4 Nicotinic acetylcholine receptors 
 
Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels of which 
nicotine is an agonist (Itier & Bertrand, 2001). Neuronal subtypes of nicotinic 
receptors consist of subunits ranging from a2–a10 and b2–b4. Since nicotine is an 
agonist for these receptors, which in turn modulate mesolimbic dopamine function, 
these receptors act as one of the primary mechanisms underlying the development of 
nicotine dependence (Tapper et al., 2004). Several genome scans indicate that genetic 
variations in these receptors may influence nicotine dependence (J. Z. Liu et al., 2010; 
Thorgeirsson et al., 2010; Tobacco & Genetics, 2010). As yet however, only one 
study has examined two polymorphisms in the a4 subunit coded by the CHRNA4 
gene and their effect on abstinence with NRT (Hutchison et al., 2007). Individuals 
with a polymorphism that affected mRNA stability were more likely to maintain 
abstinence on NRT nasal spray but not with the transdermal nicotine patch (Hutchison 
et al., 2007). 
 
 
1.6 A stratified approach to cessation treatments? 
 
There is a high degree of genetic variability that contributes to individual differences 
in smoking behavior. Since pharmacological treatments interact with the same 
neurotransmitter pathways and enzymes involved in nicotine metabolism, it is not 
surprising that there is also a degree of genetic variability in how individuals respond 
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to different therapies as the same genes are involved in moderating that response. One 
possible approach to improving cessation rates could be to target treatment to specific 
subgroups of smokers.  Individuals could be typed at an array of genetic loci related 
to these differing smoking behaviors, and personalized treatments administered 
accordingly.  
An example where this could be easily implemented would be nicotine metabolism, 
where biochemical markers (such as cotinine and trans- 3´-hydroxycotinine 
metabolite ratio) could be used to identify smokers with differing rates of nicotine 
metabolism, so that an appropriate dose of NRT could be used.  
This approach might stratify smokers into different groups according to 
fundamental biological mechanisms underlying the addictive process.  A nosological 
advance of this kind could lead to more effective use of therapies, reducing side 
effects and treatment costs whilst at the same time increasing cessation rates. 
 
 
1.7 Zebrafish as a model organism 
 
Zebrafish have risen markedly in popularity over the last few decades, particularly in 
the fields of genetics, developmental biology and behavioral neuroscience. Breeding 
and maintenance of large numbers of zebrafish stocks is both simple and economical, 
with the ability to house large numbers of animals in a relatively small area. The 
whole zebrafish genome has been sequenced, with around 70% of human genes found 
to have at least one zebrafish orthologue (Howe et al., 2013a and Howe et al., 2013b).  
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The zebrafish also provides researchers with a model amenable to embryonic 
manipulation and high-throughput screening of genetic mutations and 
pharmacological agents while also being particularly well suited to such large-scale 
screens, primarily due to prolific breeding that produces large numbers of rapidly 
developing offspring (Bang, Yelick, Malicki, & Sewell, 2002; Burns et al., 2005; 
Gerlai, 2010; Rihel et al., 2010).  
 
 
1.7 Zebrafish as a model for the study of reward and 
dependence.  
 
Zebrafish have since the 1950s become established as one of the most widely used 
comparative model species in developmental genetics, and the genome has now been 
fully sequenced. More recently, the species has emerged as a valuable model for 
behavioural neuroscience and addiction biology; the zebrafish encodes an ortholog for 
nearly every characterised human addiction-related gene including all members of the 
nicotinic acetylcholine receptor as well as the majority of the dopaminergic, 5-HT-
ergic and cholinergic receptor gene families.   As a model it allows easy access to a  ll 
developmental stages and imaging of pathological processes as well as automated 
behavioral assay in adults and larvae (Lange et al., 2013; M. O. Parker, Millington, 
Combe, & Brennan, 2012).  Using a zebrafish model it is possible to knock out genes 
of interest using a CRISPR/Cas or a TALEN system, and in doing so, investigate 
whether the gene variants lead to altered connectivity or function in the developing 
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brain that in turn may influence behaviour. Furthermore, the ability to carry out large-
scale screening and mutagenesis strategies makes it unnecessary to know the genes or 
pathways implicated beforehand.  
Recent studies have conclusively demonstrated that zebrafish readily respond 
to addictive drugs and has led to their growing use in forward genetics screens. 
Zebrafish provide a useful model system in which to address this question due to the 
established behavioural assays of drug seeking, compulsive drug taking, and relapse 
(C. Brennan et al., 2011; L. J. Kily et al., 2008). The zebrafish thus represents an 
exceptionally powerful platform for efficient whole genome functional assessments of 
genetic factors that mediate variability in addiction-associated behaviours and the 
contribution of these factors across specific endophenotypes (Gottesman & Gould, 
2003), as well as between drugs of abuse. 
Zebrafish have proven to be a useful animal model for studying genetic factors 
that underlie both complex neurobehavioral phenotypes and drugs of abuse (Bretaud et 
al., 2007; Clark, Boczek, & Ekker, 2011; Darland & Dowling, 2001; L. J. Kily et al., 
2008; Klee, Ebbert, Schneider, Hurt, & Ekker, 2011; Mathur & Guo, 2010; Ninkovic 
et al., 2006; Stewart et al., 2011). Zebrafish show conditioned place preference 
responses to cocaine (Darland & Dowling, 2001), amphetamine (Ninkovic & Bally-
Cuif, 2006), opiates (Bretaud et al., 2007) ethanol and nicotine (L. J. Kily et al., 2008) 
and the amphetamine-induced response is modified by pathways known to influence 
dopamine release in the NAc in other systems (Ninkovic et al., 2006). In addition to 
this, it has been demonstrated that adult zebrafish develop dependence-related 
behaviours, such as persistent drug seeking despite adverse stimuli or reinstatement of 
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drug seeking following periods of abstinence, on prolonged exposure to ethanol or 
nicotine (C. Brennan et al., 2011).   
 
 
1.7.1 Conservation of pathways that affect nicotine reward 
 
Despite the topography of the zebrafish brain largely differing from that of mammals, 
there have been homologous regions associated with addiction and reward identified. 
There are homologues of mammalian midbrain regions present in the zebrafish. The 
ventral tegmental area (VTA) is homologous to the posterior tuberal nucleus (PTN) 
and the nucleus accumbens has homology to the ventral and dorsal telencephalic 
nuclei (Panula et al., 2010; Rink & Wullimann, 2002b). The dorsal pallium (Dc) has 
also been described as a likely homologue of the isocortex in in mammals (Mueller, 
Dong, Berberoglu, & Guo, 2011) (see figure 4). Furthermore, there are a number of 
neurochemical pathways relevant to addiction that show homology to mammals such 
as the ascending dopaminergic pathways in the midbrain which have been extensively 
characterized using tyrosine hydroxylase staining (Filippi, Mahler, Schweitzer, & 
Driever, 2010; Rink & Wullimann, 2002b). There is little evidence of how these 
systems functionally interact however as much of the evidence pertaining to the 
cholinergic, DAergic and 5-HTergic neural clusters in the zebrafish brain has been 
generated from extensive immuno-staining of relevant cell bodies. It is the 
conservation of the mesolimbic pathway in particular that is vitally important for the 
experiments covered in this thesis 
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1.7.2 Mesolimbic reward system in zebrafish. 
 
In mammals the mesolimbic dopaminergic system consists of dopamine neurons that 
have their cell bodies in the midbrain VTA and send projections to the ventral striatum 
(NAc), PFC and amygdala (see figure 1.4).  In zebrafish, dopaminergic neurons are 
absent in the midbrain; however, experiments have identified a conserved ascending 
dopaminergic system in zebrafish that is essential for the types of reward responses 
that will be explored in this thesis.  In the zebrafish, the dopamine neurons of the 
posterior tuberculum of the dorsal hypothalamus, project to the dorsal and ventral 
(limbic) striatum.  These projections are thought to represent the meso-striatal and 
meso-limbic systems, respectively (Rink & Wullimann, 2002a). The dorsal-medial 
region of the telencephalon is considered to correspond to the mammalian amygdala 
(Peitsaro, Kaslin, Anichtchik, & Panula, 2003; Portavella, Vargas, Torres, & Salas, 
2002).  Evidence in support of the dopamine projection from the posterior tuberculum 
representing the mammalian mesolimbic projection comes from recent analysis of 
reward responses in Too few mutant fish.  Too few homozygous mutant fish lack the 
fez1 transcription factor and lack dopamine and 5HT neurons in the hypothalamus 
(Levkowitz et al., 2003; Rink & Guo, 2004).  Homozygous mutants are 
indistinguishable from their wild type siblings in terms of size, morphology, anatomy, 
fertilization, escape, feeding and prey-seeking responses but show a reduced reward 
response to opiates (Bretaud et al., 2007).  
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Figure 1.4: Schematic sagittal view comparing dopaminergic (green), serotonergic (red), and 
cholinergic (blue) neuronal populations in zebrafish (upper) and rat (lower) brains. (A) Cell body 
distribution (adapted from Manger et al., 2002; Butcher and Woolf, 2003; Mueller et al., 2004; 
Schweitzer and Driever, 2009; Panula et al., 2010). (B) Schematic drawing illustrating the location of 
dopaminergic projections in adult zebrafish and rat brains (sagittal view; adapted from Schweitzer and 
Driever, 2009). (C) Schematic drawing illustrating the location of serotoninergic projections in adult 
zebrafish (adapted from Gaspar and Lillesaar, 2012) and rat brains (adapted from Di Giovanni et al., 
2008; sagittal view). (D) Schematic drawing illustrating the location of cholinergic neuron projections 
from PPT in adult rats (adapted from (Manger et al., 2002)) and predicted projections from zebrafish 
SRN to subpallium and habenula.  
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Further evidence for conservation of neural networks involved in the regulation of 
reward comes from analysis of the acetylcholinesterase (AchE) mutant zebrafish 
(AchE).  In mammals AchE terminates cholinergic synaptic transmission and AchE 
inhibitors block cocaine and morphine induced CPP suggesting a critical role of 
cholinergic systems in the regulation of reinforcement responses to drugs other than 
nicotine.  AchE mutant fish have a loss of function mutation in the AchE gene (Behra 
et al., 2002).  Homozygote fish die by 5 days post fertilization but heterozygote fish 
are morphologically indistinguishable from wild-type siblings.  These heterozygote 
mutants naturally show reduced AchE activity and a reduced reward response to 
amphetamine as a result (Ninkovic et al., 2006) indicating conservation of the 
cholinergic regulation of drug-associated reward. 
 
 
1.8 Genetic tools and mutagenesis approaches 
 
In-breeding of mouse strains have been used to investigate associations between 
addiction related behaviors and known genetic variants. Reverse genetic approaches 
in using knockout mice to investigate the role of genes in addiction have also proven 
fruitful. Although approaches of these types have provided valuable information 
about the underlying molecular mechanisms of addictive disorders, there are some 
disadvantages to using these types of methods. Most importantly, traditional 
approaches require a high degree of knowledge prior to carrying out the experiments, 
in that the genes you investigate have to be reasonably well known and characterized 
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before a knock-out mouse can justifiably be generated. When looking at complex 
neurological disorders this can prove problematic, as it is unlikely such phenotypes 
are going to be governed by single genes of large effect, rather multiple genes 
involved in complex pathways with variable penetrance, many of which will be 
completely novel. As such, significant advances in our understanding of neurological 
disorders may prove hard to come by if these types of approaches in mice are used 
exclusively. There is a need for these studies to be complemented with forward-
genetic type screens, however this can prove near impossible in mouse models. The 
relatively long generation gap, small litter sizes and high maintenance costs make it 
difficult to generate the large numbers needed for forward genetic population screens.  
This is where the most exciting possibilities in zebrafish lie; in the ability to 
perform forward genetic screens for behavioral phenotypes including behaviors 
associated with complex neurological disorders like addiction. Forward genetic 
mutagenesis screens in zebrafish have been widely used to identify mutant alleles 
affecting various behaviors and phenotypes. A typical approach is to use a three-
generation mutagenesis screen to identify recessive alleles by screening a family in 
which 25% of the F3 offspring show a phenotype of interest. This type of classic 
diploid F2 screen has been carried out (Driever et al., 1996; Haffter, Granato, et al., 
1996) with the F3 egg clutches being examined at five stages of development (during 
the first 6–12 h and on the first, second, third, and fifth days after fertilization) for any 
signs of abnormal development evident in 25% of the growing embryos (Figure 1.5) 
(Warren & Fishman, 1998). This approach works well for recessive (or dominant) 
alleles of major effect but is less effective for complex behavioral phenotypes like 
addiction, as these behaviors are likely to be multi-allelic in nature, rather than being 
governed by variation at one locus. Nonetheless, forward genetic screens for 
Chapter 1 
 51 
behavioral phenotypes have been undertaken including screens for cocaine and 
amphetamine-induced place preference (Darland & Dowling, 2001; Ninkovic et al., 
2006). Each of these screens isolated lines of fish with differential drug seeking 
behavior, but neither have successfully isolated the causal mutations, possibly due to 
difficulties in unambiguously identifying the mutant carrier; the performance of 
control individuals often falls within the range of affected individuals and vice versa 
(Jain, Wolman, Schmidt, Burgess, & Granato, 2011) making linkage analysis 
difficult.  
 
 
Figure 1.5: Schematic outline of a typical zebrafish F2 mutagenesis screen. G0 male sperm is 
mutagenized using N-Ethyl-N-nitrosourea (ENU) before outcrossing is performed with wild-type 
females to produce the F1 generation. Each F1 fish (containing unique mutations) is incrossed with F1 
siblings to create the F2 generation.Further in corossing of the F2 generation drive mutations to 
homozygosity in the F3 embryos where they are screened for a phenotype. (Warren & Fishman, 1998). 
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Population based breeding and selection, or GFP insertion techniques can be 
used to address this problem. A good example of this is a study in which a 
“phenotyping by segregation” approach was implemented, where commonly used 
breeding and selection strategies were used to map the hypersensitive zebrafish 
houdini mutant (Figure 1.6) (Jain et al., 2011). Normally, when carrying out 
segregation mapping, mutant F2 subjects are pooled based on phenotype, before 
determining whether a chromosomal region segregates with that phenotype 
(Michelmore, Paran, & Kesseli, 1991). However, when there is a significant 
phenotypic overlap between mutant and sibling wildtype populations, often mutants 
can get misclassified at wildtype and vice versa. This makes it difficult to link genetic 
variants to the mutant pool. Therefore, to confirm that phenotypic F2 outliers at the 
larval stage were indeed homozygous mutant individuals, a phenotyping by 
segregation approach was employed where suspected larval mutants were raised to 
adulthood, test crossed, and the phenotypic ratios of the F3 larval offspring examined 
(Figure 1.4). Those putative F2 mutant adults producing F3 progeny in the ratios 
expected for homozygous mutant individuals would then be considered “validated” 
mutants and used for mapping. Using this method, potential mutants are confirmed 
both by showing an initial F2 larval phenotype and by producing F3 progeny in 
expected mendelian phenotypic ratios. 
This method was used Jain et al. to map the houdini mutant, which was 
identified in a screen for genetic factors regulating acoustic startle responsiveness that 
may be relevant to neuropsychiatric disorders. Using this approach, they were able to 
map a region of chromosome 5 as being responsible for this altered startle response 
displayed by the houdini mutant. 
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Figure 1.6: The ‘phenotyping by segregation’ strategy to map the variably penetrant houdini 
mutation. A: F3 phenotypic segregation is used to validate homozygous F2 mutants. F2 larvae at the 
top 15% of the phenotypic range of the clutch are raised to adulthood as potential mutants, alongside an 
equal number of siblings (bottom 15% of clutch) as controls. Genomic DNA is then taken from each 
raised F2 individual before randomly incrosing. Any raised F2 individual that again produced a clutch 
with a greater frequency of phenotypic outliers than the control F1 heterozygote incross is deemed a 
“validated” mutant, and is used for segregant mapping. (B-C) Distributions of startle responsiveness to 
weak sub threshold acoustic stimuli in 5 dpf larval progeny of a houdini heterozygote and a wild type 
(Jain et al., 2011). 
 
 
This strategy is attractive as it allows for fine mapping of subtle phenotypes 
that may have variable penetrance in the general population. An alternative approach 
has been to use fluorescently tagged gene breaking transposons to mutagenize 
zebrafish (Bill, Petzold, Clark, Schimmenti, & Ekker, 2009). These transposons 
permit visual sorting of carriers from non-carriers (fluorescent vs. non-fluorescent 
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larvae) and have the advantage of allowing rapid cloning of the mutagenized gene. 
This technique has been successfully used to identify two genes involved in the 
behavioral response of larval fish to nicotine (Petzold et al., 2009). 
Application of such breeding and selection-based mutagenesis screening 
approaches to the adult behavior may lead to the identification of novel genes 
contributing to complex behavioral phenotypes.  It is why such a strategy has been 
chosen as the main topic of this thesis. By screening mutant populations of fish for 
nicotine induced CPP, it is hoped novel alleles associated with nicotine reward can be 
identified. The ultimate aim being to use any alleles identified in this study to inform 
human-based studies and identify markers, which can be used to stratify people 
presenting for cessation treatment in the hope of increasing quit rates. Such studies 
will make a valuable contribution to complement genome wide association studies 
(Sullivan, 2010) and analyses of copy number variants (Cook and Scherer, 2008) 
aimed at understanding the genetics of nicotine addiction and psychiatric disease. 
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Chapter 2 
 
 
General Methodology 
 
This chapter contains descriptions of general protocols used over the course of this 
thesis. All general laboratory chemicals were purchased from Sigma-Aldrich unless 
stated otherwise. 
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2.1 RNA/DNA isolation and separation methods 
 
2.1.1 Total RNA extraction from zebrafish tissues 
 
This method was deployed at a means of obtaining total RNA stock from zebrafish 
bodies/heads for generating cDNA stocks. Total RNA from zebrafish head or whole 
zebrafish tissue was extracted following RNeasy Mini Kit protocol form Qiagen.  
o Up to 20 mg of tissue was homogenised in 350 µl of RTL lysis buffer using 
homogeniser. 
o  Lysates were cleared by centrifugation at 14000 rpm for 3 minutes.  
o Supernatants were then transferred to new tubes and 750 µl of 70% ethanol 
was added and mixed thoroughly by pipetting.  
o 700 µl of sample was added to each RNeasy mini column in a 2 ml collection 
tube and centrifuged for 15 seconds at 14000 rpm.  
o The flow-through was discarded and the column washed by adding 700 µl of 
buffer RW1.  
o The column was centrifuged for 15 seconds at 14000 rpm and the flow-
through discarded.  
o The column was transferred into a new 2 ml collection tube and 500 µl of 
buffer RPE was added to wash the membrane.  
o The column was centrifuged for 2 minutes at 14000 rpm and the flow-through 
discarded. This step was repeated without RPE buffer to dry the silica-gel 
membrane and completely remove all traces of RPE buffer as it can inhibit 
molecular reaction further down the line.  
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o To elute RNA, the column was transferred to a new 1.5 ml collection tube and 
30 to 50 µl of RNase free water were pipetted directly onto the column 
membrane and left for 1 minute.  
o The column was centrifuged for 1 minute at 1400 rpm and the RNA 
concentration determined using nanodrop ND 1000 spectrophotometer.  
 
 
2.1.2 mRNA extraction from embryos using Dynabeads® Magnetic Beads 
 
This method was used for the purpose of obtaining total mRNA from zebrafish 
embyos for use in quantitative PCR reactions. The optimal amount of tissue for 20ul 
beads is 1mg. If the tissue is stored in RNA later, remove and put in lysis buffer: 
o 2ul PK solution was added to 1mg tissue in 200ul lysis buffer.  
o Samples were incubated at 55 degrees 0C until completely digested. This can 
take 30min or even more. Samples were agitated during incubation period to 
help digest.  
o Once all tissue digested, 40ul of dynabeads was added per 200 µl lysis buffer.  
o Digest was rotated for 10min at room temperature to ensure mixing of RNA 
and beads and to allow binding of mRNA to beads.  
o Whilst rotating turn hot block was switched on to 80 degrees. Samples were 
then transferred to a magnetic rack.  
o The magnetic rack was rocked a few times to make sure all beads attracted to 
magnet. Samples were titrated again to make sure all DNA broken down and 
all mRNA has opportunity to bind.  
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o All supernatant was removed including any bubbles taking care not to disturb 
the pellet. 
o Samples were washed with 400ul buffer A (from dynabead kit) – i.e. samples 
were removed from rack, 400ul of wash buffer added and titrated to wash 
beads. Samples were then Put back in magnetic rack and the supernatant 
removed as before.  
o Beads were washed with 400ul buffer B. Supernatant was removed making 
sure all of the buffer B was removed as it inhibits RT reaction.  
o 13 µl of Tris-Hcl (from kit, 10mM) was added to re-suspend beads. All 13 µl 
is used in future reverse transcription reactions 
o  Samples were placed in heat block at 80 0C to remove mRNA from beads.  
o After 2 min at 80 degrees samples were transferred IMMEDIATELY to rack 
so that mRNA has no time to recombine with beads.  
o Put 7.5ul of RT master mix (prepared as described below) into a PCR tube 
(thin walled 0.2ml) and add all of the mRNA to it. Then set up cDNA 
synthesis reaction according to new cDNA synthesis kit. Use a mixture of both 
oligodT and random primers to prime synthesis.  
 
 
2.1.3 Quantification of nucleic acids concentration 
 
The concentration of RNA (or DNA) solution was determined using a Nanodrop ND 
1000 according the manufacturer’s recommendations. RNA or DNA concentration is 
determined by measuring sample absorbance at 260nm. 
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2.1.4 Separation of RNA by gel electrophoresis 
 
All RNA/DNA samples were typically run on a 1% (w/v) agarose gel aside from 
fragments less than 200bp. The agarose gel was prepared by mixing 1g of agarose 
with 100 ml of 1X TAE buffer in a conical flask. The mixture was heated in a 
microwave until a homogenous solution. This was then allowed to cool before 
ethidium bromide (0.5 µg/ml was added. The cooled, but still liquid, agarose was then 
poured into the casting tray containing a comb for the wells and left to solidify. The 
gel tray with comb removed was then transferred into the gel tank with 1X TAE 
buffer. Samples were then added by combing with 6x loading buffer before 
immediately being loaded into the gel wells. A parallel lane containing 5 µl of DNA 
markers was then added to determine the size of the obtained fragments. Samples 
were run a 100 V. The gel was visualized under UV light using a Uvitec 
illuminometer. 
 
 
2.1.5 Enzymatic degradation of genomic DNA in RNA samples 
 
To remove DNA contaminants from RNA solutions, samples were subjected to an 
enzymatic DNA degradation reaction in a micro centrifuge tube containing the 
following: 
o x µl Total RNA (volume = 2 µg RNA) 
o 4 µl 5X reaction buffer 
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o 1 µl DNase I 
o 1 µl RNasin 
o y µl RNase free water (add up to 20 µl total reaction volume) 
DNA digestion was carried out for 30 mins at 37oC in a water bath. Reaction was 
stopped by freezing or proceeding to phenol extraction. 
 
 
2.1.6 Phenol extraction and ethanol precipitation of RNA/DNA 
 
20 µl of RNA/DNA was extracted and precipitated as follows: 
o 30 µl of RNase free water and 50 µl of acid phenol was added to the tube and 
mixed vigorously 
o Solution was then centrifuged for 5 minutes at 130000 rpm to separate the two 
phases 
o The top transparent layer containing DNA/RNA was transferred to a new 
RNase free microcentrifuge tube and concentrated by ethanol precipitation 
o 1/10th volume 3M sodium acetate solution was added along with 2.5 volumes 
of 100% ethanol and triturated thoroughly to mix 
o Solution was left at -80 oC for 1 hour to aid precipitation 
o The sample was spun down at 13000 rpm for 10 mins and the pellet washed 
with 70% ethanol 
o The sample was centrifuged for a further 10 mins at 13000 rpm, the ethanol 
removed and the pellet allowed to air dry. 
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o The pellet was resuspended in RNase free water. 
 
 
2.1.7 cDNA synthesis from total RNA or total mRNA from embryos 
 
Reverse transcriptase PCR reaction is set up as follows:  
o 4ul 5x buffer  
o 2ul dNTP  
o 0.8ul primer mix  
o 0.4ul RNAsin  
o 0.4ul RTase  
o 12.4ul RNA  
 
The reaction was carried out in a thermocycler with the following settings: 
o 42 degrees for 30 min 
o 85 degrees for 5 min 
o 4 degrees 5 min. 
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2.1.8 Polymerase chain reaction (PCR) 
 
All reagents and templates were stored at -20. Primer stocks were stored at 100 µM in 
water, while working aliquots were stored at 10 µM. The dNTP stocks contained 10 
mM each of dATP, dTTP, dCTP, and dGTP and were obtained from Roche. The 
TAQ polymerase was from New England Biolabs.  The reaction mix (for 25µl 
reaction, for 50 µl reaction double values etc.) contained: 
o 2.5µl reaction buffer 
o 1µl F+R primers 
o 0.5 µl dNTPs 
o 1µl template 
o 19.875µl ddH20 
o 0.125 µl TAQ polymerase 
Standard settings on the thermo cycler were as follows: 
o Denature at 94° C for 5 min  
o Denature at 94° C for 30 sec  
o Annealing step at X° C for 30 sec (temp dependant on primer tm) 
o Extension 68° C for X min (dependant on template size, 1kb = 1min) 
o  Repeat steps 2-4 35 times  
o 68° C for 10 min 
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2.1.9 Extraction and purification of DNA from agarose gel 
 
DNA was extracted and purified according to the QIAquick Gel extraction Kit as 
follows: 
o The area of agarose gel containing DNA fragment of interest was excised 
using a scalpel before being place in a microcentrifuge tube and weighed 
o 3 volumes of buffer QG were added per 1 volume of gel 
o The tube was incubated for 10 minutes at 50 ° C until the gel slice was 
dissolved 
o 1 volume isopropanol was added to the solution before inverting several times. 
o The resulting solution was then added to a QiaQuick spin column in a 
collection tube and then bound to the column membrane by centrifuging at 
13000 rpm. 
o The flow through was discarded and 0.5ml of buffer QG was added to remove 
remaining traces of agarose. 
o The column was spun for 1 minute at 13000 rpm. 
o To wash the membrane 750 µl of buffer PE was added to the column before 
centrifuging for 1 minute at 13000 rpm 
o The flow through was discarded before centrifuging for a further 1 min to 
eliminate all traces of buffer PE 
o To elute the column was transferred to a 1.5 ml eppendorf and the DNA eluted 
into 30 µl of distilled water 
Concentration of the DNA was determined using the nanodrop as previously 
described. DNA was stored at -20°C. 
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2.1.10 Making competent cells 
 
o A 100 ml aliquot of frozen cells was taken from the -80oC and innoculate 
about 500 ml to 1 L sterile LB broth. Antibiotic was not added, since these 
cells do not contain a plasmid. Care was taken to work as sterile as possible.  
o The cells were grown on a shaker at 37oC until they reached an OD @ 600nm 
of 0.3 to 0.4 (1 cm path length). 
o Cells were then centrifuged in a Sorvall GSA rotor (250 ml centrifuge bottle) 
at 5,000 RPM for 10 minutes at 4oC. Ice down 100 mM CaCl2 and 100 mM 
MgCl2 solutions at this point. 
o The bacteria pellet was gently resuspended on ice in 1/4 volume of ice cold 
MgCl2, taking 3 to 5 minutes for this procedure. Centrifuge he cell suspension 
at 4,000 RPM in the Sorvall GSA rotor for 10 minutes. 
o  The bacteria pellet was gently resuspended on ice in 1/20 volume of ice cold 
CaCl2 and then add an additional 9/20 volume of CaCl2. Keep this suspension 
on ice for at least 20 minutes. 
o The cell suspension was centrifuged at 4,000 RPM in the GSA rotor for 10 
minutes and the cell pellet resuspended in 1/50 volume of ice cold, sterile 85 
mM CaCl2 in 15% glycerol w/v. Dispense in 100 mL aliquots and freeze cells 
at -80oC. 
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2.1.11 Clonong into pGEM®-T Easy 
 
The pGEM®-T and pGEM®-T Easy Vector Systems have been optimized using a 1:1 
molar ratio of the Control Insert DNA to the vectors. The pGEM®-T and pGEM®-T 
Easy Vectors are approximately 3kb and are supplied at 50ng/µl. To calculate the 
appropriate amount of PCR product (insert) to include in the ligation reaction, the 
following equation was used: 
 
The steps for ligation of amplified PCR product into the pGEM®-T Easy vector were 
as follows: 
o Briefly centrifuge the pGEM®-T or pGEM®-T Easy Vector and Control 
Insert DNA tubes to collect the contents at the bottom of the tubes.  
o Set up ligation reactions as described as follows: 5µl ligation buffer, 1µl 
pGEM®-T Easy Vector, Xµl PCR product (see above for volume calculation), 
1µl T4 DNA ligase, Nuclease-free water up to a final volume of 10µl. 
o Incubate the reactions for 1 hour at room temperature (Alternatively, reactions 
can be incubated overnight at 4°C). 
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2.1.12 Preparation of LB-Agar plates 
 
o 17.5 g of LB-agar powder was added to 500ml distilled water and then 
autoclaved 
o After autoclaving, agar was left in a water bath at 50 oC and allowed to 
equilibrate temperature 
o Once agar was 50 oC, 500 µl of ampicillin was added close to a sterilizing 
flame 
o Agar was then poured into petri dishes with approx. 20-25ml of agar put in 
each dish and then allowed to dry for 1 hour. 
o 50 µl of X-Ga and 100 µl of IPTG solution were poured onto each plate using 
a spreader fashioned out of a Pasteur pipette and the plates were left to dry for 
a further 30 mins. 
 
 
2.1.13 Transformation of competent cells 
 
o Two LB/ampicillin/IPTG/X-Gal plates for each ligation reaction were 
prepared and equilibrated to room temperature.  
o 2 µl of each ligation reaction was transferred to a sterile 1.5ml eppendorf tube 
on ice  
o Frozen competent cells were removed from storage and placed in an ice 
bucket for 5 mins until thawed. Mix the cells by gently flicking the tube.  
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o 50µl of competent cells were transferred into each of the tubes containing the 
ligation reactions. The contents were gently mixed by flicking 
o 6. Cells were heat-shocked for 45–50 seconds in a water bath at 42°C. and 
Immediately returned to ice for 2 minutes.  
o 950µl room-temperature LB broth was added to the tubes and Incubated for 
1.5 hours at 37°C with shaking at ~150rpm.  
o 100µl of each transformation culture was plated LB/ampicillin/IPTG/ X-Gal 
plates.  
o Plates were Incubated overnight (16–24 hours) at 37°C.  
 
Successful cloning of an insert into the pGEM®-T or pGEM®-T Easy Vector 
interrupts the coding sequence of β-galactosidase; recombinant clones can be 
identified by color screening on indicator plates. White colonies generally contain 
inserts; however, inserts may also be present in blue colonies. 
 
 
2.1.14 Culturing transformed bacterial cells 
 
o Next to a sterilizing Bunsen burner flame, 5 ml of sterile LB broth 
supplemented with ampicillin (1:100 dilution) was placed in a 25ml falcon 
tube 
o For maxi-prep, 250ml of broth was used in a conical flask 
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o A colony was picked (white one if blue/white selection) using a sterile pipette 
tip from agar plate and transferred into tune (tip included) 
o Colonies were allowed to grow over night by placing at 37°C with 225 rpm 
shaking for 16 hours overnight. 
 
 
 
2.1.15 Preparation of glycerol stocks 
 
500 µl of transformed bacteria culture was added to a sterile microfuge tube 
containing 500 µl of sterile glycerol. The solution was mixed thoroughly and the tube 
stored at -70°C. 
 
 
2.1.16 Preparation of up to 20 µg of high-copy plasmid 
 
The QIAprep miniprep kit was used following QIAGEN instruction. 5ml of LB broth 
was inoculated with a single colony or from glycerol stock and incubated overnight 
using the instructions above.  Plasmid was extracted as follows: 
o The bacterial cells were harvested by centrifugation at 3000 rpm for 15 
minutes at 4°C and the bacterial pellet resuspended in 0.3 ml of buffer P1 (cell 
suspension solution).  
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o 0.3 ml of buffer p2 (cell lysis solution) was added and the cell lyse=ate 
suspension vigorously mixed by inverting the tube several times. 
o 0.3 ml of chilled buffer N3 (neutralization solution) was added and the tube 
contents mixed vigorously by inverting the tube. 
o The tube was left to rest on ice for 5 mins and then centrifuged at maximum 
speed in a microcentrifuge for 10 mins. 
o The supernatant containing plasmid DNA was transferred into a QIAprep spin 
column and centrifuged for 1 minute at 13000 rpm.  
o The flow through was discarded and the column wash by adding 0.75 ml of 
buffer PE before centrifuging again at 13000 rpm 
o The column was transferred to a new microcentrifuge tube and the DNA 
eluted in 20-50 µl of distilled water. 
 
 
2.1.17 Preparation of up to 100 µg of high-copy plasmid 
 
The plasmid maxi kit was used following the QIAGEN instructions. 250 ml of 
selective LB broth medium was inoculated with 100 µl from a bacterial glycerol stock 
and incubated overnight using the instructions above.  Plasmid was extracted as 
follows: 
o The bacterial cells were harvested by centrifugation at 3000 rpm for 15 mins 
at 4°C 
o The resulting bacterial pellet was gently resuspended in 4ml of buffer P1. 
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o 4 ml of buffer P2 (cell lysis solution) was added and the cell lysate suspension 
vigorously mixed by inverting the tube several times and incubating at room 
temperature for 5 minutes. 
o 4 ml of chilled buffer P3 (neutralization solution) was added to the mixture, 
again vigorously mixed by inversion several times. 
o The tube was left to rest on ice for 15 mins before centrifugation at ~20000 x 
g for 30 mins at 4°C.  
o The supernatant containing plasmid DNA was transferred to a new tube and 
centrifuged again for 15 mins. 
o A QIAGEN-tip 100 was equilibrated by applying 4 ml of buffer QBT 
(equilibration buffer) and allowed to pass through by gravity.  
o The QIAGEN tip was then washed twice with 10 ml of buffer QC (wash 
buffer).  
o The DAN was then eluted with 5 ml of buffer QF (elution buffer) 
o DNA was precipitated from the solution by adding 3.5 ml of 70 % isopropanol 
followed by centrifugation at 15000 x g for 30 mins at 4°C 
o The DNA pellet was washed with 2 ml of 70% ethanol and the tube 
centrifuged at 15000 x g for 10 mins at room temperature. 
o The DNA pellet was air dried for 5 to 10 mins and resuspended in 100 µl of 
distilled water. 
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2.1.18 Restriction digests 
 
A number of restriction digests were used throughout this thesis to linearize vectors 
for probe synthesis or to verify the presence of an inserted fragment after bacterial 
transformation. A standard digestion reaction contained the following components: 
o x µl (volume corresponding to between 100 – 500 ng) 
o 2 µl 10X reaction buffer 
o 1 µl restriction enzyme 
o y µl distilled water (add until 20 µl total volume) 
Each digestion reaction was incubated in a water bath at 37°C for a minimum of 2 
hours. If the amount of DNA digested was greater than 5 µg, the total reaction volume 
was increased to 40 µl and other components were adjusted equivalently. 
 
 
2.1.19 Genomic DNA extraction 
 
Genomic DNA extraction was carried out according to the DNeasy® Blood & Tissue 
handbook as follows 
o Zebrafish fin-clip was placed in a 1.5ml microcentrifuge tube. 180 µl Buffer ATL 
was added. 
o 20 µl of proteinase K was added. Contents were mixed thoroughly by vortexing and 
incubated at 56°C until the tissue had completely lysed. 
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o 200 µl of Buffer AL was added to the sample, and mix thoroughly by vortexing. Then 
add 200 µl ethanol (96–100%), and mix again thoroughly by vortexing.  
o 200 µl of Buffer AL was added to the sample, and mix thoroughly by 
o Then 200 µl of ethanol (96–100%) was added and mixed again thoroughly by 
vortexing 
o The mixture from step 3  was pipetted (including any precipitate) into the DNeasy 
Mini spin column placed in a 2 ml collection tube).  
o Columns were then centrifuged at 6000 x g (8000 rpm) for 1 min. and the flow-
through discarded. 
o The DNeasy Mini spin column was placed in a new 2 ml collection tube, and 500 µl 
Buffer AW1 was added,  
o The spin-column was centrifuged for 1 min at 6000 x g (8000 rpm).  
o The DNeasy Mini spin column was then placed in a new 2 ml collection tube 
(provided), and 500 µl Buffer AW2 added. 
o The column was then centrifuged for 3 min at 20,000 x g (14,000 rpm) to dry the 
DNeasy membrane.. 
o The DNeasy Mini spin column was placed in a clean 1.5 ml microcentrifuge tube and 
eluted by applying 200 µl Buffer AE directly onto the DNeasy membrane and then 
centrifuging for 1 min at 6000 x g. 
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2.1.20 PCR Purification of PCR products, 100 bp to 10 kb 
   
Procedure: 
-­‐ 5 volumes of Buffer PB was added to 1 volume of the PCR sample and mixed.  
-­‐ If the colour of the mixture was not yellow 10 µl of 3 M sodium acetate, pH 5.0, 
was added until the mixture turned yellow. 
-­‐ A QIAquick spin column was placed in a 2 ml collection tube. 
-­‐ To bind the DNA, the sample was applied to the QIAquick column and 
centrifuged for 30–60 s. 
-­‐ Discard flow-through. Place the QIAquick column back into the same tube. 
-­‐ To wash, 0.75 ml Buffer PE was added to the QIAquick column and centrifuged 
for 30–60 s. 
-­‐ The flow-through was discarded and the QIAquick column placed back in the 
same tube before centrifuging for an additional 1 min.   
-­‐ QIAquick column was placed in a clean 1.5 ml microcentrifuge tube. 
-­‐ DNA waseluted by adding 50 µl Buffer EB (10 mM Tris·Cl, pH 8.5) or water 
(pH 7.0–8.5) to the center of the QIAquick membrane and centrifuge the column 
for 1 min.  
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2.2 In-situ hybridization 
 
2.2.1 Generation of template for RNA probe synthesis 
 
Template for probe synthesis was created using a plasmid containing the cDNA of 
interest and M13 primers to amplify up that cDNA using the previously mentioned 
PCR protocol. The resulting fragment wad then PCR purified and used s the template 
in the reaction below. 
 
2.2.2 Anti-sense RNA probe synthesis 
 
To generate probes, the following reagents were mixed in the following order at room 
temperature (all reagents were obtained from Roche):  
o 10 µl sterile distilled water  
o 4 µl 10x transcription buffer  
o 2µl 0.2 M DTT  
o 2 µl nucleotide mix  
o Linearised DNA (0.5 µg/µl; 1µl) 
o Ribonuclease inhibitor (0.5 µl) 
o RNA polymerase 0.5 µl 
Probes were synthesised as follows: 
o The reaction was incubated at 37°C for over 2 hours up to 5 hours. 
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o A 1% agarose gel was cast while the sample was incubating.  
o A 0.5 µl aliquot was taken and run on a 1% agarose/TBE gel to estimate 
amount of RNA synthesized. The idea being to look for an RNA band about 
20-fold more intense than DNA band, indicating around 10 µg probe 
synthesized.  
o After the probe was synthesised the reaction was diluted to 200 µl with water 
and add 20 µl of 3 M NaOAc (pH 5.5), 1.3 µl of acetic acid (add this in fume 
hood), and 550 µl of ethanol.  
o The solution was left at -80°C for 30 minutes.  
o The solution was spun in a microfuge for 10 minutes and the liquid decanted 
liquid.  
o Pellet was washed with 70% ethanol and air dried.  
o Pellet was re-dissolved in low TE (10mM Tris, 0.1 mM EDTA, pH 8.0) at 0.1 
µg/µl and store at -20°C.  
o The probe was titrated when first used - i.e. to test run at 1/100 to 1/500 
dilution. 
 
2.2.3 Whole mount in-situ hybridisation (pretreatment of embryos)  
 
Embryos are fixed and stored as follows: 
o Embryos were hand-dechorinated in fish water then transfer to eppendorf, 
remove liquid and fix in 4% paraformaldehyde/PBS at 4°C overnight or 2hour 
at room temperature.  
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o Fixed embryos were washed once with PBS, once with methanol, and then 
store in methanol at -20°C. Embryos can be stored in methanol indefinitely. 
Fixed embryos are readied for in situ hybridization as follows: 
o Methanol was removed with a pipette ensuring embryos did not dry out.  
o Embryos were rehydrated by taking fixed embryos through:  
o 5 minutes in 75% methanol/PBT,  
o 5 minutes in 50% methanol/PBT,  
o 5 minutes in 25% methanol/PBT  
o 4x 5 minutes in 0.5 ml PBT  
(Tween20 used in all solutions to prevent the embryos sticking together)  
o Embryos were treated with 10 µg/ml proteinase K in PBT for 20 minutes (for 
24 hour old embryos, add 20 minutes for every additional day in age  
o Embryos were washed once with PBT and refixed in 4% 
paraformeldehyde/PBT for 20 minutes.  
o The Embryos were washed for 5 x 5 minutes with PBT.  
o Next there was a prehybridisation step for at least 1 hour at 65°C in 
hybridization mix (~100 µL, just enough to cover the embryos). Embryos can 
be stored at -20°C after prehybridising. 
o Hybridization mix was replaced with fresh mix and probe and incubated 
overnight at 65°C.  
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2.2.4 Whole ISH (post-hybridization washes and digoxygenin detection) 
 
The following washes were performed at 65°C (have all wash solutions at 65°C too):  
o 3x 10 minutes 25% formamide/2x SSC  
o 10 minutes 2x SCC 
o 3x 20 minutes 0.2 SSC.  
The rest of the protocol was carried out at room temperature as follows: 
o 4 x 5 min with PBT at room temperature  
o Embryps were incubated in [PBT containing 2% sheep serum and 2 mg/ml 
BSA] or MABlock: [MAB 1x with maleic acid buffer] with gentle agitation 
for >1 hour at room temperature.  
o The above solution was replaced with anti-DIG-AP antibody (1:5000) 
dilution in PBT containing 2% blood sheep serum and 2 mg/ml BSA and 
incubate for 2 hours at 4°C (Or 4°C overnight)  
o Wash embryos 8x 15 minutes in PBT at room temperature (or you can wash 
overnight at 4°C) 
o 3x 5 minute washes in BCL buffer. This step brings the ph to 9.5.  
o Incubated with BCL buffer including 4.5 µl NBT, 3.5 µL BCIP per ml (or 
BM Purple) and leave on bench top.  
o When colour has developed to the desired extent, wash 3x 5 minutes with 
PBT and refix embryos in 4% paraformaldehyde/PBS for 30 min - 2 hours. 
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2.3 Quantitative PCR 
 
2.4.1 Collection of embryos to generate cDNA 
o The larvae were killed in MS-222 at 28hr, 3dpf and 5dpf before being placed 
in RNAlater until assay (4ºC). 
o Batches of n=5 embryos were pooled and the mRNA isolated using 
Dynabeads® Oligo(dT)25 protocol outlined in the previous section. 
o cDNA was generated from total mRNA to generate samples for analysis 
 
2.3.2 Making standard for target genes 
 
Every gene run with the qPCR protocol was run with a standard curve in order to 
relatively quantitate the Ct values for the samples. The protocol starts with 20μl of 
cDNA sample generated in the previous steps. 
o PCR fragments were amplified using qPCR primers for target genes using 
standad PCR protocol 
o The PCR products were PCR purified, their concentration determined using 
the nanodrop before being diluted to 1011 fragments using the Avogadro 
constant. 
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2.3.3 qPCR reaction set-up  
 
The following negative controls were included:  
o non-template control (H2O + SYBR Green + primer) 
o no primer/no template control (H2O + SYBR Green). 
All qPCR reactions were carried out in triplicate. Reactions were set up on ice in each 
well as follows: 
o 2µl of cDNA 
o 2µl each of forward and reverse primer 
o 10µl SYBR® Green PCR Master mix (Applied Biosystems) 
o 6µl water (for a total reaction volume of 20µl) 
Reactions were carried out using a MJ Research PTC-200 Thermo Cycler.   
 
2.3.4 Thermocycler settings 
 
The MJ Research PTC-200 Thermo Cycler was set up as follows: 
o 1: Thermocycling begins with 95°C for 5 mins  
o 2: 55 cycles of amplification at 95°C for 10 sec,  
o 60°C for 6 sec,  
o 72°C for 6 sec  
o 76°C for 1 sec (data acquisition).  
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2.3.4 Real-time qPCR data analysis 
 
Relative mRNA expression ratios in the qPCR were calculated with respect to 
reference gene cycle-threshold (Ct) values, and then subjected to a two-way factorial 
(between-subjects) analysis of variance (ANOVA). Significant main effects and 
interactions were followed up with pairwise comparisons All test statistics were 
evaluated with respect to a type-1 error rate of 0.05. All descriptive statistics are 
reported as estimated marginal means ± SE unless otherwise indicated. 
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Chapter 3 
 
 
The conditioned place preference assay 
 
This chapter explores the conditioned place preference (CPP) assay as a means of 
measuring the rewarding effects of nicotine and other drugs of abuse. Its uses are 
explored in the literature before being tested on a range of compounds to assay the 
robustness of the procedure. 
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3.1 Introduction  
 
The aim of the project is to use a forward genetic screen in zebrafish to find genes 
affecting nicotine-seeking behavior in humans. It is based on the hypothesis that as 
zebrafish are vertebrate with conserved neurocircuitry of reward, homologues of 
genes that affect zebrafish drug seeking will also affect human drug seeking.  In order 
to demonstrate conservation of reward processes and therefore justify the use of 
zebrafish, the first results chapter of this thesis explores the zebrafish conditioned 
place preference assay as a means of demonstrating the conservation of reward 
responses to common drugs of abuse in zebrafish  
An organism’s likelihood of survival often hinges upon rapidly learning the 
conditions and the behavioral responses necessary to obtain natural rewards necessary 
for survival and propagation, as well as the environmental cues that predict them 
(Bell, Meerts, & Sisk, 2010; Collier, Khan, Caramillo, Mohn, & Echevarria, 2014; 
Lau, Bretaud, Huang, Lin, & Guo, 2006). Conditioned learning is primarily mediated 
by the motivational centers of the mesolimbic system, which are also readily activated 
psychoactive substances (Alderson, Robbins, & Everitt, 2000a, 2000b; Childress et 
al., 1999; Everitt & Robbins, 2005a, 2005b). Following the consumption of rewarding 
drugs, it rapidly becomes paired with a place or emotional state, due to integrated 
signaling to the memory and motivational centers of the limbic system (McLellan, 
Lewis, O'Brien, & Kleber, 2000). This pavlovian learning process means that 
exposure to cues associated with a drug may induce cravings and play a large part in 
the transition from casual drug use to more habitual and compulsive behaviors  
(Childress et al., 1999 Alderson et al., 2000 and Everitt and Robbins, 2005). The 
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identification and understanding genetic components that contribute to this particular 
facet of addictive behavior would be key to facilitating new treatment strategies. 
Conditioned place preference (CPP) is a form of pavlovian conditioning used 
to measure the motivational effects of objects or experiences (Tzschentke, 2007b). 
When drugs of abuse are applied to this paradigm, it can be used as a measure of their 
reinforcing properties. Animals are conditioned to associate drug exposure with 
specific environmental cues and a compound is considered rewarding if subsequent 
testing in the absence of the drug reveals a preference for the drug-paired cue. As 
such, it an ideal model for this particular conditioned learning component of 
addiction.  
This procedure is generally comprised of three testing phases that occur on 
consecutive days. During the first phase the animal is permitted to explore all 
compartments of the apparatus, and the time spent in each compartment is measured 
and used as baseline place preference. In the second phase, animals are sequentially 
restricted to each compartment for a period of time in which they receive either a drug 
or control treatment. In the final phase, the animal is once again allowed access to all 
compartments and final place preference is measured. Change in preference is 
calculated by subtracting the baseline place preference from final phase preference. If 
a significant change towards the experimental compartment is observed, CPP is 
established. 
Conventionally, rats and mice have been utilized while investigating the 
reinforcing properties of drugs, primarily due to them sharing a high degree of 
anatomical and genomic homology with humans (Lieschke & Currie, 2007). Another 
common model used in rodents for measuring the reinforcing properties of drugs is 
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the self-administration paradigm. Drug self-administration consists of recording the 
number of times an animal produces a response (a button/lever press) that results in 
an intravenous infusion of drug. There are also a number of differences between the 
models. CPP is able to provide a measure of both rewarding and aversive effects of 
drugs, while self-administration can only distinguish the latter. CPP utilizes classical 
conditioning requiring a maximum of 1 week training, whereas the operant 
conditioning of self-administration requires extensive training, which is not ideal for 
high throughput screening. Crucially, no surgery is required for CPP while self-
administration requires a catheter implantation, a procedure that would seem 
unfeasible in a zebrafish model. Another notable difference is that while both CPP 
and self-administration studies are in agreement with regards to the rewarding effects 
of a lot of drugs, including psychostimulants and opiates, some drugs produce CPP 
but may not be self administered (LSD, buspirone, and pentylenetetrazole), 
conversely, others show self-administration but do not induce CPP (pentobarbital and 
phencyclidine) (Bardo & Bevins, 2000). It is also apparent that the precise 
mechanisms that mediate drug-induced CPP and self-administration of a drug may 
differ. For instance, D2 receptor antagonists have minimal effects on the ability of 
cocaine to produce CPP, whereas self-administration for cocaine can be readily 
attenuated (Bardo, Valone, & Bevins, 1999). 
Rodents clearly provide a powerful model to investigate the reinforcing and 
rewarding properties of drugs using either the CPP or self-administration however, 
challenging husbandry, difficult developmental manipulation, and being unsuited to 
high-throughput screening impairs utility of rodent models. The zebrafish provides an 
opportunity to overcome these limitations utilizing a CPP paradigm. 
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An important methodological concern to consider in CPP studies is the 
whether the conditioning apparatus is biased or unbiased. A biased CPP relies on the 
apparatus being designed in such a way that subjects consistently display place 
preference for one compartment prior to conditioning (Tzschentke, 2007a). This is 
opposed to an unbiased design where animals do not display a significant initial 
preference for one stimulus before the conditioning phase of the procedure. The two 
manifestations of the procedure have been investigated in a mouse assay of ethanol 
place preference in mice (Cunningham, Ferree, & Howard, 2003) where both designs 
were utilized. Using the biased apparatus, CPP was only observed when ethanol was 
paired with the non-preferred side. However, when using the unbiased apparatus CPP 
was observed regardless of which side the ethanol was paired with. It is therefore 
important to consider apparatus design when evaluating the rewarding effects drugs 
with the unbiased design being the most predominately used method.  
Previous work has shown that widely abused compounds such as cocaine 
(Darland & Dowling, 2001), amphetamine (Ninkovic et al., 2006), nicotine and 
ethanol (C. H. Brennan et al., 2011; L. J. M. Kily et al., 2008), morphine (Lau et al., 
2006) are rewarding in zebrafish, reliably inducing CPP in a variety of manifestations 
of the procedure. Nicotine has previously been reported to be reinforcing in zebrafish 
(C. H. Brennan et al., 2011; L. J. M. Kily et al., 2008) using an un-biased conditioning 
paradigm and a tank divided into equal zones with distinct spot versus stripe 
environmental cues.  In order to assess the robustness of this assay and the 
conservation of reward pathways in zebrafish, CPP responses of adult zebrafish to a 
range of compounds from different classes of commonly abused drugs were 
determined.  The compounds tested were the stimulants nicotine, amphetamine and 
caffeine, the opiate fentanyl and the general anesthetic phencyclidine (PCP).   
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3.2 Material and Methods 
 
3.2.1 Test subjects 
 
All zebrafish were bred and reared in our aquarium facility according to standard 
husbandry protocols outlined in chapter 2 of this thesis. Fish were housed in a 
14h:10h light:dark cycle (08:30am–22:30pm). All fish were 3-5 months old at the 
start of testing. The housing and testing rooms were maintained at ~25–28◦C. Fish 
were fed 3 times daily with live artemia (twice daily) and flake food (once).  Fish 
were housed in aquarium water consisting of de-ionized water with added salts. All 
procedures were carried out under the Animals (Scientific Procedures) Act, 1986, and 
under local ethical guidelines.  
 
3.2.2 Conditioned place preference assay 
 
CPP was carried out in opaque rectangular tanks of dimensions (l x w x h) of 33cm x 
16.5cm x 17cm with a central removable plastic divider (Fig 3.1) containing 3L of 
water. Both ends of the tank have distinct visual cues; one end “spots” has 1.5cm 
diameter black spots uniformly dispersed on all sides and the other end, “stripes”, has 
0.6cm wide black and 2.1cm wide white stripes.   
The fish to be tested were singly housed in individual tanks on a re-circulating 
system (Techniplast) for 3 days prior to habituation to the testing apparatus. On the 
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fourth day individual fish were placed in the testing tank in 3L of system water and 
allowed to swim freely (without the divider) for 10-20min. Fish were then returned to 
their single housing for the weekend. On the Monday a baseline preference was read; 
fish were individually placed into the CPP tanks, without a divider, for a ten-minute 
period and tracked real-time using an overhead camera connected to a PC running 
Ethovision software (Noldus, UK). Videos were routinely saved for record and future 
re-analysis. The baseline preference for each fish was determined by the time spent in 
either spots or stripes side over the second 5 minute period (min 5-10 of the 10min 
period). This time period was used to minimise variation in swimming behaviour due 
to stress responses on initial placement in the tank (fish habituate to a novel 
environment over a 5 min period (Parker et al, 2012). Entry into a side was defined as 
the mid point of the fish body over the mid-line of the tank. Any fish that had a 
baseline preference for one side over 80% was excluded from the study. 
Fish that had a baseline preference of less than 80% were pseudo-randomly 
sorted into 5 groups such that all groups had approximately the same basal preference 
that was as close to 50% as possible with each group having approx. equal in-group 
variance.  Fish were conditioned to one of the 5 doses (4 drug concentrations plus a 
vehicle control) on each of three consecutive days.  For conditioning, fish were placed 
individually into the testing tank and restricted to their preferred side (the side where 
they spent the majority of time during the basal preference test) for 20min.  After this 
time the divider was lifted and the fish allowed (or shepherded) to enter the least 
preferred side where it was restricted for the following 20min whilst exposed to the 
test compound: Once the fish had entered the least preferred side the divider was 
replaced and the drug administered. Drugs were administered in a volume of 50ml 
system water that was equally divided between the two halves of the tank to minimise 
Chapter 3 
 88 
the establishment of concentrations gradients across the tank. Drugs were poured 
gently into the tank down the divider. Each drug was tested at four concentrations, 
with a vehicle control group (i.e. fish water), to determine a dose-response curve. 
After 20min the fish was returned to its housing tank. 
  After 3 days of conditioning any change in preference was determined using a 
probe trial; Similarly to the baseline reading, the fish were placed in the testing tank 
in the absence of divider and filmed over a 10 min period. The time spent in either 
end of the tank in the second 5 min (min 5-10 of the whole period) was determined. 
Results were then calculated as a change in preference (proportion of time spent in 
drug-paired side after conditioning minus proportion of time spent in drug paired side 
before conditioning). Drugs were considered rewarding if they induced a change in 
preference at any dose that was significantly greater than vehicle controls.   
 
Figure 3.1: CPP tank in zebrafish CPP assay. Overhead view of CPP chamber with removable 
Plexiglas divider and visual cues on either end of the tank. Tanks are 33x16.5cm in dimension and hold 
3 liters of water. 
 
 
Chapter 3 
 89 
3.2.3 Conditioned place preference data analysis 
 
The data extracted included distance travelled and time spent in the vicinity of the 
spots and stripes. Data from the first preference test were extracted to determine basal 
preference for spots or stripes. Fish that fell outside this criterion were excluded from 
conditioning training. The proportion of time spent in the vicinity of each of the 
stimuli (i.e., for spots, Timespots/(Timespots+Timestripes)). Following conditioning, probe 
trial data (again, including distance travelled and time spent in vicinity of spots and 
stripes) were extracted, and the time spent in the vicinity of spots and stripes was 
again calculated as a proportion of total time. The proportion of time spent in the 
vicinity of the least preferred stimulus during basal (i.e., the subsequently drug-paired 
cue) was the subtracted from the proportion of time spent by the drug-paired cue 
during the probe trial to produce a single preference change score for each fish. The 
change in preference scores was subjected to both linear and polynomial regressions, 
with dose as the predictor and change in preference as the response variable. To 
assess the model fit, the model with the highest adjusted (corrected) R2 value was 
chosen. The p-values were then compared for each of the regression coefficients to 
ascertain the best fit of the data. Statistical significance for dose of each drug affecting 
change in preference was set at α=0.05 with the data being analysed in SPSS 21 for 
Macintosh. 
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3.2.4 Toxicity testing 
 
Compounds were assessed for effects on pH before use.  None of the compounds used 
caused a significant change in pH at the dilutions used (pH range 7.0-7.5). Prior to 
CPP analysis, all compounds were assessed for potential toxic effects on the fish: 5 
fish were exposed to the proposed highest dose in a volume of 500ml for 20min and 
observed for signs of toxicity – hyper respiration, difficulty in swimming, subsequent 
death. 
 
3.2.5 Drugs and doses 
 
Table 3.1 lists the compounds tested, supplier and dose range. Dose ranges were 
based on previous zebrafish studies or those found to be reinforcing in rodent and 
with maximum of double the mammalian effective dose. Compounds with no known 
reinforcing properties were tested at similar ranges to those used in mammals.  All 
compounds were made up as stock solutions in water and stored frozen where 
applicable.  Compounds were diluted from frozen and added in a volume of 50ml of 
fish water 10 min prior to use.  
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3.2.6 Nicotine treatment and preparation of brain samples 
 
Fish were placed in 1L tanks containing 5 µM nicotine for a duration of either 5, 10 or 
20mins. At each time point, fish were removed and killed using an ice bath, at which 
point the brain was dissected. Brains were pooled at 3 brains per microfuge tube (2 
tubes per time point) and homogenizing in 0.1M HCL before storing at -20 oC. 
 
3.2.7 Determining nicotine brain concentrations 
 
Samples were analysed by high performance liquid chromatography (HPLC) by Mira 
Doig at ABS Laboratories, Welwyn Garden City, Hertfordshire UK. 
Sample was thoroughly mixed with 1.4 mL of 0.5 mol/L sodium hydroxide. Samples 
were then transferred to prepacked Extrelut®-3 glass columns (Merck KGaA). The 
columns had been washed with 15 mL of dichloromethane and left to dry overnight 1 
day before analysis. 
The analytes were introduced to the MS detector by injecting 20 μL of sample 
through a HPLC system consisting of an Alliance 2690 separations module (Waters) 
connected to a μBondapak C18 2 × 300 mm column (particle size, 10 μm; Waters) 
operated at 30 °C Samples were separated isocratically, using a methanol-acetonitrile-
aqueous buffer solvent system (see above) at flow rate 0.5 mL/min. Runtime was 15 
min.  
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3.3 Results 
 
3.3.1 Analysis of baseline 
 
Before continuing on to drug testing, it was important to establish the validity of the 
exemplars in use. If the zebrafish shows significant preference for one or the other 
they cannot be justifiably used in the CPP model. The fish had their preference 
baseline measured, followed by 3 days conditioning to saline, then a ‘probe’ 
measurement was taken. The results show the fish (n=20) to have a baseline 
preference of 0.53 for ‘stripes’ and a baseline of 0.47 for ‘spots’ while in the ‘probe’ 
trial a preference of 0.46 for ‘spots’ was observed. There was no significant difference 
in preference for either exemplar between the two trials (T-test, P=0.59), indicating 
the conditioning process to have no effect on basal preference. 
 
Figure 3.2: Baseline and probe for saline treated fish. Analysis of baseline for n=20 fish showed a 
preference of 0.53 for ‘stripes’ and a preference of 0.47 for ‘spots’ with the ‘probe’ fish showing a 
minimal change to 0.46 for ‘spots’ with there being no significant difference in preference for either 
exemplars between the two trials (T-test, P=0.59). 
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3.3.2 CPP results 
 
A total of 5 compounds (including nicotine) were tested at 4 doses in the CPP 
paradigm and all of the compounds showed statistically significant dose-dependent 
induction of place preference. The drugs that were tested were the stimulants nicotine 
(p=0.01), amphetamine (p=0.02), caffeine (p=0.01), the opioid compound fentanyl 
(p=0.01), and the general anesthetic PCP (p=0.03). Nicotine showed a dose dependent 
CPP over a range of 0.5 – 10 µM with a maximum occurring at 5 µM. Statistical 
analysis showed this to be significant when analyzed using both a linear (P=0.01) and 
polynomial (P=0.01) regressions. Post-hoc t-tests showed only the 5 µM to be 
significant from control. Amphetamine showed CPP over a range of 2.5 – 15 mg/L 
with the greatest preference change occurring at a dose of 10 mg/L. This was 
significant when analyzed with both linear (P=0.01) and a polynomial (P=0.01) 
regression. The 5 mg/L dose was shown to be significantly different from control 
post-hoc. Caffeine gave a dose response curve over a range of 5 – 50 mg/L with a 
maximum change at 10 mg/L. This was significant when analyzed using both a linear 
(P=0.01) and polynomial (P=0.01) regressions. However there were no individual 
doses significantly different from control post-hoc. Fentanyl showed dose dependent 
CPP over a range of 0.004 – 0.16 mg/L with the highest response being at 0.04 mg/L. 
This was significant when analysed using both a linear (P=0.01) and polynomial 
(P=0.02) regressions. The 0.016, 0.04, 0.16 mg/L doses were all significantly 
different from controls. PCP showed a dose dependent response over a range of 0.1 – 
1 mg/L with 1 mg/L being the highest.  
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Figure 3.3: Nicotine dose response curve. Nicotine was shown to be highly reinforcing and was 
significant when analyzed using both a linear (P=0.01) and polynomial (P=0.01) regressions. There 
was a peak change in preference at a dose of 5µM, which was significant when compared with saline 
vehicle (p=0.04). 
 
 
Figure 3.3: Amphetamine dose response curve. Amphetamine was highly reinforcing with the 10 
mg/L dose showing the highest CPP. The dose response curve was significant when analyzed with both 
linear (P=0.01) and a polynomial (P=0.01) regression. 
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Figure 3.4: Caffeine dose response curve. Caffeine was shown to be highly reinforcing with the 
10mg/L dose showing the highest CPP. The caffeine dose response was significant when analysed 
using both a linear (P=0.01) and polynomial (P=0.01) regressions.  
 
       
Figure 3.5: Fentanyl dose response curve. Fentanyl was shown to be highly reinforcing with the 0.04 
mg/L dose showing the highest CPP. The caffeine dose response was significant when analysed using 
both a linear (P=0.01) and polynomial (P=0.02) regressions. 
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Figure 3.6: Phencyclidine dose response curve. Phencyclidine was shown to be reinforcing with the 
1mg/L dose showing the highest CPP. The caffeine dose response was significant when analysed using 
a linear regression (P=0.01) but not by polynomial (P=0.01). 
 
 
3.3.3 Nicotine brain concentrations 
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After 10 mins exposure brain concentration rose to 0.77 uM, while after 20 mins 
exposure brain concentration was at 1.26 uM. 
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Figure 3.7: Zebrafish nicotine brain concentrations. Graph showing the brain concentration (n=2 
for each time point) of nicotine in adult zebrafish brains when submerged in water containing nicotine 
at 5 uM for 5, 10 and 20 minutes.   
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3.4 Discussion 
 
3.4.1 Nicotine 
 
The results gave a typical dose response curve, with a peak at 5 µM which was 
significant when analyzed with both a linear and polynomial model. The only dose 
significant in post-hoc tests was the 5 µM. As such, 5 µM was selected as the dose to 
be administered for the mutagenesis screen in the next chapter of this study.  
 The average blood concentration for a typical smoker (both male and female) 
varies between 0.004 and 0.72 µM with an average concentration of 0.2 µM (Russell, 
Jarvis, Iyer, & Feyerabend, 1980). Since the 5 µM present in the water here would be 
lethal in humans if a corresponding blood concentration was reached (Mayer, 2014) it 
was important to determine the rate of nicotine uptake in the fish to identify whether 
the dose being used was translationally relevant. In zebrafish, after 5 mins exposure to 
5 µM nicotine brain concentrations were at 0.5 µM, after 20 mins an accumulation of 
nicotine was observed with a brain concentration of 1.26 µM recorded. This is in 
concordance with approximate brain concentrations you would find in humans who 
show similar rates of nicotine accumulation using PET scans and 11C-nicotine loaded 
cigarettes (Rose et al., 2010). 
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3.1.2 Caffeine 
 
Caffeine is a stimulant compound belonging to the xanthine class of chemicals 
naturally found in coffee, tea, and chocolate making caffeine the world's most widely 
used psychoactive drug. Caffeine's mechanism of action differs from that of most 
other addictive drugs by being an adenosine receptor A1 and A2A antagonist. 
Adenosine A1 receptors are presynaptic and reside in many areas of the brain, 
including the cerebral cortex and hippocampus, where they inhibit the release of 
dopamine, glutamate, and acetylcholine (Fisone, Borgkvist, & Usiello, 2004). 
Adenosine A1 and dopamine D1 and receptors also form functionally interacting 
heteromeric complexes providing another means by which caffeine may affect DA 
signaling (Svingos, Colago, & Pickel, 1999). 
The results showed caffeine to be reinforcing at 10-20 mg/l. Previous research 
has shown that low doses (1–10 mg/kg) of caffeine are reinforcing for CPP in rats, 
while high doses (20–30 mg/kg i.p.) are aversive (Bedingfield et al. 1998). 
 
3.1.2 Amphetamine 
 
Amphetamine is a potent psychomotor stimulant that is commonly used in the 
treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. 
Amphetamine exerts its psychoactive properties by diffusing into dopaminergic cells 
via the dopamine transporter (DAT), which are found pre-synaptically and is 
responsible for removing dopamine from the synaptic cleft. Once amphetamine has 
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diffused into dopaminergic cells, it indirectly causes phosphorylation of DAT. This 
alters the directionality of DAT, meaning there is no dopamine reuptake but instead 
there is dopamine release into the presynaptic cell. It also pushes dopamine out of the 
vesicles in the presynaptic cell, which in turn is released through the reversed DAT. 
These processes are cumulative and result in increased dopamine levels in the synapse 
by pushing dopamine out the presynaptic cell and blocking reuptake. At high doses 
amphetamine has been shown to also inhibit monoamine oxidase-A (MAO-A) 
reducing dopamine degradation (D. E. Clarke, Miller, & Shore, 1979; Ramsay & 
Hunter, 2003).  
The results for amphetamine and caffeine also validate previous reports that 
stimulants are reinforcing in zebrafish, as they are often are in humans and rodents 
(O’Connor et al. 2011). Amphetamine, has been shown in previous CPP studies to be 
reinforcing in adult zebrafish (Collier & Echevarria 2013), and in rats intravenous 
injections of amphetamines exhibit a conditioned place preference at a range of 1–3 
mg/kg of the drug (Bardo et al., 1999).  CPP has also been observed with intracranial 
injections and intracerebroventricular injections rodents (Gerdjikov & Beninger, 
2006; O'Dell, Sussman, Meyer, & Neisewander, 1999).  
 
3.1.3 Fentanyl  
 
Fentanyl is a potent, synthetic opioid analgesic with a rapid onset and short duration 
of action, mainly due to being a strong agonist at the μ-opioid receptors (MOR). 
Activation of μ-opioid MORs, which are located predominantly on GABAergic cells 
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in the VTA (Dilts & Kalivas, 1989; S. W. Johnson & North, 1992; Svingos et al., 
1999) selectively hyperpolarizes GABAergic interneurons, thereby disinhibiting DA 
neurons and increasing dopamine release (Di Chiara & Imperato, 1988; S. W. 
Johnson & North, 1992). A variety of opiates have been demonstrated to produce CPP 
in animal models including morphine and heroin (Ashby, Paul, Gardner, Heidbreder, 
& Hagan, 2003; Cicero, Ennis, Ogden, & Meyer, 2000; L. A. Parker, Corrick, 
Limebeer, & Kwiatkowska, 2002; Paul, Dewey, Gardner, Brodie, & Ashby, 2001), 
while fentanyl has been shown to induce CPP at 56 μg/kg in rodents (Suzuki et al., 
2005). 
Opiates are known to have strong rewarding properties in both humans and 
rodents. Fentanyl was also shown to be significantly reinforcing in zebrafish. Two 
independent studies on fentanyl have shown that concentrations of 0.004 and 0.016 
mg/kg, in Sprague-Dawley and Long Evan rats respectively, are reinforcing in adult 
male rats using CPP (Miller & Nation 1997; Vitale et al. 2003), and this is in 
agreement with the zebrafish results that show  reinforcement at between 0.004-0.04 
mg/l. 
 
3.1.4 Phencyclidine (PCP) 
 
Phencyclidine, more commonly abbreviated to PCP is a recreational 
dissociative anesthetic, whose main mechanism of action is as an NMDA receptor 
antagonist (Giannini, Loiselle, Giannini, & Price, 1985). PCP also shows similar 
affinity to 5-HT receptors as it does for NMDA, while also showing partial agonism 
at the D2 receptor (Kapur & Seeman, 2002).  
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In the zebrafish model, PCP (0.1-1 mg/L) induced place preference. In the 
literature there are mixed reports of reinforcement for rodents using PCP.  PCP dose-
dependently produces place aversion at 4 and 8 mg/kg in rats and mice (Noda & 
Nabeshima 1998; Noda et al. 1998). Place aversion is governed by the same 
principles at place preference except the testing animal associates the visual cues with 
a negative stimulus (the drug in this case). However at lower doses (comparable with 
the doses used in this study) PCP has also been shown to produce reinforcement in 
rodents when administered at a smaller dose (0.45 mg/kg) with shorter exposure 
duration (Marglin et al. 1989).   
 
3.1.5  Summary 
 
It was noted during baseline filming that a proportion of fish (~10%) showed 
large preferences of one of the paired stimuli. Despite habituating subjects to the 
testing apparatus the week before, when a test subject is added to the testing tank for 
baseline measurement a freezing response can occur during initial filming. It was for 
this reason that the last 5 minutes of the total 10 minutes trial was only used as a 
measure of baseline. This minimized subject loss due to freezing behavior for the 
most part. Any fish that showed persistent freezing, or an extreme bias for either cue 
with a basal preference greater than 0.75 was omitted from further testing. Removing 
these subjects from further analysis was important in minimizing the possibility of 
habituation responses being misinterpreted as drug-induced CPP.   
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Overall the results indicate a good degree of correlation between results found 
in zebrafish CPP and mammalian self-administration and/or CPP assays. Since the 
assay has been shown to induce robust CPP with multiple drugs, it should be sensitive 
enough to pick up genetic variations that may affect the sensitivity of zebrafish to 
rewarding properties of nicotine. As such, it can be implemented in the population 
mutagenesis strategy discussed in the next chapter.  
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Chapter 4 
 
 
A behavioral genetic screen for nicotine 
reward in zebrafish.  
 
With the parameters of the CPP assay defined and validated, this chapter explores 
using the assay to screen mutagenized zebrafish for mutations affecting nicotine-
induced reward.  
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4.1 - Introduction 
 
Human genome-wide association studies (GWAS) have identified a number of 
alleles associated with tobacco use and response to cessation treatment (Brock, 
Takeda, Brennan, & Walton, 2011; Caporaso et al., 2009; J. Z. Liu et al., 2010; Y. Z. 
Liu et al., 2009; Siedlinski et al., 2011; Thorgeirsson et al., 2008; Thorgeirsson et al., 
2010; Tobacco & Genetics, 2010). The majority of the genes showing high statistical 
associations with smoking behaviors are those in the cholinergic receptor gene 
clusters, variants in acetylcholine pathways and those in dopaminergic pathways 
(Saccone, Saccone, et al., 2009; Saccone, Wang, et al., 2009) (W. Berrettini et al., 
2008; Tobacco & Genetics, 2010). However, despite the high concordance rates for 
smoking, only a fraction of the variation can be explained by candidate genes 
identified from GWAS analysis (M. Munafo, Clark, Johnstone, Murphy, & Walton, 
2004). Although animal models cannot replicate all the complexities of human 
smoking, they can help with the identification of genetic factors influencing various 
components of addictive behavior such as reward sensitivity, consumption, persistent 
drug taking, and relapse. As mentioned in the previous chapter, zebrafish have been 
show to respond to the rewarding effects of substances by demonstrating CPP to a 
number of drugs including nicotine. Sensitivity to the rewarding effects of nicotine is 
one facet of smoking behavior and as such CPP can be used to screen lines of 
zebrafish for genetic variants that affect that behavior. 
By using animal models, it has been possible to track naturally occurring 
variations in genes using breeding and selection to identify genetic variants that 
Chapter 4 
 106 
segregate with behaviours of interest. These studies are obviously limited by both the 
numbers of important variants that occur naturally and by the severity of the 
phenotype they induce, meaning a number of important loci are likely to be missed. 
Mutagenesis is a technique that can introduce 1000s of point mutations into the 
genome thus dramatically increasing variation and potentially inducing mutations 
affecting the phenotype of interest.  
Large-scale mutagenesis screens have facilitated forward genetic strategies for 
identifying the role of genes in behaviour (Hrabe de Angelis et al., 2000; Nolan, 
Hugill, & Cox, 2002). Nolan et al. reported a large study in which phenotype-driven 
mutagenesis was used in the identification of novel genes and pathways utilizing a 
mouse model. Over 26,000 mice were generated and screened, with some 500 new 
dominant mouse mutants recovered (Nolan et al., 2000). However, the mouse is a 
relatively expensive and complex model organism to use, and along with relatively 
long generation gaps and small litter sizes, this makes in vivo genome-wide genetic 
approaches impractical in many important scientific scenarios (Sivasubbu, Balciunas, 
Amsterdam, & Ekker, 2007).  
In contrast, chemical ethylnitrosurea (ENU) mutagenesis has been used to 
great effect in zebrafish and has led to the generation of large numbers of fish lines 
carrying multiple mutations. The external fertilization, high fecundity, rapid 
development, and production of optically clear embryos, and relatively short 
generation time allows for high throughput screening of the development and 
behavior of these mutant lines, offering a significant refinement on mouse models. 
Recently zebrafish have gained interest as a behavioural model raising the possibility 
of performing a forward genetic screen in zebrafish for drug seeking behaviour. 
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Zebrafish are an extremely effective model for investigating genetic factors that 
contribute to drug seeking behaviour and as such, are increasingly being used to 
address these questions.   
So far, advances in our understanding have relied heavily on hypothesis driven 
and candidate gene approaches. However, by utilising these large-scale mutagenesis 
approaches in zebrafish, it is not necessary to know the genes or pathways involved in 
advance. Such approaches are more likely to lead to novel and unexpected 
breakthroughs and lead to greater leaps in our understanding of genes and pathways 
the contribute to disease (Panula et al., 2010). This is particularly important when 
investigating genetic factors which may contribute to complex neurological disorders 
like addiction, as due to the complex neural pathways involved there is unlikely to be 
one or two genes of large effect, but rather a combination of multiple genes of 
variable penetrance and additive effect. Such factors are unsuited to more traditional 
reverse genetics experiments, as subtle differences in naturally occurring genes of 
minor effect will fail to segregate with behaviour due to the subtle phenotypes they 
confer. However, by introducing a gene breaking mutation by ENU, genes of 
previously minor effect will have greater penetrance and be selected for in a 
population screen. This way genes are selected for that would previously be masked 
in studies of this type. 
Mutagenesis studies in zebrafish have been used to good effect in the past. In a 
special issue of Development in 1996, 37 papers presented the results of two large 
zebrafish mutagenesis screens performed in Tübingen and Boston (Nusslein-Volhard, 
2012). Around 1500 mutations in more than 400 new genes were identified, involved 
in processes such as development and organogenesis. Up to this day, the mutants 
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provide a rich resource for many laboratories studying embryogenesis, neuronal 
networks, regeneration and disease. Christiane Nüsslein-Volhard’s lab performed a 
large scale mutagenesis screen which resulted in the identification of approximately 
1,000 mutants affecting processes such as early development, organ formation and 
axonal pathfinding (Brand, Heisenberg, Jiang, et al., 1996; Brand, Heisenberg, 
Warga, et al., 1996; Haffter, Granato, et al., 1996; Haffter & Nusslein-Volhard, 1996; 
Haffter, Odenthal, et al., 1996; Hammerschmidt et al., 1996; Heisenberg et al., 1996; 
Odenthal et al., 1996; van Eeden, Granato, Schach, Brand, Furutani-Seiki, Haffter, 
Hammerschmidt, Heisenberg, Jiang, Kane, Kelsh, Mullins, Odenthal, Warga, 
Allende, et al., 1996; van Eeden, Granato, Schach, Brand, Furutani-Seiki, Haffter, 
Hammerschmidt, Heisenberg, Jiang, Kane, Kelsh, Mullins, Odenthal, Warga, & 
Nusslein-Volhard, 1996; Whitfield et al., 1996). Wolfgang Driever’s group also 
presented data from a similar ENU mutagenesis strategy to screen F3 embyos from 
over 2000 families for developmental abnormalities. A total 2383 mutations resulting 
in abnormal embryonic phenotypes affecting pigmentation, motility, muscle and body 
shape were identified (Abdelilah et al., 1996; Driever et al., 1996; Malicki, Neuhauss, 
et al., 1996; Malicki, Schier, et al., 1996; Neuhauss et al., 1996; Pack et al., 1996; 
Schier et al., 1996; Solnica-Krezel et al., 1996; Stainier et al., 1996; Stemple et al., 
1996; Weinstein et al., 1996). More recently, a rapid total coagulation activity (TCA) 
assay has been used to screen ENU mutants for coagulation defects in individual adult 
zebrafish (Jagadeeswaran, Gregory, Johnson, & Thankavel, 2000), by screening 1000 
lines of these mutant fish, 6 lines were identified with defective clotting.  
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4.1.1 - Experimental design 
 
The fish used in this screen were obtained through the Welcome Sanger Trust 
as part of the zebrafish mutation project, an open resource in which they seek to 
identify, phenotype and distribute a large number of mutant zebrafish lines. The aim 
of the Sanger project is to identify mutations in the zebrafish using whole exome 
sequencing, outcrossing followed by re-sequencing until stable lines containing a 
single mutation in a coding region are generated. Mutants are analysed for 
morphological and molecular differences and distributed to the community upon 
request. Through collaboration with the Sanger we obtained a number of these ENU-
induced mutant lines at the F2 stage, before the process of outcrossing (Figure 2.1). 
As a result, the fish have thousands of mutations across the genome including 
functional mutations in between 10 to 15 coding regions. This means that with F1 
outcrossing followed by an F2 incross there can conservatively by up to 3.75 
mutations for every F3 family generated. Since 30 lines were generated, it can 
reasonably be estimated that around 112 mutations were included in the first F3 
screen. The high numbers of SNPs combined with mutation in known coding regions 
make these fish ideal candidates for participation in a mutagenesis screen. The F2 
siblings can then be inbred to generate F3 fish with these high numbers of SNPs 
(figure 4.1). The first reason F3 lines were generated, is so that lines could be 
generated with fish of similar age (within three months). This minimizes any age 
related effects that may contribute to varied nicotine response. It also means that the 
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screen will theoretically be able to pick up any recessive phenotypes, which may 
present themselves. 
 
Figure 4.1: Strategy to generate F2 families with multiple gene breaking mutations as outlined on the 
Sanger website (http://www.sanger.ac.uk/Proj ects/D_rerio/zmp/). After this genotyping and 
outcrossing will be used to generate lines containing a functional mutation in one gene. For this project 
the lines were obtained before outcrossing, meaning the fish in the screen have multiple gene-breaking 
mutations as well as a number of markers in non-coding regions. 
 
The ‘Humphrey Bogart’ (HumBog) line, which has previously displayed 
decreased locomoter response to nicotine (Petzold et al., 2009), was included in the 
screen as a positive control. The line contains a gene breaking transposon in the 
gabbr1.2 gene, which codes for the GABAB receptor, responsible for inhibiting the 
release of GABA, which is a major inhibitory neurotransmitter in the VTA. A knock 
out at this locus would essentially increase dopaminergic transmission by reducing 
GABA mediated inhibition of dopamine neurons. 
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Using this experimental design, distinct lines can be generated over 4 
generations, with screening and selecting fish at the extremes resulting in families that 
carry mutations affecting nicotine CPP. The screen may pick up dominant or 
recessive mutations of major effect, which can be verified by screening outlier 
siblings. The continued selective breeding allows the amalgamation of alleles of 
lesser effect to generate multiallelic phenotypes. Once these distinct lines are 
generated the possibility exists in the future to perform highly detailed SNP-mapping 
procedures to identify SNPs associated with increased and decreased reward seeking 
behavior.  
 
4.1.2 - Screening for persistent CPP and relapse 
 
While drug-induced reinforcement can be assessed easily using a CPP paradigm, drug 
addiction is much more complex and multi-faceted encompassing a range of elements 
including compulsive drug seeking, relapse, loss of control/impulsivity, and continued 
compulsive drug seeking (Sanchis-Segura & Spanagel, 2006). While it is impossible 
to model addiction (an exclusively human behavior) in its entirety in a lab 
environment, specific elements of addictive behavior have been adequately modeled. 
Therefore it would be ideal to screen the mutant lines for multiple behaviors 
influencing addiction where possible. Since differing neural pathways control these 
behaviors, there are going to be different subsets of genes involved. 
The primary aims of this study are to show the CPP paradigm to be 
sufficiently sensitive to detect Humbog mutant clustering and use the lines provided 
by the Sanger Institute and screen them for nicotine reward to identify families that 
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may house dominant or recessive mutations and to determine if CPP in zebrafish 
shows significant heritability as in humans. If heritability is established, breeding and 
selection will be carried out to generate families containing dominant and recessive 
genotypes influencing behavior. The protocol will also be expanded to allow an 
additional screening for persistent CPP that lasts following a period of abstinence or 
in the face of an adverse stimulus. Assaying for CPP in this way acts as a model for 
both drug reward and drug dependency, an important factor process of addiction, and 
would allow for selection of mutations encompassing additional components of 
addictive disorders.  
Continued seeking and taking of drugs despite adverse legal, health, 
economic, and societal consequences is a central hallmark and most debilitating 
aspect of human drug use disorders (Koob & Volkow, 2010; Tiffany & Conklin, 
2000). As such, a pre-clinical model of this compulsive drive for drugs has been 
modeled in rodents using cocaine and ethanol (Deroche-Gamonet, Belin, & Piazza, 
2004; Hopf, Chang, Sparta, Bowers, & Bonci, 2010; Lesscher, van Kerkhof, & 
Vanderschuren, 2010; Vanderschuren & Everitt, 2004). In rodent models, drug taking 
is considered ‘compulsive’ when extended drug-taking history renders drug seeking 
impervious to adverse stimuli such as signals of punishment (Vanderschuren & 
Everitt, 2004). 
Normally drug-seeking behavior can be readily suppressed by aversive 
environmental stimuli (Kearns, Weiss, & Panlilio, 2002; Killcross, Robbins, & 
Everitt, 1997), this is known as conditioned suppression. Heyne and Wolffgramm 
showed this conditioned suppression to be abolished after long periods of voluntary 
drug consumption even when the drug was administered with a bitter quinine flavor. 
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This observation demonstrated persistence in drug consumption regardless of the 
adverse consequences associated with it. 
Kily et al. described a zebrafish version of the aforementioned rodent 
paradigm of persistent drug seeking despite adverse consequences, the model that will 
be used here. As a continuation of the normal CPP procedure (baseline; 3 
conditioning sessions; probe trial) the zebrafish were conditioned for a further 3 week. 
Subjects were then placed in the testing apparatus and punished when entering the 
drug paired side, first by restriction (mild punishment) and secondly by removing 
from the tank by netting (severe punishment). The number of times the subjects 
persisted with entering the drug-paired side despite negative reinforcement was taken 
as a measure of compulsive drug seeking period (L. J. Kily et al., 2008). 
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4.2 - Materials and Methods 
 
4.2.1 – Fish housing 
 
Fish were housed in a 14h:10h light:dark cycle (0830–2230). All fish were 3-5 
months old at the start of testing. The housing and testing rooms were maintained at 
~25–28◦C. Fish were fed 3 times daily with live artemia (twice daily) and flake food 
(once).  Fish were housed in aquarium water consisting of de-ionized water with 
added salts. All procedures were carried out under the Animals (Scientific 
Procedures) Act, 1986, and under local ethical guidelines (Queen Mary University of 
London).  
 
4.2.2 - Breeding strategy to generate F3 lines for screening 
 
The zebrafish lines included in the experiment were all generated at the Sanger 
Institute, as part of the Zebrafish Mutation Project. F2 siblings, heterozygous for a 
number of gene-breaking mutations (generated using the breeding strategy in figure 
4.2) were obtained and inbred to generate F3 lines as to allow the inclusion of 
homozygous mutations in to population screen. Each F3 family was created from a 
different F2 family that has different F1 parents. A total of 100 ENU-induced F3 
mutant zebrafish were initially selected for screening. Both male and female 
individuals were selected as evenly as possible from 30 distinct lines (3-4 fish from 
each line), each containing between 10-15 known mutations in coding regions and a 
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large number unknown mutations across the entire genome (based on an expected 
mutation rate of 1/300 kb in the F0 founder fish (D. Stemple, personal 
communication). All fish were removed from their colonies, and housed individually 
in 29.7 x 15.2 cm tanks 1 week before commencing, and during the behavioral 
screening. Following the completion of the CPP screen the individuals in the upper 
and lower 5% of the change in preference distribution curve with the top and low 5% 
change scores were kept for analysis and further inbreeding, all remaining fish were 
terminally anesthetized by immersion in MS-222. As a positive control, 5 individuals 
from the ‘Humphrey Bogart’ line containing an insertion in intron 6 of the zebrafish 
gabbr1.2 gene were included in the screen were. The ‘Humphrey Bogart’ line has 
previously displayed a decreased nicotine response profile in a larval motility assay 
(Petzold et al., 2009). 
 
Figure 4.2: Breeding strategy. A general overview of the crosses used to obtain the F3 fish used in the 
mutagenesis screen. At the Sanger Institute, male sperm was mutagenized and used to fertilize wild-
type female oocytes. The resulting F1 were then outcrossed again to generate F2 fish. After generating 
an F3 in-cross, the fish were then screened for nicotine reward in the CPP paradigm. Both male and 
female individuals were selected as evenly as possible from 30 distinct lines (3-4 fish from each line), 
each containing between 10-15 known mutations in coding region.  
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4.2.3 - Conditioned place preference (5µM Nicotine) 
 
The conditioned place preference procedure was carried out in the same tank as 
before (W x L x H; 16.5cm x 33cm x 15 cm) and containing 3L water. The visual 
cues (black spots or black vertical lines) were located on the walls of the tanks (see 
Figure 3.1). One day prior to the start of the experiment (on Thursday) fish were 
singly housed. Of the 30 families included in the screen, 4 individuals were selected 
from each to make a total of 120 fish. The experiment began the following day 
(Friday), all fish were first placed in the conditioning tanks (including exemplars), 
with no nicotine added, for a period of 40 mins. CPP procedure was carried out as 
previously mentioned in chapter 3. 
 
4.2.4 Persistent CPP despite adverse stimuli  
 
The subjects used in the CPP were conditioned for a further 4 weeks, at which point 
the effect of punishment as well as restriction on the number of returns made to the 
drug treatment side over a 10 minute period was determined. Zebrafish were placed in 
the conditioning apparatus, afforded a 5-minute habituation period and then each time 
the fish entered the side to which they were conditioned to nicotine, the subject was 
restricted to the non-drug-treatment side for 30 seconds using a white plastic divider. 
After 30 seconds the divider was removed and the fish allowed free access to the 
whole tank. The number of returns made over a 10-minute period was determined. An 
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hour later each fish was returned to the testing apparatus, allowed 5 min to settle and 
then each time the fish entered the drug treatment side it was removed from the tank 
to the air for 3 seconds. On return to the tank, the fish was restricted to the non-drug-
treatment side for 30 seconds to allow recovery. After this time the divider was 
removed and the fish allowed free access to the tank. Again the number of returns 
made over a 10 min period was determined.  
 
Drug seeking despite adverse stimuli was tested by placing individual fish 
were placed in the testing apparatus, allowed to settle for 5 min and then each time the 
fish entered its preferred side it was punished by removal from the tank to the air for 3 
s. On return to the tank the fish was restricted to its non-preferred side for 30 s to 
allow recovery. In each case the number of returns to the preferred side over a 10-
minute period was determined. 
 
4.2.5 Breeding and selection over 3 generations 
Following completion of the first round CPP screen the individuals in the upper (H) 
and lower (L) 5% of the change in preference distribution curve were kept for 
analysis and further breeding.  All remaining fish were terminally anesthetized by 
immersion in tricaine solution (MS-222).  To generate subjects for the second round 
screen fish were bred H:H and L:L. 100 progeny from both the high and low crosses 
were included in the screen (200 in total) with equal representation from each 
individual cross. A similar strategy was used for the third round screen. 
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4.2.6 - Statistical analysis 
 
CPP preference scores were calculated as the proportion of time spent in the vicinity 
of each of the stimuli (i.e., for spots, Time(T)spots/ [Tspots + Tstripes]). For the dose-
response curve, we fitted the preference scores to a polynomial regression. This 
allowed us to account for an inverted U-shaped preference curve. Population means 
between generations were compared using independent 2-sample t-tests, and effect-
sizes were ascertained using Cohen’s d (Cohen, 1992).   
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4.3 - Results 
 
4.3.1 - First-generation screen and HumBog mutants 
 
Using the breeding strategy outlined in Figure 4.1, 30 lines of F3 zebrafish were 
generated and 4 fish from each line included in the first generation population. 
Change in preference (Cp) for the conditioned cue was normally distributed in the 
first generation (Shapiro-Wilks test p = 0.83), with the mean Cp being an increase of 
0.11 (Figure 4.3). Four fish from a Humbog line (Obtained from Stephen C. Ekker, 
Mayo Clinic, USA) were included in the screen as a positive control. Humbog fish 
have a Gaba-B receptor 1.2 (gabbr1.2) knock-out that has previously been shown to 
alter sensitivity to nicotine (Petzold et al., 2009). The gabbr1.2 knockouts clustered at 
one end of the distribution, this demonstrated the assays ability to identify specific 
genetic lines with altered nicotine response phenotypes. 
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Figure 4.3: First generation screen (n=100). The mean change in preference of was 0.12. The top 
five centiles had a change in nicotine preference of 0.6, with the lowest five showing an aversion to 
nicotine of 0.4. The blue shading on the graph indicates the lowest 5% of fish that were in crossed to 
generate the ‘low responder’ lines for the second-generation screen. The pink shaded region of the 
distribution represents top 5% of responders that were in crossed to generate the  ‘high responder’ lines 
for the second-generation screen. 
 
4.3.2 – Conditioning for 5 weeks 
 
After two weeks conditioning to 5μM nicotine (3 per week, 6 sessions total), the 
mean preference change was 0.15 compared with 0.12 after 1 week conditioning 
(Figure 4.4), though this change in place preference was not significant. 5 weeks 
conditioning to 5uM nicotine (3 per week, 15 sessions total). The mean preference 
change was 0.18 compared with 0.12 after 1 week and 0.15 after 2 weeks 
conditioning (Figure 4.5). Change in CPP was not significant compared with week 2 
(p = 0.21) though this change in place preference was significant between week 1 and 
week 5 (p = 0.0009). Comparison between different weeks of screening was analyzed 
using a one-way analysis of variance in SPSS. 
HumBo
g
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Figure 4.4: Probe of CPP after 2 weeks conditioning. Histogram of F3 ENU population after two 
weeks conditioning to 5uM nicotine (3 per week, 6 sessions total). The mean preference change was 
0.15 compared with 0.12 after 1 week conditioning, though this change in place preference was not 
significant. 
 
 
Figure 4.5: Probe of CPP after 5 weeks conditioning. Histogram of first generation ENU population 
after 5 weeks conditioning to 5uM nicotine (3 per week, 15 sessions total). The mean preference 
change was 0.18 compared with 0.12 after 1 week and 0.15 after 2 weeks conditioning. Change in CPP 
was not significant compared with week 2 (p=0.21) though this change in place preference was 
significant between week 1 and week 5 (p=0.0009). 
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4.3.3 - Drug seeking despite adverse stimuli 
 
When the subjects were restricted with the divider there was a mean number of 12.29 
returns to drug pared side within the 10-minute testing period (figure 4.6). The 
smallest number of returns was 3 with a high of 18. The distribution was negatively 
skewed. Fish punished by netting showed a mean of 3.49 returns within a 10-minute 
period (figure 4.7). The least number of returns after netting was 1 with the maximum 
being 7. The distribution was positively skewed which is indicative of how adverse 
the netting punishment was.  
 
 
 
Figure 4.6: Drug seeking despite restriction. The mean number of returns was 12.29. The smallest 
number of returns was 3 with a high of 18. A total of 94 subjects were included in this assay. 
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Figure 4.7: Drug seeking despite netting. Punishment by netting showed a mean of 3.49 returns 
within a 10-minute period. The least number of returns after netting was 1 with the maximum being 7. 
 
4.3.4 - Comparison of netting, restriction and CPP data 
 
The three assays were compared using a Pearson's product-moment coefficient. 
Netting and restriction were shown to correlate with one another (R2=0.532; p<0.001). 
Number of returns when restricted did not correlate with 1 week CPP (R2=-0.049; 
p=0.643), 2-week CPP (R2=0.037; p=0.72) or 5-week CPP (R2=0.016; p=0.881). 
Netting did not correlate with 1 week CPP (R2=0.057; p=0.59), 2-week CPP 
(R2=0.093; p=0.376) and 5-week CPP (R2=0.137; p=0.192). When the mean number 
of returns for punished (netting) vs. unpunished (restriction) was compared (Figure 
4.8) there were significantly fewer returns (Students T-Test, p < 0.0001) when the fish 
was netted. 
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Figure 4.8: Comparison of the number of mean returns to drug-paired side when restricting the 
zebrafish with a divider and netting. This identies netting is an effective aversive stimulus.  
 
 
4.3.5 - Second and third-generation screen (F4 and F5) 
 
The second generation showed a shift in mean preference of 0.08 for low responders 
(Student t-test, p = 0.0002) and 0.07 for high responders (Student t-test, p = 0.001) 
when compared with the first generation (Figure 4.9).  The third generation screen 
gave mean place preference change scores of 0.21 for the high responder lines and 
0.01 for the low responder lines (Figure 4.10). There was a large effect size (Cohen’s 
d = 1.64) indicating the difference in response to the rewarding effect of nicotine has 
been genetically maintained. The increase in effect size with each successive 
generation (d = 0.89 to d = 1.64) indicates that the two populations are becoming 
more genetically distinct with each generation. These data demonstrate that nicotine-
preference is heritable in zebrafish as it is in humans. . 
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Figure 4.9: F4 Screen (n=184). The mean change score for the high responders was 0.17, while the 
low responder mean was 0.05. There was a large effect size (D=0.89). There is a statistical shift in 
nicotine preference for both the high (p=0.03) and low (p=0.01) populations when compared with the 
first generation screen. 
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Figure 4.10: F5 screen (n=187). The high responder generation had a mean of 0.21 compared with a 
population mean of 0.01. There was a larger effect size than the previous generation (D = 1.64). 
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4.4 - Discussion 
  
The aim of this chapter was to identify lines and individuals showing differential 
responses to nicotine reward, to determine whether CPP behavior is heritable in 
zebrafish and generate lines showing differential phenotypes. This was addressed by 
first running a CPP assays across a large population to see if normal distribution and 
get evidence that screen was likely to be sensitive enough to detect differences, which 
was shown by the clustering of humbog mutants as well as other lines (discussed in 
next chapter. The screen was continued for a further 2 generations by inbreeding the 
outliers at either end of the distribution and screening the offspring for nicotine 
reward. With each subsequent generation there was a significant shift in mean 
preference change for both ‘high’ and ‘low’ responders indicating the occurrence of a 
type directional genetic selection.  
  The second-generation showed a shift in preference in either direction (low 
responders: p = 0.03; high responders: p = 0.01) when compared with the previous 
generation. The mean change score for the high responders was 0.17, while the low 
responder mean was 0.05. In the case of the third generation screen, there was further 
divergence from the original population mean with the high responder line showing a 
change score of 0.21 compared with a preference change of 0.01 in the low 
responders. There was a large effect size (d = 1.64) indicating the difference in 
response to the rewarding effect of nicotine has been genetically maintained. The 
increase in effect size from the second generation (d = 0.89) indicates the two 
populations are becoming more genetically distinct with each generation. 
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  The subjects were conditioned for a further 4 weeks after the initial 1-week 
conditioning period. After 5 weeks there was a marginal but significant shift in place 
preference from 0.12 to 0.17. After this, the population was tested to see if drug 
seeking persisted in the face of adverse stimuli, in this instance restriction using a 
plastic partition and removal from the tank using a net. Both behaviors showed a 
normal (if skewed) probability distribution, however they failed to correlate with 
previous CPP data. While you would not expect these behaviors to correlate perfectly 
as they will be governed by different subsets of neuronal pathways, there was almost 
no relationship between them whatsoever with R2 values being close to 0. As a result, 
it is impossible to say with any confidence that compulsive drug seeking is the 
behavior being observed in this instance. Another limitation of the procedure is the 
length of time it takes to assay each fish. It takes 10 minutes in total, though due to 
the fact only one fish can be assayed at any one time (manual restriction and netting), 
the 100 fish screen had to be done over multiple days (3 in total).  It is for these two 
reasons that it would not be feasible to screen the fish this for 3 generations. 
Nicotine reward in the zebrafish CPP paradigm was established as a heritable 
characteristic over 3 generations. Now that heritable variation has been displayed and 
lines with distinct behavioural phenotypes have been established, there is now the 
potential to use the ENU markers in SNP based genome-association analysis of the 
families. It will be possible to sequence the parental F3 fish that gave rise to the lines, 
identify the various ENU markers and use them to identify linked regions associated 
with the differing nicotine response phenotypes. Once these regions are identified, 
high density SNP mapping can be used identify linked alleles. The Sanger Institute 
has in their possession, a 2000 SNP array that can be used now this stage has been 
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reached (Derek Stemple, personal communication), though this will not occur in time 
for inclusion in this thesis. 
By taking the outliers and incrossing to generate distinct lines, it will then be 
possible to screen 40 individuals from each family and see whether each ‘high’ family 
vary significantly from the average of ‘low’ families (and vice versa). If there are 
recessive alleles segregating it is possible to look at all 40 and expect 10 recessive 
homozygotes (range c 4-16) to be confident of getting two individuals for breeding if 
there are recessive alleles segregating. By back corossing this identified high lines 
with low lines it will be possible to identify the alleles that made the extreme 
individuals have their phenotype by looking at the segregation in backcrosses. 
Using this strategy of SNP mapping the lines generated in this screen it will 
theoretically be possible to identify linked genes of major effect.  It also has the 
power to identify both ENU-induced linked single nucleotide mutations and naturally 
occurring linked using the principles of mapping by admixture linkage disequilibrium 
(MALD).    The principles of MALD is that any loci in linkage disequilibrium with a 
locus responsible for vulnerability to nicotine reward will have a greater than 
expected proportion of markers with ancestry from the high response population. The 
approach assumes that near a disease causing gene (in this case addiction) there will 
be enhanced ancestry from the population that has greater risk of getting the disease 
(high responder lines). An unexpectedly large bump of ancestry in a localized 
genomic region then suggests that the region may harbor a disease-bearing gene (see 
Figure 4.10). 
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Figure 4.10: Schematic of how a disease locus will appear in an admixture scan. (Taken from 
ANCESTRYMAP documentation).   Around the locus, there should be an unusually high proportion of 
ancestry from one of the parental populations, because of patients inheriting high-risk alleles from that 
group.  
 
 
The linkage mapping of this type can be carried out using ANCESTRYMAP, one of 
the leading software packages for analysis of this nature. The program uses data from 
individuals genotyped at a set of markers, where the markers chosen are preferably 
the ones that differ significantly in frequency between the two ancestral populations. 
The algorithm calculates a Bayesian-likelihood ratio test to scan for disease 
association anywhere in the genome. In this calculation, individual ancestry estimates 
along the genome are averaged across all the individuals to identify genomic regions 
where there is enhanced ancestry from one of the parental populations, indicating the 
presence of a disease gene nearby (Patterson et al., 2004). 
  The results of the first round screen showed that in addition to the humbog 
clustering, 2 others lines did. The nature of these lines and how they may influence 
CPP are explored in following chapters. 
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Chapter 5  
 
 
Characterization of 2 outlier families and 
the identification of slit3 in ‘QMhigh’ line 
 
The first generation screen is revisited to identify gene-breaking mutations of major 
effect. Individuals from two of the mutant lines clustered at either end of the 
distribution indicating the possibility of a dominant mutation being present which 
may be dictating the phenotype.  These two lines are investigated further looking at 
the known functional mutations in the lines and identifying candidate genes, which 
may be causal factors in these observed nicotine-seeking phenotypes. This chapter 
also explores an initial molecular characterization of the QMhigh line to identify 
possible mechanisms accounting for the observed phenotype.  
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5.1 Introduction 
 
In the previous chapter, a three-generation selection screen was performed in which 
zebrafish response to the rewarding effects of nicotine was shown to be heritable. 
ENU-mutagenised fish were used in the screen, allowing mutations linked to genes 
affecting the phenotype to be selected for over multiple generations and assimilated 
using an inbreeding strategy. This facilitates the possibility of using these genetic 
markers to SNP map regions of the chromosomes affecting the phenotype, using 
admixture-mapping strategies. 
In bred lines with differential nicotine seeking behavior have been established 
but the SNP mapping is outside the scope of this thesis. However, due to the nature of 
the lines obtained from the Wellcome Sanger Trust, fish that occur at the extremes of 
the population distribution curve may be there because they house a dominant 
mutation of major effect, are homozygous for a recessive mutation of major effect or 
multiallelic for variants of more minor effect. The fish have thousands of mutations 
across the genome including 10-20 functional mutations in coding regions. In the 
first-generation, it was apparent the screen was able to identify mutations affecting 
nicotine seeking due to clustering of the gababr2.2 mutant, which has previously 
shown altered nicotine sensitivity (Petzold et al., 2009). Since 4 individuals from each 
of the 30 F3 lines generated were included in the screen, any appearance of fish at the 
extremes suggests family contains a dominant mutation affecting nicotine seeking and 
warrant further investigation in the siblings of that line. 
As previously discussed, the first generation screen gave a normal distribution 
of phenotypes with a mean change in preference of 0.14. The highest responders had 
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a 0.6 change in preference, with the lowest responders showing an aversion to 
nicotine of 0.4 (Figure 5.1). The population that was initially screened was made up 
of 30 families with distinct genetic backgrounds that were generated using the 
breeding scheme outlined in Figure 5.1. Each line contained a possible 10-15 gene 
breaking SNPs, as well as a large number in non-coding regions.  
Of the 30 lines, 1 family clustered towards the right extreme (QMhigh) of the 
distribution with all 4 fish falling in the top 10 percentile, while another line (QMlow) 
clustered in the lowest 10 percentile (Figure 5.1). This indicates the screen has 
identified two lines containing a dominant mutation that affects nicotine reward. It 
can be assumed there is a dominant mutation involved since 4 F3 fish from each line 
were randomly selected from a pool theoretically containing 25% homozygous 
mutants, 50% heterozygous mutants and 25% wild type. The probability of each line 
clustering at either end of the distribution due to a recessive mutation would be low 
due to all 4 individuals having to be homozygous for that mutation. In the case of the 
high responders, the chance of pulling 4 homozygous individuals from the original 
tank of 15 would be just 0.4%. For the low responders the chance would be 0.4%. 
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Figure 5.1: First generation outliers. The screen gave a normal distribution of phenotypes with a mean 
change in preference of 0.14 with the highest responders chowing a 0.6  preference change, with the 
lowest responders showing an aversion to nicotine of -0.4. The gabbr1.2 knockouts clustered towards 
the right side of the distribution. Two mutant lines (named QMhigh & QMlow) clustered toward either 
end of the distribution in the top and bottom 10 percentiles. 
 
By screening the remaining QMhigh (n=11) and QMlow (n=14) siblings for nicotine 
induced place preference, it is possible to reafirm the presence of a genetically 
induced alteration in nicotine seeking through a perseverance of the phenotype in the 
lines. Exome sequencing (performed at the Sanger) of the parental F1 fish identified a 
total of 14 possible nonsense mutations that may be contributing to the phenotype in 
the QMhigh line (Table 5.1a) and 12 possible mutations in the QMlow line (Table 
5.1b). By genotyping the siblings at each of these loci, it may be possible to unravel 
the identity of specific mutations of causal effect by seeing how they segregate with 
nicotine seeking behaviour. 
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Table 5.1: Summary of the known possible functional mutations in coding regions of outlier lines 
QMhigh and QMlow. A: QMhigh line has a possible 14 gene-breaking mutations in the exome. 
B: QMlow line has a possible 12 gene-breaking mutations in the exome. SNPs were identified at 
the Sanger Institute through sequencing of the F1 exome. Information regarding SNPs was 
obtained from Elisabeth Busch, Wellcome Trust Genome Campus, Hinxton, Cambridge.  
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5.2 Materials and methods 
 
5.2.1 Site-specific polymerase chain reaction (SSPCR) 
 
Four primer pairs were designed to carry out PCR genotyping as previously desribed 
(Hamajima et al., 2000). For each line, a primer was designed with 3’ 
complementarity to the ENU-SNP with a second primer ~100bp downstream. The 
second pair had one primer with 3’ complementarity to the wild-type base with a 
second primer ~200bp upstream (figure 5.2). The resulting PCR results in one 100bp 
fragment if homozygous for the mutation, two bands if heterozygous, and one 200bp 
fragment if homozygous wild-type. A third band is always generated regardless of 
genotype at around 300bp due to the opposing nature of each primer pair. The 4-
primer groups were designed with Tm’s as close as possible using the NCBI primer 
design tool and were ordered from Eurofins, MWG operon. 
 
Figure 5.2: Site-specific polymerase chain reaction (SSPCR). Schematic of the logic of polymerase 
chain reaction with confronting two-pair primers. a, size for X allele; b, size for Y allele; c, size 
between primers 1 F and 2 R; d, sum of the sizes of primers 2 F and 1 R. In this case a fragment of 
~200bp was used for wild-type allele and a ~100bp fragment for the mutant allele. This leaves an 
internal control fragment of ~300bp. 
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Primer Name Sequence 
cacna1baWT-F GAG TTC TTA AAG CTG CGC A (19 bp) 
cacna1baWT-R AAA TAG AAG AGT GAC TGG ATT TTT (24 bp) 
cacna1baSNP-R CTT TCG ATC TGC TGT TGT CA (20 bp) 
cacna1baSNP-F TGT TCA TGG ATG TGT CTG C (19 bp) 
vcana-WT-F TTT CCA TCA ACA GAG TCA G (19 bp) 
vcana-WT-R TCT GCT TTG TGG TTC ACT (18 bp) 
vcana-SNP-R GTC CCA TGT TTT GAA CTT G (19 bp) 
vcana-SNP-F TCA GAG AAC ATA GTT GGC (18 bp) 
evpl-WT-F GGT ACT AAA CCA AAA ACA GG (20 bp) 
evpl-WT-R TGC ATA CAT TTT ATT AAC GAT TCA (24 bp) 
evpl-SNP-R TCA ATA TAT TGA ATG TGT ATT CAC AT (26 bp) 
evpl-SNP-F AGC TGT ATG AGC CAT TGA AC (20 bp) 
mob3a-WT-F GAA AAG GCG CTC GCT CGG (18 bp) 
mob3a-WT-R CGT CGT TTT TAA TGG CGT GAC CA (23 bp) 
mob3a-SNP-R GTG TAC AAT GAA GTT GAG GCA AAC TTA T (28 bp) 
mob3a-SNP-F CGA ACA AAA CTG AAA GCT GGG GA (23 bp) 
prkg1-WT-F GCA GTG CAG ATG GTA ATT TCG (21 bp) 
prkg1-WT-R ACA TCA ATG GTG CAG GCA GA (20 bp) 
prkg1-SNP-R TGC TTT TGT CAC TGT GGC CTA (21 bp) 
prkg1-SNP-F CCA GCT TCC TGT CAG AAA ATC (21 bp) 
glis3-WT-F CCC TCT AAC TGT CCC TTC ACA A (22 bp) 
glis3-WT-R GCA GGG TTT CAT GCC TTT TGT TG (23 bp) 
glis3-SNP-R CAA TTA TTC AGC AAA GCT CAT GGA TAT  (29 bp) 
glis3-SNP-F CAC AAA GTC ACG CTC CGA TAC (21 bp) 
tulp2-WT-F CCG TCG CTC TGA GCA GAT AA (20 bp) 
tulp2-WT-R TTA AAG ACG CGC GTG GAG AAG (21 bp) 
tulp2-SNP-F CTT TTC ACA GTC ACT GCA ATC AAT AAA G (28 bp) 
tulp2-SNP-R AGG GGG AGG GAA AGA GTC TAA (21 bp) 
slit3WT-F ACG TGT TCT GTC TTC TTT TTT CTA (24 bp) 
slit3WT-R TAA GCC AAG CAA AAG AGC GA (20 bp) 
slit3SNP-R TTG TTG TTG TTG AGA GTG CC (20 bp) 
slit3SNP-F TCT GCT ACA GTG TGT TGT CT (20 bp) 
DCHS1_WTF CTA AAC CTG CTG TAG GGC (18 bp) 
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DCHS1_WTR AAT CCT CAG TTC TGT CTC CT (20 bp) 
DCHS1SNPR GAT AAG TGG GGA AAT GTT CA (20 bp) 
DCHS1SNPF TCC CCT TAT TAC TTC TGT AG (20 bp) 
FAD1_WTF TGC TGC AGG CAT TGC CTC (18 bp) 
FAD1_WTR CCG GTG AGT GTA GTC AAA AGC (21 bp) 
FAD1_SNPR TCT TGA CCG CTC TCC TAA TCT A (22 bp) 
FAD1_SNPF GTT CCC AAC AGA CCT TCT CC (20 bp) 
si:ch211-WT-F130 TGG ATG GGC ACT GGG CC (17 bp) 
si:ch211-WT-R130 GGG CCG CAA GAA CTA GGA TT (20 bp) 
si:ch21-SNP-R164 TCC CCT TTT CAG AGC ACA GTC (21 bp) 
si:ch21-SNP-F164 TCA GGT GTG TTT TGT CTG CTC T (22 bp) 
magi2-WT-F CTC AGG ACC CCC AGA CAC T (19 bp) 
magi2-WT-R CAT CAC CTT GGC AAC CTT CTT C (22 bp) 
magi2-SNP-F TGG TTC TAG GGT CTC AGC TTG (21 bp) 
magi2-SNP-R CCA TCC TCG CAT GAT TAC ATA CC (23 bp) 
trimm55-WT-F TTG TTT GTT GCA TTG ACT GAC AGT GA (26 bp) 
trimm55-WT-R TCT AGC AAC CCC GAA ATC TGG A (22 bp) 
trimm55-SNP-F GGG TGG TCA GAT ACA CCG TTT (21 bp) 
trimm55-SNP-R GCC TAT CAG GAT TGC AGC AGT (21 bp) 
capn3SNP-R AAG AGA TTC GCA CCC AAC TA (20 bp) 
capn3WT-F AAA ACA GAC GTA AAG AAC GCA (21 bp) 
capn3SWT-R ACG GCG AAA CGT GAA ACA A (19 bp) 
capn3SNP-F GGA GGA TGA TGA AGT GGC (18 bp) 
a9WT-F GTT TTG TGT TTC TTA CAG GAA AAT AT (26 bp) 
a9WT-R TCA GGT GTT GTG CAG TTC TC (20 bp) 
a9SNP-R ATG GTC ATT GTT GCA ATG TAC (21 bp) 
a9SNP-F CCC AGC AAC TGA TTG TGT TA (20 bp) 
snrnp70-WT-F GGG GGT CTT GGT GGC AC (17 bp) 
snrnp70-WT-R CGC GAT CAC TGC AAA ATA AGA CA (23 bp) 
snrnp70-SNP-R TCT GCG CCT CCT CGC CTT A (19 bp) 
snrnp70-SNP-F CGA GGA CCT TGC CTA TCC C (19 bp) 
CABZ-SNP-F GCC TAT CCC ACC ATG CTC AAA T (22 bp) 
CABZ-SNP-R TCA CAC CCT CAC CTT CGA CT (20 bp) 
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CABZ-WT-R TGG AAG AGA CAC ACA CCC TG (20 bp) 
CABZ-WT-F CAC CTG CTG CTG CAT TTC CC (20 bp) 
wu:fa96e12-WT-F CTG CTT TAG ATC TTC TAA TCA AAG (24 bp) 
wu:fa96e12-WT-R CCA TAT TTC ACA GCC CTA ACT (21 bp) 
wu:fa96e12-SNP-R TCA TAC AAT ATA TAA ACA AAA GAA CTC AA (29 bp) 
wu:fa96e12-SNP-F GAC ACG TGC ATT GTC GTT TA (20 bp) 
kctd4-WT-F CAG CGA CAA CAC CTT CAT CG (20 bp) 
kctd4-WT-R CAT CAC CGT CTC CAG CTT CA (20 bp) 
kctd4-SNP-R CAG CCG GTT CTT GAC CTT CTA (21 bp) 
kctd4-SNP-F CGA ACC TGC CTT CCT GGA G (19 bp) 
SLC19A3-WT-F CCT TCT AGT AAC TTC ACA GTC TAC (24 bp) 
SLC19A3-WT-R TTA TTT CTT GGC CTG ACT GTT AGC (24 bp) 
SLC19A3-SNP-R GTG CCT CCG CTC CTC CAT T (19 bp) 
SLC19A3-SNP-F GGC TAC AAC CAG ACG GTC AA (20 bp) 
tspan3aWT-F GAG ACC TTT ATC CTG AGG T (19 bp) 
tspan3aWT-R TTA GCC TCC CGT GTT TAT GT (20 bp) 
tspan3aSNP-R TGA CAA AGC AGC TGT TAT TTC TTT (24 bp) 
tspan3aSNP-F CTG GTT TAA GGA GTC CAA G (19 bp) 
raspnWT-F CTG CAG AAG GAA TAT GAT AAG GT (23 bp) 
raspnWT-R TGG GGG CTA ATT TGC AAT AAC T (22 bp) 
raspnSNP-R TTA TCT AAA AGA CAC AAT TAA ATC TTG C (28 bp) 
raspnSNP-F GTC CTC CAT GTG CAT AAT GTC (21 bp) 
slc6a11-WT-F CCA GTT CGA GGT CTC CAT GT (20 bp) 
slc6a11-WT-R GTG GTG CTC TCG ACA CAG AA (20 bp) 
slc6a11-SNP-R CCA ATG TGT GGA TGA AGC AGG (21 bp) 
slc6a11-SNP-F AGC AGA GCA GAG CCG AGT AG (20 bp) 
PKH-WT-F AGG GGG AGG GAA AGA GTC TAA (21 bp) 
PKH-WT-R AGG AAA CTG GCC ATT GTG TAA CTA (24 bp) 
PKH-SNP-R ATG TGA ATG AAT GGC GGT GTG TG (23 bp) 
PKH-SNP-F ATG CGC GTG TCA GAT TTA CCC (21 bp) 
???_WTF ATT AGA CAA CTG TTT CAA GCT G (22 bp) 
???_WTR ACC TGT ATT GCC TGT TCA AGA (21 bp) 
???_SNPR AGT GCA TTT ATA AAA TGT TTC ACC TAT (27 bp) 
???-SNP-f TTT TGA GGT GAG TAG CAG TG (20 bp) 
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klf11a-WT-F TCT AAA ACC ACA TCC CAG ACT ATG T (25 bp) 
klf11a-WT-R GCC CTG TGG TTG TTG ATG GA (20 bp) 
klf11a-SNP-R GCT CTG TTG GTC AAG GCT GAT (21 bp) 
klf11a-SNP-F AAA CTT CAG GCA CAG CGG TT (20 bp) 
 
Table 5.2: Primer sequences used for SSPCR. Primers used in the genotyping of the QMhigh and 
QMlow lines. ??? denotes a gene breaking mutation in a locus with no known human homologue. 
 
5.2.3 Genomic DNA extraction 
 
Zebrafish were anaesthetised using MS-222 in a 1-litre tank of aquarium water. They 
were then removed from the tank and 4mm2 of the tail fin removed using a scalpel. 
The fin-clips were then placed in an eppendorf containing 1ml of 100% ethanol and 
stored at -20°C until ready to be processed further.  
Genomic DNA was extracted from fin-clips by first digesting with proteinase-K for 1 
hour at 56°C before extraction using QIAGEN DNeasy® Blood and Tissue Kit. 
Samples were eluted into distilled water and stored at -20°C until later use. 
 
5.2.4 CPP phenotypic analysis of outlier siblings and sa202 
 
The remaining fish from the QMhigh (n=11) and QMlow (n=14) were screened in the 
CPP paradigm along with control fish (with and without 5uM nicotine) as described 
in chapter 3. Fish from the sa202 (n=20) line were obtained from the Sanger and 
assayed for CPP to nicotine along with controls (with (n=10) and without (n=10) 5uM 
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nicotine). All lines were fin-clipped and genotyped using SSPCR after CPP. The CPP 
procedure was carried out as described in chapter 3. 
 
5.2.5 Quantitative PCR of QMhigh embryos 
 
The cDNA from zebrafish embryos was generated as described in chapter 2. All 
qPCR reactions were carried out in triplicate. Reference genes used were β-actin, 
ef1α and rpl13α based on previous findings (Tang, Dodd, Lai, McNabb, & Love, 
2007). Target genes used were slit3, drd1b, drd2a, drd3, dbh, dat, chrnb2b, chrnb3, 
chrna2, chrna3, chrna4, chrna5, chrna6 and chrna7 (for primers see table 5.3). 
Absolute quantification was calculated by generating standards for each gene, 
prepared using the relevant primers to amplify fragments from cDNA. Samples were 
then PCR purified and diluted to 1011 fragments per µl using the Avogadro constant 
(Gemenetzidis et al., 2010; Teh, Gemenetzidis, Chaplin, Young, & Philpott, 2010). 
Relative mRNA expression ratios in the qPCR were calculated with respect to 
reference gene cycle-threshold (Ct) values, and then subjected to a two-way factorial 
(between-subjects) analysis of variance (ANOVA). 
 
Gene Primer 
 
β-actin-F CGA GCT GTC TTC CCA TCC A (19 bp) 
β-actin-R TCA CCA ACG TAG CTG TCT TTC TG (23 bp) 
eF1α-F CTG GAG GCC AGC TCA AAC AT (20 bp) 
eF1α-R ATC AAG AAG AGT AGT ACC GCT AGC ATT A (29 bp) 
rpl13α-F TCT GGA GGA CTG TAA GAG GTA TGC (24 bp) 
rpl13α-R AGA CGC ACA ATC TTG AGA GCA G (22 bp) 
chrna2-F  GCG GAA AAC CGG ATA AAA ACA CTC (24 bp) 
chrna2-R  AGT TTG TCC TCT GCG TGT GCA T (22 bp) 
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chrna3-F  TGT ACA TCC GCC GAT TAC CGC T (22 bp) 
chrna3-R  TCC GCA GTC GGA GGG CAG TA (20 bp) 
chrna4-F  TTA CAA GAG GTT TGG GCG CT (20 bp) 
chrna4-R  ACA GAC CAG TAG ATC ATC ACT CC (23 bp) 
chrna5-F  GGC TCC CAG GTC GAC ATT (18 bp) 
chrna5-R  AAC CCC GGT TAC CAG TGG CCT (21 bp) 
chrna6-F  CTT TGG GCC TCT TCC TGC AA (20 bp) 
chrna6-R  TCA GAG TCT TGA TGT AGT GAC GG (23 bp) 
chrna7-F  ACC GTG TCA CAT TGT TCA TTC TC (23 bp) 
chrna7-R  ACA GGT CTC TCC AGT GGG TTA (21 bp) 
chrnb2-F  GGC TGC CTG ATG TTG TTC TT (20 bp) 
chrnb2-R  TGG TGG CAA CCA GAA GAC ACT T (22 bp) 
chrnb3-F  CAG GAG TCA ACC TCC GCT TT (20 bp) 
chrnb3-R  TGA ATC TGA ACG CAC TGG CT (20 bp) 
chrnb4-F  TGA TCA CAT GAT GGG GAA TGA CG (23 bp) 
chrnb4-R  CAC CAC ACA CAC GAT CAC AAA G (22 bp) 
drd1-F  TGG TTC CTT TCT GCA ACC CA (20 bp) 
drd1-R  AGT GAT GAG TTC GCC CAA CC (20 bp) 
drd2-F  TCC ACA AAA TCA GGA AAA GCG T (22 bp) 
drd2-R  CAG CCA ATG TAA ACC GGC AA (20 bp) 
drd3-F  ATC GAG TTT CGC AGA GCC TT (20 bp) 
drd3-R  TCC ACA GTG TCT GAA AGC CG (20 bp) 
dat-F  TAT GTG GTC CTG ACC GTG CT (20 bp) 
dat-R  CAC ATG TGT AGG CGC AGG AA (20 bp) 
nat-F  AGG TGA CAT TGT TTG AGA TGT CTT (24 bp) 
nat-R  TGT CTT GGT AGT GTC AAG TTG T (22 bp) 
oprm1-F  CCG TAT GTG ACA GGA CGC CA (20 bp) 
 
 
Table 5.3: Quantitative real-time PCR primer sequences.  Reference genes used were β-actin, 
ef1α and rpl13α. 
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5.2.6 Statistical analysis 
 
CPP change scores were calculated as previously described. For the rescreen of 
outlier siblings, lines were compared using an independent two-sample t-test. To 
determine association between SNPs and phenotype, for each locus, CPP change 
scores were grouped based on genotype (wildtype vs. +/- and -/-) before comparing 
means using a t-test. The independent sa202 line, were compared by independent two-
sample t-test after genotyping.  
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5.3 Results 
 
5.3.1 Rescreen of QMhigh and QMlow siblings  
 
The fish used from each family were selected at random from a tank of at least 20 
siblings, and as a result of the breeding strategy, only 25% of the family would be 
expected to be homozygous at any single locus. Therefore clustering of a particular 
family in the distribution suggests that there is a dominant mutation within the line 
that influences response to nicotine.  To test this hypothesis we screened siblings from 
the QMhigh and QMlow families for nicotine-induced place preference.  QMlow 
showed a significant reduction (Student t-test, p=0.04) and QMhigh a significant 
increase (Student t-test, p = 0.01) in nicotine-induced place preference compared to 
wild type controls consistent with the existence of dominant mutations affecting 
nicotine preference within the lines (figure 5.3).  
 
Chapter 5 
 145 
 
Figure 5.3: Rescreen of siblings. Siblings of QMhigh and QMlow lines were rescreened to verify the 
genetic component of the phenotype. QMlow (n=14), QMhigh (n=10) and control (n=10) fish were 
tested for nicotine induced CPP using 5uM nicotine hemisulphate. Phenotypes were similar to those 
seen from outliers in the population screen; QMlow showed a significant reduction (p=0.04), while 
QMhigh siblings showed an increase in preference change compared with controls (p = 0.1). There was 
a significant difference between the QMhigh and QMlow lines (p<0.001). 
 
 
5.3.2 SSPCR of QMhigh and QMlow line 
 
Exome sequencing of the parental F1 fish used to generate the QMhigh and QMlow 
families identified 14 gene-breaking splice mutations in the AJBQM1 line and 12 in 
the QMlow line (Table 5.1), plus up to 1000 additional missense mutations. The 
screen fish and siblings from the QMhigh and QMlow lines were genotyped at each 
of the known gene-breaking loci and results compared with each individual’s place 
preference change scores (Table 5.4 and 5.5). None of the known candidate gene-
breaking mutations present in the QMlow line segregated with the behavior 
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suggesting that the causal mutation may in fact be a missense mutation with linkage 
to the low responder phenotype.  Of the 14 candidate mutations present in the 
QMhigh line only 1 (figure 5.4b) segregated with the ‘high responder’ phenotype 
(Students T-Test, p < 0.001).  This mutation introduces a stop codon at position 176 
in the slit3 coding domain.  
 
 
 
Table 5.4 PCR genotyping of QMhigh outlier siblings. The siblings were genotyped at each of the 
14 candidate loci using SSPCR and results compared with each individuals place preference 
change scores. Slit3 (top row) was shown to segregate with high responder phenotype (see figure 
5.6). 
 
 
 
SNP$Name Allele$Number Location Description
cacna1ba&(Cacna1b) sa1562 Zv9:5:31016641 voltage:dependent&N:type&calcium&channel&subunit&alpha:1B
vcana&(VCAN) sa1563 Zv9:5:48057817 novel&protein&similar&to&vertebrate&chondroitin&sulfate&proteoglycan&2
si:ch211:157f15.1&(EVPL) sa1564 Zv9:6:21645941 envoplakin
mobkl2a&(MOBKL2A) sa1565 Zv9:8:20954361 mps&one&binder&kinase&activator:like&2A
ENSDARG00000068026&(PRKG1) sa1566 Zv9:8:53199402 protein&kinase,&cGMP:dependent,&type&I
glis3&(GLIS3) sa1567 Zv9:10:663606 zinc&finger&protein&GLIS3
si:dkey:220f10.4&(TULP2) sa1568 Zv9:12:21973687 novel&tub&family&member&protein
slit3&(SLIT3) sa1569 Zv9:14:25591202 slit&homolog&3&protein
dchs1&(DCHS1) sa1570 Zv9:15:31441900 dachsous&1
flad1&(FLAD1) sa1571 Zv9:16:25049338 Molybdenum&cofactor&biosynthesis&protein:like&region&FAD&synthase&region
si:ch211:199m3.2&(AKD1) sa1572 Zv9:20:33741430 adenylate&kinase&domain&containing&1
si:dkey:4c23.3&(???) sa1573 Zv9:22:25367694 novel&protein&similar&to&vitellogenin&1&(Vg1)
magi2&(MAGI2) sa1574 Zv9:25:21478784 membrane&associated&guanylate&kinase,&WW&and&PDZ&domain&containing&2
zgc:101050&(TRIMM55) sa158 Zv9:23:17631394 hypothetical&protein&LOC445187&(tripartite&motif:containing&55)
0.32 0.15 0.07 0 0.01 0.44 0.51 0.6 0.47 0.43
SLIT3 HET WT WT WT WT HET HET HET HET HET 7.6592E-05
CACNE MUT WT WT WT HET WT WT WT WT HET 0.691
VCAN MUT HET WT HET HET HET WT WT HET WT 0.259
EVPL WT WT WT WT WT WT WT WT WT WT 1
MOB3a MUT MUT HET HET HET WT WT HET HET HET 0.236
PRKG1 HET HET HET HET HET HET MUT MUT HET HET 1
GLIS3 WT HET HET WT HET WT WT HET HET WT 0.602
TULP2 WT HET WT MUT MUT HET WT WT HET HET 0.481
DCHS1 WT WT WT WT WT WT WT WT WT WT 1
FLAD1 WT HET WT MUT MUT WT HET HET HET WT 0.981
AKD1 WT HET WT MUT MUT HET WT WT HET HET 0.418
MAGI2 HET WT HET HET WT WT MUT HET WT MUT 0.73
TRIMM55 WT HET WT WT HET WT HET WT WT WT 0.51
CPP5Change5ScoreGENE p-value
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Table 5.5: PCR genotyping of QMlow outlier siblings. The siblings were genotyped at each of the 
12 candidate loci using SSPCR and results compared with each individuals place preference 
change scores. No SNP was found to significantly segregate with behavior.  
 
 
 
Figure 5.6: Co-segregation of slit3 genotype and CPP phenotype. a: Graph comparing QMhigh with 
controls. Data points shaded in black were positively genotyped for the slit3 mutation indicating a clear 
segregation of phenotype with genotype. b: Site-specific PCR electrophoresis gel. ~100bp band 
indicates presence of mutant allele. 
 
 
SNP$Name Allele$Number Location Description
capn3&(CAPN3) sa150 Zv9:17:45493087 calpain:3
chrna9&(CHRNA9) sa975 Zv9:1:22190803 cholinergic&receptor,&nicotinic,&alpha&9
snrnp70&(SNRNP70) sa976 Zv9:3:32068963 U1&small&nuclear&ribonucleoprotein&70&kDa
zgc:158677&(SV2B) sa977 Zv9:7:16060160 synaptic&vesicle&protein&2B&homolog
wu:fa96e12&(AC103686.1) sa978 Zv9:7:44124381 DNA:dependent&protein&kinase&catalytic&subunit
kctd4&(KCTD4) sa980 Zv9:9:19495015 potassium&channel&tetramerisation&domain&containing&4
LOC557854&(SLC19A3) sa981 Zv9:15:34443534 solute&carrier&family&19,&member&3
tspan3a&(TSPAN3) sa984 Zv9:18:26858396 tetraspanin&3
rapsn&(RAPSN) sa985 Zv9:18:20289900 43&kDa&receptor:associated&protein&of&the&synapse
si:ch211:132b12.1&(SLC6A11) sa986 Zv9:18:38859333 hypothetical&protein&LOC100034467
pkhd1l1&(PKHD1L1) sa987 Zv9:19:23349482 polycystic&kidney&and&hepatic&disease&1&(autosomal&recessive):like&1
klf11a&(KLF:11) sa988 Zv9:20:29529553 kruppel:like&factor&11a
0.04 $0.17 $0.17 $0.09 $0.23 $0.21 $0.12 $0.27 $0.28 0.07 $0.07 $0.09 $0.38 $0.18
tspan3a HET HET HET WT WT WT WT HET HET HET HET WT HET WT 0.583
raspn WT MUT MUT WT WT WT WT WT MUT MUT MUT WT WT MUT 0.792
a9 HET HET WT HET WT WT HET HET WT HET HET HET WT WT 0.339
capn3 WT WT HET HET WT HET WT HET HET WT WT WT HET WT 0.911
klf11a HET WT HET WT HET WT WT WT WT WT WT HET WT WT 0.318
kctd4 WT HET WT HET HET WT HET WT WT WT HET HET HET WT 0.252
slc6a11 HET HET HET WT WT HET WT HET HET WT WT WT HET WT 0.697
pkhd1l1 WT HET WT WT HET MUT WT WT WT MUT WT WT WT MUT 0.499
slc19a3 WT WT WT WT WT WT WT WT WT WT WT WT WT WT 2
sv2b HET WT HET HET WT WT MUT HET WT MUT MUT MUT WT WT 0.269
snrnp70 WT WT WT WT WT WT WT WT WT WT WT WT WT WT 2
ac10103686 WT WT WT WT WT WT WT WT WT WT WT WT WT WT 2
CPP<Change<ScoreGENE p$vlaue
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5.3.3 Phenotype conserved in independent slit3 allele  
 
SSPCR suggests that a mutation in the slit3 gene underlies the high nicotine 
preference. To confirm this possibility a second independent allele was obtained from 
the Sanger. The independent slit3 allele sa202 with a nonsense mutation that 
translates to a protein truncated at amino acid 163 showed a similar high responder 
phenotype to the QMhigh line when compared with controls. The control fish 
conditioned to saline showed a preference change of -0.03, with those conditioned to 
nicotine showing a preference of 0.1 to the drug paired side. The sa202 fish wildtype 
at the slit3 locus showed a place-preference (0.13) similar to the wildtype fish when 
conditioned to nicotine. The sa202 fish heterozygous for the slit3 mutation showed a 
preference change of 0.26, nearly double that of those without a mutation (Figure 
5.5). 
 
   
Figure 5.5: CPP of independent slit3 (sa202) line. The high CPP response was conserved in this new 
mutant when compared with wild-type fish (p<0.001).  Additionally, after screening, the mutant line 
was genotyped at the slit3 locus and those individuals heterozygous (+/-) for the SNP showed 
significantly higher CPP (p<0.05) to nicotine than those homozygous (+/+) wild-type. 
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Figure 5.6: sa202 genotyping. Site-specific PCR electrophoresis gel. ~100bp band indicates presence 
of mutant allele, n=27. 13 subjects were found to be carrying a mutant allele. 
 
5.3.5 qPCR analysis of SLIT3 embryos 
 
Quantitative PCR was carried out on 2, 3 and 5 d.p.f embryos to assay expression 
levels for cholinergic and dopaminergic related gene expression during development 
in slit heterozygous incross progeny and in wildtype. No difference was seen when 
gene expression in progeny from a slit+/+ cross compared to progeny from a slit3 +/- 
cross at 2 and 3 dpf. At 5 days differences between the gene expression in wildtype 
and mutant begin to emerge. There is a down regulation of drd1b at day 5 with 
relative expression levels in the slit3 embryos being around a quarter that seen in the 
wildtype (Figure 5.7a). Drd2a also showed a down regulation at day 5 with a slight 
up-regulation at 3dpf (Figure 5.7a). There was also a down regulation of the other 
dopaminergic genes drd3 and slc6a3 at 5dpf (Figure 5.7b). Both chrnb2b and chrnb3 
(Figure 5.7d) showed a noticeably large down regulation in the slit3 mutants, with 
there being very little expression in both genes when compared with the controls 
(Figure 5.7c). There were no noticeable expression differences between the two 
groups for chrna2 and chrna3 (Figure 5.7e) for all three of the time points. There was 
a down regulation for chrna4 and chrna6 (Figure 5.7f & g) at 5dpf while there was 
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no difference in expression levels between the two groups for chrna7 (Figure 5.7g). 
There was a slight up-regulation in chrna5 in slit +/- in-cross fish (Figure 5.7f), which 
was significant when subjected to two-way factorial (between-subjects) analysis of 
variance (p<0.05). There is no change in slit3 expression across all 3 time points.  
 
A 
 
 
B 
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Figure 5.7: Quantitative PCR results. Mean (± SE) mRNA expression ratios of chrnb2b, chrnb3, 
chrna2, chrna3, chrna4, chrna5, chrna6 and chrna7 genes to β-actin, ef1α and rpl13α of slit3 +/- 
incross progeny and control (+/+) zebrafish at different periods post-fertilization.  Only chrna5 showed 
significant change on expression levels. Note: * p < 0.05.   
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5.4 Discussion 
 
Of the thirty families included in the screen, one clustered at the right extreme 
(QMhigh) of the distribution, while another (QMlow) clustered to the left. This 
clustering on either arm of the distribution curve is a strong indicator of the presence 
of a genetic component influencing behaviour, in this case to nicotine reinforcement. 
Due to the lines being obtained from the Sanger, they were exome sequenced at the 
F1 stage before outcrossing, meaning it was possible to obtain a list of potential 
mutations in the F3 fish. This led to the possibility of identify specific mutations 
contributing to the observed phenotype by rescreening the siblings and genotyping at 
each locus. Exome sequencing of parental fish identified the presence of a 12 possible 
gene-breaking mutations within the QMhigh line.  
The QMlow line was genotyped at all the candidate loci and none of the SNPs 
were shown to significantly associate with behavior. The SNP showing the closest 
association with behavior was chrna9 with a p-value of 0.29. When the QMhigh 
siblings were genotyped for candidate mutations, 1 SNP segregated with the increased 
nicotine seeking phenotype, suggesting causality. This interaction of the slit3 knock-
out with increased CPP phenotype was confirmed in an independent allele 
Slit ligands together with Robo receptors form one of the most important 
ligand-receptor couples among the axonal guidance molecules. Robos were first 
identified in Drosophila in a screen for genes that regulate the midline crossing of 
transverse axons connecting the two hemispheres of the brain (Seeger, Tear, Ferres-
Marco, & Goodman, 1993). Similarly, Slit was discovered in Drosophila as a protein 
secreted by midline glial cells (Rothberg, Jacobs, Goodman, & Artavanis-Tsakonas, 
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1990). The Slit/Robo pair not only functions in axon guidance but also in diverse 
developmental processes including cell migration, axonal branching, axonal targeting 
or cell differentiation (Chedotal, 2007). There have been studies investigating the role 
of slit 1, 2 and 3 in the growth and guidance of longitudinal dopaminergic projections 
in both mice (Bagri et al., 2002; Dugan, Stratton, Riley, Farmer, & Mastick, 2011) 
and zebrafish (Kastenhuber et al., 2009) in vivo studies. 
It has been suggested that during development the combined action of 
Slit:Robo interactions may initiate a strong repellent signal for midbrain 
dopaminergic axons with Slit3 expressed in the caudal midbrain being responsible for 
the repulsive action (Smidt & Burbach, 2007). It is thought that these Slit:Robo 
repulsive cues in combination with attractive signals from the forebrain, provide 
important signals that guide the axons to the ventral forebrain. In addition to these 
effects on dopaminergic axon guidance, Slit proteins have been implicated in 5-HT 
guidance. In slit1 and slit2 knock-out mice, 5-HT fibers enter the telencephalon 
normally, but a significant percentage abnormally crossed the midline in the basal 
telencephalon (Bagri et al., 2002). Although the majority of neural studies to date 
have focused on slit1 and slit2, since dopaminergic and serotonergic neural systems 
are intricately linked to reward and addiction and slit3 is expressed in the developing 
central nervous system, these findings suggest that variants at the slit3 locus may lead 
to increased drug seeking behavior through a neurodevelopmental role affecting 
pathfinding and circuit formation. 
As well as this axon guidance role, Slit:Robo interactions regulate 
neurogenesis. In Drosophila, Slit has been shown to modulate neurogenesis by 
promoting asymmetric terminal division in particular neural lineages (Mehta & Bhat, 
Chapter 5 
 155 
2001). In mammals, Slit:Robo signaling modulates the proliferation of central 
nervous system progenitors (Borrell et al., 2012). As deficits in adult hippocampal 
neurogenesis are linked to drug seeking behavior (Noonan, Bulin, Fuller, & Eisch, 
2010) and slit3 is highly expressed in the adult hippocampus (Marillat et al., 2002), 
these finding raise the possibility of the slit3 mutations leading to a reduction in 
hippocampal neurogenesis and increased drug seeking behavior. 
This presents two mechanisms by which slit3 variants could affect drug 
seeking behavior. Molecularly, Slits bind to the Robo Ig1 domains through the 
concave face of the leucine-rich repeat (LRR) 2 domain of Slit, a domain that is 
highly conserved among all Slits across species. In the outlier line the gene breaking 
mutation causes a truncation at amino acid 276 just before the LRR 2 domain, 
essentially removing the domain responsible for slit3’s functional interaction with 
Robo proteins. The independent allele sa202 has a truncation at amino acid 163, 
resulting in a similarly truncated protein. This loss of function would in all likelihood 
impact dopaminergic axon guidance in development or neurogenesis and in doing so, 
affect the response of adult zebrafish to nicotine reward in the CPP paradigm. 
There have been studies looking at slit3 knockout mice and the effect on heart, 
diaphragm and kidney development (J. Liu et al., 2003; Zhang et al., 2009) but no 
other phenotypes have been observed in a mouse model. SLIT3 was previously 
assumed dispensable for neural development but required for non-neuron–related 
developmental processes, such as the genesis of the diaphragm and kidney (Zhang et 
al., 2009). These experiments suggest that there may be more subtle behavioral 
phenotypes occurring in a SLIT3 knockout mouse worth investigating and the gene 
may not be as dispensible for brain development as once thought, 
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As way of further investigation, quantitative PCR was performed on 2, 3 and 
5-d.p.f slit3 (sa202) +/- incross and control embryos comprising of a +/+ wild type in-
cross. Quantitative PCR was carried out on dopaminergic and cholinergic genes to 
test the hypothesis that the slit3 mutation affects development of the reward circuitry. 
As such, dopaminergic genes drd1b, drd2a, drd3, dbh and dat; cholinergic genes 
chrnb2b, chrnb3, chrna2, chrna3, chrna4, chrna5, chrna6 and chrna7; and slit3 were 
analysed. There was little difference in expression levels for any genes on 2 and 3 
d.p.f, though differences begin to emerge between slit3 +/- and control 5-day old 
embryos. There was a general trend of down regulation of dopaminergic gene 
expression seen in drd1b, drd2a, slc6a6 and drd3, though these did not reach 
significance. For the cholinergic genes there was a noticeable relative down 
regulation of chrnb2b, chrnb3, chrna4 and chrna6 when compared with controls 
embryo, though these also failed to reach significance. There was however a 
relatively small but significant (p=0.001) increase in relative chrna5 expression in 
slit3 5-d.p.f embryos, presenting another possible mechanism by which a slit3 
knockout zebrafish may show altered nicotine induced CPP. 
Variations in α5/α3/β4 nicotinic receptors have previously been shown to 
associate with vulnerability to nicotine addiction in genome-wide association studies, 
with the α5 subunits showing particularly strong association in independent studies 
(Bierut, 2010; Exley, McIntosh, Marks, Maskos, & Cragg, 2012; Saccone, Wang, et 
al., 2009; Thorgeirsson & Stefansson, 2008). Previous studies in rodents have shown 
CHRNA5 gene deletion to result in decreases in acetylcholine mediated dopamine 
release (Grady, Salminen, McIntosh, Marks, & Collins, 2010; Salminen et al., 2004). 
α5 (along with β3) act only as accessory subunits in heteromeric nicotinic receptors 
forming nAChRs with the stoichiometry (α4β2)2α5 and therefore do not take part in 
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forming acetylcholine-binding sites (Kuryatov, Onksen, & Lindstrom, 2008). α4 and 
β2 on the other hand, can form binding sites as well as assembling in the accessory 
position to form nicotinic AchRs with stoichiometries like (α4β2)2α4 (Kuryatov, Luo, 
Cooper, & Lindstrom, 2005; Nelson, Kuryatov, Choi, Zhou, & Lindstrom, 2003). The 
α4β2 AchRs are the primary subtypes which show a high affinity to nicotine with 
(α4β2)2α4 being the most prevalent in humans (Nelson et al., 2003). Human 
(α4β2)2α5 subtypes have a higher permeability to Ca2+ and lower desensitization rates 
than (α4β2)2α4 when expressed in Xenopus laevis oocytes using a higher number of 
free α5 subunits to induce greater formation of this stoichiometry (Tapia, Kuryatov, 
& Lindstrom, 2007). The up-regulation of chrna5 in the slit3 knockout zebrafish may 
induce greater formation of the (α4β2)2α5 nAChR assembly with greater Ca2+ 
permeability and a subsequent increase in the regulation of dopamine transmission. 
This increased dopamine transmission when nAChRs are activated by nicotine during 
the conditioning stage of the CPP paradigm, may contribute to the slit3 knockout fish 
finding nicotine significantly more reinforcing. 
There were flaws with these qPCR experiments however. The main problem 
was that no homozygous mutant was identified. Numerous individuals were 
genotyped yet no homozygous mutant were ever identified. Slit3 homozygous 
knockout mice suffered from diaphragmatic hernia. This was caused by a central 
tendon that remained fused to the liver. In the defective tendon, the collagen fibers did 
not form tight bundles. Due to the herniation, the orientation of the heart was twisted 
(J. Liu et al., 2003). Such serious defects would decrease the survivability of 
homozygous mutants, certainly into adulthood (6-month to 1-year) when the fish were 
being used for breeding. As such, future experiments will look into genotyping 
Chapter 5 
 158 
offspring at various developmental time-points to see if fish are viable up to a certain 
age. It would also be possible to pool mutants at young age and monitor survival. 
The progeny analyzed for qPCR were the result of a heterozygous cross. As 
such it was decided to pool 5 progeny of a heterozygous in-cross to make sure the 
target mutation was most likely represented in the sample that was analysed. This is 
not ideal as the resulting samples analysed will have an undetermined assortment of 
mutants and wild-type which may have muddied the results. This may explain the 
lack of significant results despite seeing noticeable trends in down regulation in the 
dopaminergic genes. The plan to continue these experiments will be to genotype 
individual empryo’s by sequencing genomic DNA from the tail of a heterozygous 
incross before pooling based on genotype. This would result in decreased variance 
and help to tease out subtle differences in gene expression.  
This series of experiments identified a dominant mutation in one of the outlier 
lines in the first generation screen. This was shown to replicate in an independent line 
with a mutation in the same gene. Identification of the slit3 mutation as well as 
changes in α5 expression in 5-day embryos presents possible mechanisms underlying 
the altered nicotine seeking phenotype displayed in the QMhigh line. Now a gene has 
been established in the zebrafish model, the next objective is to address the second 
goal of this thesis, the translational aspect in which data from these studies is used to 
inform association studies in humans. This will be explored in the next chapter.  
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Chapter 6  
 
 
Analysis of slit3 SNP panel in human 
cohort for association with smoking 
behaviors 
 
With a causal mutation affecting nicotine seeking identified in the zebrafish model, 
this chapter investigates the human homologue for associations with smoking 
behaviors in human cohorts with varying smoking status. 
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6.1 Introduction 
 
In chapter 4, the CPP population screen was explored, during which the heritability of 
nicotine reinforcement was established over three generations. In so doing, lines with 
distinct nicotine seeking phenotypes were generated. The first generation screen 
identified a mutant line, which showed higher nicotine reinforcement than the 
population mean and clustered at the right of the distribution.  The four individuals 
from this line were selected from an F3 generation containing a mixture of 
homozygous, heterozygous and wild-type individuals suggesting the line contained a 
dominant mutation affecting the phenotype.  Candidate genes from a list of known 
possible null mutations (obtained from The Wellcome Sanger Trust) were 
investigated in this ‘QMhigh’ line and identified the presence of a slit3 mutation that 
segregated with the observed phenotype. An independent line (sa202) with a nonsense 
mutation in a similar region of the slit3 gene was then acquired through the zebrafish 
mutation project. This line also showed increased nicotine CPP indicating the slit3 
mutation was causal as opposed to other linked alleles which may be co-segregating 
and causing the observed phenotype. 
The aim of this project was to demonstrate that a fish screen in zebrafish could 
be used to inform human GWAS and find genes/alleles affecting behavior.  In order 
to test that hypothesis and demonstrate the translational relevance of the work in the 
fish population screen, the SLIT3 locus was investigated in people.  In order to do 
this, a range of SNP markers covering the SLIT3 locus were selected, firstly based 
firstly on previous association with disease in literature, and secondly based on 
showing linkage disequilibrium (LD) with other SNPs. The SNPs selected for 
analysis are summarized in Table 6.1. 
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SNP  Phenotype Literature MAF 
rs11742567 Smoking Cessation, G-allele associated with more increased cessation rates Uhl et al., 2010 0.39 
rs3733975 Schizophrenia-Schizophrenia, gender differentiated in males. Shi et. al., 2004 0.34 
rs2938774 Schizophrenia-Schizophrenia, gender differentiated in females. Shi et. al., 2004 0.39 
rs12521041 Schizophrenia-Schizophrenia, gender differentiated in males. Shi et. al., 2004 0.31 
rs11134527 Cancer, T-allele associated with more increased cancer rates Zhou et al., 2010 0.33 
rs9688032 Parkinsons, GWAS HIT replicated, associated with Vit D levels Li et al., 2008 0.39 
rs17665158 Bipolar disorder. Glessner et al., 2010 0.22 
rs13183458 Alzheimer's disease. Antonell et. al., 2013 0.24 
rs17734503 Obesity (BMI) Vogel et al., 2009 0.25 
rs12654448 Obesity (BMI) Vogel et al., 2009 0.19 
rs4282339 Height. Lango Allen et. Al. 2010 0.19 
rs12515725 GWAS of type II diabetes mellitus Saxena et. al. 2007 0.5 
rs295994 
Multiple continuous traits in DGI 
samples-Height in Type II Diabetes 
Mellitus Controls;Multiple continuous 
traits in DGI samples-Waist/height ratio 
squared;Multiple complex diseases-Type 
II Diabetes Mellitus, combined control 
dataset. 
Liu et. al., 2002 0.48 
rs7728604 HIV-1 disease progression-HIV-1 viral load at set point.  Anand, et. al 2013 0.3 
rs10036727  G [Gly] ⇒ S [Ser] AA Change 0.433 
rs297886 High LD with other SNPS n/a 0.275 
rs11749001 High LD with other SNPS n/a 0.167 
rs1345588 High LD with other SNPS n/a 0.175 
rs1559051 High LD with other SNPS n/a 0.293 
rs1421763 High LD with other SNPS n/a 0.267 
 
 
Table 6.1: Summary of SNPs used in association analysis. The rs-numbers are provided along 
with references, phenotype and minor allele frequencies (MAF) where applicable. 
 
 
The idea is to use these genetic predictors (20 SNPs) to see if they are associated with 
various smoking outcomes. The impact of SNPs on smoking initiation can be 
investigated by comparing those who have never smoked with other participants ((Ex 
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+ Current) v Never). A measure of persistent smoking can be obtained by comparing 
the genotype of current smokers against the rest (Current v (Ex + Never)). Figures for 
the number of cirgarettes smoked every day were also recorded and can be compared 
as a continous variable against genotype. 
The SNPs for analysis were initially selected based on biological significance, 
specifically with regard to their presence in the literature as having previously 
associated with a disease phenotype in a human GWAS. The rationale for selecting 
SNPs like this in the first instance, is that a previous association with disease in a 
GWAS means the SNP is more likely to be a mutation affecting (or acting as a marker 
for genetic code affecting) expression patterns of SLIT3, and thus having an effect on 
phenotype. The most interesting of these SNPs in the literature was rs11742567, 
which was shown to associate with smoking cessation success in 925 european-
american smokers given 16mg NRT and varying degrees of behavioral support (Uhl, 
Drgon, Johnson, Walther, et al., 2010). Also of particular interest were 3 SNPs 
(rs3733975, rs2938774 and rs12521041) associated with schizophrenia susceptibility 
in the Chinese Han population (Shi et al., 2004). Schizophrenia is a disorder that is 
partly caused by altered dopamine signaling in the mesolimbic pathway of the brain. 
It is also a disorder which has historically correlated with smoking, with sufferers 
showing a high rate of self-medication with nicotine; the therapeutic effect most 
likely occurring due to dopaminergic modulation through activation of nicotinic 
acetylcholine receptors (de Leon & Diaz, 2005; Keltner & Grant, 2006). Interestingly 
rs9688032, was shown to have an association with Parkinson’s disease, the 
degenerative disorder of the central nervous system (Y. Li et al., 2008). The loss of 
motor function often associated with Parkinson’s are a result of dopaminergic cell 
death in the substantia nigra, which is compelling given the role of SLIT3 in 
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dopaminergic axonal path finding. 
One SNP (rs10036727) was selected due to the polymorphism conferring an 
amino acid change at protein residue 618 from glycine (G) to serine (S). This is the 
only missense mutation present in a coding region of the SLIT3 gene and is included 
due to the possibility of an amino acid change affecting the properties of the 
translated protein. This in turn has the possibility of having an effect on phenotype, 
which may influence smoking behaviours. 
The final SNPs that make up the list were selected due to being in linkage 
disequilibrium (LD) with the highest number of other SNPs in the SLIT3 gene. The 
SNPs in the hapmap input file are then tagged for linkage disequilibrium using the 
tagger tool incorporated into haploview. Tagger is a tool for the selection and 
evaluation of tag SNPs from genotype data such as that from the International 
HapMap Project. Linkage disequilibrium is the occurrence of combinations of alleles 
in a population more often or less often than would be expected from a random 
formation of haplotypes from alleles. The amount of linkage disequilibrium depends 
on comparing the difference between observed allelic frequencies and those expected 
from a homogenous, randomly distributed model. In this context, the tagger provides 
a list of alleles which associate with the target SNP at a significantly greater rate than 
if they were just to segregate randomly. What this allows in terms of the experimental 
design, is to look for associations between the target SNP and smoking phenotype, as 
well as those SNPs with which it shows a significant degree of genetic linkage. 
Correlations among nearby variants can improve the cost-effectiveness of these types 
of studies, guiding selection of informative 'tag' SNPs and providing information 
about nearby variants not genotyped (Daly, Rioux, Schaffner, Hudson, & Lander, 
2001; Gabriel et al., 2002; G. C. Johnson et al., 2001; Patil et al., 2001). For instance, 
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rs297886 shows high LD with 17 other SNPs in the slit3 locus and by including it in 
the panel; it provides greater genetic coverage when looking for association between 
variants at this locus and smoking outcomes. This increases the likelihood of 
identifying genetic associations for the four smoking behaviours. The International 
HapMap Project is a resource that provides empirical genome-wide data to support 
such analyses 
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6.2 Methods 
 
6.2.1 Human cohort 
 
Subjects were recruited from a separate cross-sectional study conducted in London, 
UK, investigating environmental and genetic determinants of vitamin D status in 
patients with chronic obstructive pulmonary disease (COPD). The participants were 
therefore derived from three separate cohorts: a group with COPD (ViDiCO; n=272), 
a group with asthma (ViDiAs; n = 293) and a group containing residents and carers in 
sheltered accommodation schemes who did not have COPD (ViDiFLU; n=298).  
Principal exclusion criteria for the COPD study were smoking history <15 
pack-years; age <40 years; and ratio of forced expiratory volume in one second 
(FEV1) to forced or slow vital capacity (VC) after inhalation of 400 micrograms 
salbutamol >70%. The cohort comprised of subjects with mild, moderate or severe 
chronic obstructive pulmonary disease (COPD) treated with the same bi-monthly 3mg 
vitamin D3 intervention. Inclusion criteria was medical record diagnosis of COPD, 
emphysema or bronchitis and an age of 40 years or over. Exclusion criteria also 
included known asthma, sarcoidosis, hyperparathyroidism, terminal illness and 
malignancy other than non-melanoma skin cancer. The mean age of the cohort was 
64.6 (s.d. 8.5), 40% were female and 42% were current smokers. 
Asthma patients were selected on the basis of their lack of smoking history, 
which had to be < 15 pack-years. They were adult patients with asthma treated with 
inhaled corticosteroids treated with a bi-monthly 3mg vitamin D3 intervention. 
Inclusion criteria were a medical record diagnosis of asthma (plus corticosteroid 
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treatment) with an age between 16 and 80 years. The mean age of the participants was 
47 (s.d. 14.3), 56% were female while 7% of participants were current smokers.  
Principle exclusion criteria for the general population cohort in sheltered 
accommodation were: age <16 years and diagnosis of COPD or asthma. The cohort 
was comprised of older adults in sheltered accommodation given 10 mcg vitamin D3 
daily as well as bi-monthly 3mg vitamin D3 interventions. Participants needed to be 
residents or carers in sheltered accommodation aged 16 years or over. Exclusion 
criteria included known asthma, COPD, sarcoidosis, hyperparathyroidism, terminal 
illness and malignancy. Anyone taking thiazide and calcium supplement, cardiac 
glycoside, carbamazepine, pentobarbitol, phenytoin, primidone or long-term 
immunosuppressant therapy was also excluded. The mean age of participants was 
66.8 years (s.d. 13.1), comprised of 66% females and 18% were current smokers. 
The studies were approved by East London and The City Research Ethics 
Committee 1 (refs 09/H0703/76 and 09/H0703/112) and written informed consent 
was obtained from all participants before enrolment.  
 
 
6.2.2 Ordering TaqMan assays from the Applied Biosystems 
 
 TaqMan assay kits were ordered from http://www.appliedbiosystems.com, 
specifically the TaqMan SNP Genotyping Assays product page. Assays can be found 
by searching for gene name, SNP ID, Assay ID, Assay type or SNP type. There were 
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15 SNPs for which Applied Biosciences already had genotyping assays available, 
these are listed in table 6.2. 
To design SNP targeting primers for the 5 remaining alleles the sequences shown 
below in figure 6.1 were entered into the Custom TaqMan® Assay Design Tool web 
site in the 5’ to 3’ direction. The sequences entered are roughly between 500 and 1000 
basepairs in length and generated to the following parameters:  
- Use only A, C, G, T, and N, except where SNP or indel target sites are 
marked.  
- Convert the IUPAC codes R, Y, M, K, S, W, H, B, V, and D to N, except for 
marked SNP target sites where you translate the ambiguity code to the 
appropriate bases.  
- Enclose each target site with square brackets [ ].  
- SNP targets: Enter the base for the first allele followed by a forward slash (/), 
and then the base for the second allele. For example, convert R to [A/G]. 
Assays that are designed in regions of a sequence that contain repeats and 
polymorphisms are likely to produce nonspecific amplification and probe binding. 
To reduce the likelihood of nonspecific amplification and probe binding, these 
regions need to be masked (which is accomplished by replacing such regions with 
an ‘N’ as mentioned above. 
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SNP  Taqman Assay 
rs11742567 Not Available 
rs3733975 C__25753801_10 
rs2938774 C___1457640_10 
rs12521041 C__31235183_10 
rs11134527 C__30743954_10 
rs9688032 C___3220724_10 
rs17665158 C___3073893_10 
rs13183458 C___1457618_10 
rs17734503 C__32834038_10 
rs12654448 C___3220757_10 
rs4282339 C__27909684_10 
rs12515725 C___3200020_10 
rs295994 C___1030672_10 
rs7728604 Not Available 
rs10036727  Not Available 
rs297886 C___1012759_10 
rs11749001 Not Available 
rs1345588 Not Available 
rs1559051 C___3200034_10 
rs1421763  C___7526127_10  
 
Table 6.2: List of 20 SNP rs numbers included in smoking status association study along with the 
TaqMan assay numbers. SNPs that do not include a TaqMan number in the second column indicate 
that a pre-designed assay did not currently exist. Those 5 need to be custom designed. 
 
rs11749001 
AATGCATTTGGGAAANGCACATCTANACATTTGGGAAGCTGATGTTCACA
TCCTCCGCCTCAAATACCTCTGAGGTAATGAATTCCATAAAATTGACATCT
GCTCTTACAGCACAACTTCCCATTCATGCATTTTTTCCATTAAAAAATATT
TTAGNNCTGTACTAAACCCTGCTAATAAAAAATAAAANTACAATTCCC[C/
T]GCTCACAAGTAGCTCATAGCATGGTNGGGAAGGCAGTTAAAGCACNAG
TCTCGGAGTTGGAGTATGGCTGATGCTCAATAATAGTTTGCTGGGGAAGC
TAGAGCTAGAAGAAGTCTTTCTAATAAATAAGACCAGCATAGTCAGGGAG
GGCTTCCTAGAGGTGGAGAGATGAGCAATGAATTTTAAAGAACGAGATTC
AGCCTGTAATCCCAGCACTTTGAAAGGCGCAGAGGGGTGGATACCNTTGA
GGTCGGGAGTTCGAGACCAGGCTGACTAACATGATGAAACCCCGTCTCTA
CTAAAAATACAAAATTAGCTGGGTGTGGTGGCACATGCCTATAATCCCAG
CTACTTGGGAGGTTGAGGCAGGATAATCGCTTGAACCCGGGAGGCGAGG
GTTGCAGTGAGCNAAGATCGCGTCTTTGCACTCCAGCATGGGCAACAAGA
GTGAAACGCCATCTCAAAAACAAAAAAGAAT 
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rs1345588 
TGCTATCTGTCCATCCTGTTTGGGTGGGGAGCTATCTGAGCTGTGCAGAGG
TGGCAGGGGTGGGCCCTGCTGAGGAATGCAGCAAGGGGCTCACCCCACG
ACCCACAGATGCATGACCCTGCCCAAGGGAGGGCTTCTCATCTTACTCAG
CCTCAGCTAGAAGCCAGTGGTGACACATTCNGGGGTGTCTATTCCTATCCT
GAGATAGAGCCACATGGAAATTCAAAAGATGAAATCNCAGAAGCAGTTT
ATCACCCAAGTATAAAGACAGGCATCTGTCAACAAAGGAACATGATCATA
GCTGAGTGTTCCTTGAGTGGCTTTTCCTTCATTGCTCTCAAAGCCTTTTGAG
ATCTCGAAAAGTCTCCAGTGGGCAAGACTTGACATTCTATGTGTGAGACA
CAGATGCAGAATCAGACATGGATACCGTGATTCGCTGCTACATGNCCGGT
GTCTTCAGCTCANNTCTGCTCACTCACACANGAGGTGACCAATCCCAAT[A
/G]ATNGGGGATCCTGTCCCAGCCCCCAGTTCTCCAGCAGTGTCTCCTGGCT
CCCCTCTTTAGANCCAGCACCACTCTCATTCTTGCAAGCCACCTGACTCAT
GGCTTTCCCATTCACCTCCTGCCCTGTCCTTGGTACCCCACATTGCTCTGG
ACACCACAGTGCCCTGTATAGCCACTGGTCCCATGGCGGGGATCCTCAGG
CAGAGAGAAGATACTAAAATCAACTCACTTGCAAACAGGCCCTCTTCCTC
ACAAACTGGAAGATGGATCCTAGCCAAATGNNAAAAAAAAANNAAAAGC
TTAAATTTTTAGGTTTTAAAAAAATCAATGTAAGGAAAATTCTCAAATGGT
TGAAAAATATTCAATCTACAGTAGGCCTTGGGGATGTGTATTTTTTTGGCT
AGGGGACCTCCTGAGTTTCTTTAATCACACCAAATAAATGATTCTCTTCTC
CAACTATGGATAAGGCTGGCTCTGATTGGTATATGAGATCACACACATAT 
 
rs7728604 
TATTAGGNAGTCCTGGAGCTTGTGGAATGAGTTGCTCTGCCTAAGAGCAT
GNAAGAGAAAAGAATTCCCAACACCCCATTCTGGCACAATAATAGATAGC
CCAGGTGTCAGGCCTACCAGTCAGTTAANCAAATTTGCAAGACCGAGGGG
CTGTCTCCAGTGCTTTCTACTGNTTCTCTGCTTTGATACAGGTTGAGTATCC
CTAATCCAAAAATCCAAAANTCTGAAATGCTCCAAAATCTGAAACTTTCT
GAGCACTGACATGANNTCACAAGTGGAAAATTCCACACCTGACCTCATGT
GACTGATGGATTGCAGTCAAAACTTCATATCATGCACAAAATTATTAAAA
ACTTTGTATAAATTACCTTCAGCCTATGTGTGTGAGGTATATATGAAACAT
AAATGAGTTTCATNNTTAGACTTGGATTCCATTCTCAAGATATCTCATTAT
GTATGTGAAAATATTCCAAACTTTGAAAAATTCAGAACGCTGAAATG[C/T]
TTTTGGCCCCAAGCATTTTGGATAAGGAATACTCAACCTTTTAGTTTGTAC
TTGGAATGTTTTTTATACNAAGGTAACCACTAGGAATAGGCAGAGACAAA
GCCATTCATTCAGAGAGAATTCTTTTTTTTNCTCTCCCCCCTCCCCTTTTTT
CTTTTCTTTTTTGGTAAGAGANAAGAGCAGGATGTGNTTCAGTCACAGTTG
AGGGGGAAACTTCCTCCTGTTAGATATTAGGGATAAACTGGTCACGTATA
TTTAGGAAAAATTAGGGTTTTGAAATCCATTCTCACCAGGGACCCTACCTC
TCCCAAACCATTGATTGCACTTCAGTCTAGGTTTCTGAAGTTCCATTAGTC
GAACATTTTTAAGTGTGCTCTCTTCTCTATTGCCATCCTCTTGGGGGAAAA
AAAGGGCATCATAATAAATATCAGTAGCATCATAAGTGATCAAAAATTAA
ATTCACTTTCCAGGTCGTGACTGAGAAGGTCTTATGAATTTTGA 
 
rs10036727 
GTAGAGAAGGGGTTTCACCATGTTGGTCAGGCTGGTTTCGAATTCCTCACC
TCNGGTGATCCACCCACCTCAGCCTCCCAAAGTGNTAGGATTACAGGCGT
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GAGCCACCATGCCTGGCCTTCCAGCTTGGGTTTTCAAATCACTGTGGACAT
GCTTTCTGTGGCAATTCACTATGCTGTGAGTTCCAGGAAGGAGGGGCNNG
GTGTGTGCAGCCTCAACACCTAGACGATGCCTGCCTGGCACATACAGAAA
GCCTGANGAGTTTTTAAGTGGACAGACAGATAGATGAGCCTGGCTAGAGG
TAGCAGGGAGCTGGGAGGAGAGAGCGCTGCAGAGTGGGANCCCAGAGTC
CGTGGGCAGTGGACCCAGGAGAACTTACATGGTGGACAGGGAGACAAGC
GTGGTGAAGGCCCCAGGGGTGATGGTGGTGATCCGATTGTNATAGAGGGA
CAGCAGTCTCACCGAANTCAGGCCGGCAAAGGTGTCATTACTCACACAGC
[C/T]GATCAAGTTACNTCCTCAGCATCNTACAGGNAGAGGGGTGGGGATG
AGAGAGCACAGGCATGATCTTTTCTGTCCCAAATGGTGCCACGGTGGTGT
GTGTGTGTGTATAGGTGAGATGCTTTTGCCAATTCTAAGCTCAGTCCAGCC
ATGTTGATCAGGTTTGTCCTGTGATAGCAGGGACTGGAGCCCCACTGGGG
CTGTGTGTAAATGTGTATGTACATTATTGTTTGTGCATGCTTTCTTGGAAG
CACATGTCATGCATATGTGTGTATACACACGCATATTGTGTGGCTGCTAGG
GTGTGCACACATATTNCTGGGAAGAGAAGAGAGAATCAAGACGTGGTTGT
AGACATCAGCTTGTATGTATGTGTGTGCTTGTGTGTCTGTGCCTGTTTGTA
TATATGTTTATGTGCATGTTGCACGTGTCTGCATNTATCATTTTTATAAAG
GTCCTTATGCTTATGTTTGTGGGTAAATGTCTGTTTGTGTGCCTCCTTCA 
 
rs11742567 
CCTGAGAGGGTACAATAGATTTGGAAAATGCATTCAATCCAGAAAAGGGC
TGTGTGCCTGACAGNGTTTCATCTCCAAGAACAACTTCTCCCCTCCTCCTT
TCTGAATTCTGGCACTCATAGAGATTAGGATAATACAGATAATGAAGCTC
AGGTACAGAAGGAGATACTTNAAGCAACAGCCTCCAGGAGATGTTAGAA
GAGGGTCATTGGCAGTGAGGAAGTTCTGATGATCTTTGGGATAATCTACA
CTGTGATCTGACTCCTTCCAGGCAAATTGTCTAAAAGCTCTGGAAACCCTC
CCAGAGGCTGAAGATGTACAGAAATAAAGTTGAGGGTTGTAGTGAGGTG
AGGAGGTAAGAAAAAGAGAGGAAGTCAGCGGGCTAAGGCACTGCAGTTT
GGGAGAAGTTGAAGCCACTTCCTAGTGTCTACCCCACTGTAACCTTAAAT
GTTCAGCTTGATCATGAAGAAAGGATTCTTGGAACATTGCTCCGGATCTA
C[C/G]TAACCCTAACACTCTTTGTGATATGGCACTAGAGTTCCTCTTATGTG
GCCCACTCTGTTCCACNGAGGAAACATGAACATGCCAGGGCAGGGTGGG
GAGGGGCTGTGCCTGGGCTGCGGCTGCCCAGAGGTTGGAGTTTGGCAGGC
AGCACTGCAGCTCAAGGACATGGGACTTGTNTATGTCTGTGCTTTCTTGTA
ACTTTTCAGAAGACCATTAAACAAGTGAAACCTCAATGGTAGAGGTGAGA
TGCTATCCTGGGGCCATCTGCTGATAAAATCAGTATGCTTCAGAAAAGCT
CAAAATTATCTTCCACCAAAGCAGGAAAGCAATTCAGCAAGAGCTCAGCA
CCNTGAGTTGCAAAGCTGGCCTCCAGAAGCCCAGTAACGGATGAAATATA
TAGGAGCTTAAGCCATTAAGCTATGTTAATACTATAGAATGACNTTTCTCA
TCATGACCCCATGCGCTATTTATTGTTCCATTCAAAGCAATTACAGTTATT
G 
 
Figure 6.1: Sequences sent to Applied Biosystems for the design of custom TaqMan SNP genotyping 
probes. The site for the SNP of interest is donated with two square brackets with the two possible 
bases. Areas where other polymorphisms and insertions may occur are marked or masked by inserting 
an N at that location. 
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6.2.3 Allelic discrimination plate read and analysis 
 
Each DNA sample was diluted with DNase-free water to deliver a final DNA mass in 
the range of 1 to 20 ng per well. A total of 2.25 µL of genomic DNA was added to 
each well in a 384-well reaction plate. The master mix was then prepared as to give 
for each reaction well as follows:  
- 2.5 µL TaqMan Universal PCR Master Mix (2X)  
- No AmpErase UNG,  
- 0.25 µL 20X working stock of SNP Genotyping Assay.  
The plates were run on an Applied Biosystems 9800 Fast Thermal Cycler, 
using the 9700/9600 emulation mode and the following thermal cycling conditions:  
o 95°C for ten mintutes 
o Denature for 15 seconds at 92°C and an anneal/extention step of 1min at 60°C 
for a total of 40 cycles. 
After the PCR amplification, the plate was read using an Applied Biosystems Real-
Time PCR System. The software used the fluorescence measurements made during 
the plate read to indicate which alleles were in each sample. 
 
6.2.4 Downloading dbSNP files and SNP tagging using haploview 
Initially, it is necessary to generate a hapmap style input file for the slit3 gene, which 
can be done on dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/) by searching for 
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the gene, selecting the whole gene (plus any flanking sequence of interest) and 
selecting export.  This generates an output file of the gene of interest containing all 
known SNP. 
Haploview is based on Paul de Bakker's Tagger. Tagger is a tool for the selection and 
evaluation of tag SNPs from genotype data such as that from the International 
HapMap Project. It combines the simplicity of pairwise tagging methods with the 
efficiency benefits of multimarker haplotype approaches (de Bakker et al., 2005). As 
output, Tagger produces a list of tag SNPs and corresponding statistical tests to 
capture all variants of interest, and a summary coverage report of the selected tag 
SNPs. 
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SNP  Haploview Tagged SNPs 
rs11742567 rs11134544, rs11742567, rs12521361, rs3923474 
rs3733975  
rs2938774  
rs12521041 
rs11741109, rs11744726, rs11748325, rs2194099, rs898401, rs2054274, rs10475884 
rs12521041, rs11746295, rs1864953, rs7705016, rs17553140, rs4868519, rs4867894 
rs4867802, rs11750194, rs4868530, rs10056503, rs17553274, rs1870563, rs4868094 
rs10516049, rs17553085, rs2277933, rs17732425 
rs11134527 rs9784690, rs1368355, rs6860336, rs11134527 
rs9688032  
rs17665158 rs1048307, rs11743244, rs17665158, rs13179467, rs2303002, rs12655287 rs11749992, rs1460100, rs6869359, rs10516048, rs1155191, rs11750308 rs17665285  
rs13183458 rs13183458 
rs17734503  
rs12654448 rs17734605, rs1432898, rs17666992, rs3749674, rs2278386, rs7700954, rs17667033 rs12654448, rs17734593, rs1059160, rs6887076, rs6555846 
rs4282339 rs6555846, rs2974438 
rs12515725 rs7722860, rs12515725, rs2879149 
rs295994 rs295994, rs6863538 
rs7728604 rs7728604, rs3797717 
rs10036727  rs7706177, rs1549909, rs10036727 
rs297886 rs297886, rs297811, rs297873, rs297884, rs297869, rs190935, rs297867, rs297878 rs297822, rs297876, rs10462982, rs297882, rs297819, rs297877, rs7700961 rs297885, rs7701204 
rs11749001 
rs6873937, rs11742763, rs11744997, rs11745045, rs6881546, rs4867734, rs4868340 
rs17637311, rs10516061, rs4868339, rs17637230, rs297868, rs9313447, rs11749001 
rs10462980, rs4868338 
rs1345588 rs8180402, rs297850, rs745682, rs1345588, rs17735527, rs978902, rs12514330 rs12516235, rs177073, rs11745049, rs17735570, rs10866632, rs10866631, rs172472 rs11738097 
rs1559051 rs297820, rs17637212, rs297864, rs297865, rs10058857, rs297823, rs17637323 rs297817, rs297863, rs17556404, rs297815, rs1559051, rs297818, rs10063923 
rs1421763 rs9313446, rs1421762, rs297874, rs1421763, rs17667652, rs10516060, rs17667664 rs7704526, 
rs2112193, rs1006329, rs7732724 
 
Table 6.3: Table of haploview tagging results for each of the target SNPs. 
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6.2.5 Generation of LD plot in Haploview 
 
The hapmap input file was loaded in haploview, before selecting the target SNPs from 
this study for inclusion. Once selected, LD plots can be generated by selecting the 
‘LD view’ tab. Haploview calculates several pairwise measures of LD, which it uses 
to create a graphical representation. The output visualizes the occurrence of haplotype 
blocks, which are sizable regions over which there is little evidence for historical 
recombination with only a few common haplotypes occuring. 
 
6.2.6 Statistical analysis 
 
Genetic association analysis was carried out using PLINK v1.07 (Purcell et al., 2007). 
We combined smokers of European ancestry from the three cohorts. There was a total 
of 486 smokers, 254 from the COPD cohort, 100 from the asthma cohort and 132 
from the general cohort. Of twenty SLIT3 SNPs genotyped, one – rs13183458 - 
exhibited departure from Hardy-Weinberg equilibrium, and was excluded from 
analyses. Linear regression was performed on the average number of cigarettes 
smoked per day, controlling for age, sex and cohort under an additive genetic model.  
Binary outcomes were analyzed using logistic regression against the additive 
genotype model, again controlling for age, sex and cohort. Multiple testing was taken 
into account using the Benjamini-Hochberg adjustment controlling for a false 
discovery rate of 10%. For analyses on heavy smokers there were 249 individuals 
from the COPD cohort, 17 from the asthma cohort and 66 from the general cohort. 
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6.3 Results 
 
6.3.1 TaqMan and allelic plate read analysis 
 
In total 843 individuals from across the three trials were genotyped successfully at the 
20 different loci. When broken down, this included 293 from the ViDiAs trial, 272 
from ViDiFlu and 278 from ViDiCO. Allele frequencies from the genotyped cohort 
(Table 6.5) were comparable to values derived from the Ensembl genome browser 
(Table 6.4). As well as showing allele and genotype frequencies for each of the target 
SNPs, table 6.5 shows Hardy-Weinberg frequencies. All SNPs were found to be in 
Hardy-Weinberg equilibrium apart from rs13183458 (X2 = 4.008, p = 0.04). When the 
ratios of homozygous and heterozygous genotypes significantly differ from the 
prediction under HWE assumptions, it can indicate genotyping errors, batch effects, 
population stratification. Typically departure from HWE is an indicator that a marker 
should be discarded. As such, rs13183458 was disregarded from further analysis 
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Table 6.4: Allele and genotype frequencies according to data from the Ensembl genome browser.  
 
 
 
Table 6.5: Allele and genotype frequencies of each SNP in the cohort of 843 participants in the 
ViDiAs/CO/Flu trials. Hardy Weiberg frequencies were calculated for each allele and then assessed for 
whether it deviated from predicted Hardy Weinberg equilibrium. 
 
SNP Allele$1 Allele$2 1/1$freq 1/2$freq 2/2$freq
rs11742567 C"(0.6) G"(0.4) 0.34 0.52 0.14
rs7728604 C"(0.61) T"(0.39) 0.39 0.45 0.17
rs1345588 A"(0.14) G"(0.86) 0.02 0.24 0.74
rs17734503 A"(0.9) G"(0.1) 0.8 0.2 0
rs11134527 A"(0.21) G"(0.79) 0.024 0.38 0.6
rs10036727 C"(0.5) T"(0.5) 0.28 0.44 0.28
rs3733975 C"(0.73) G"(0.27) 0.57 0.33 0.11
rs4282339 A"(0.21) G"(0.79) 0.06 0.31 0.64
rs11749001 C"(0.87) T"(0.14) 0.75 0.22 0.02
rs12521041 C"(0.73) T"(0.27) 0.57 0.33 0.11
rs297886 G"(0.73) T"(0.27) 0.53 0.4 0.071
rs295994 C"(0.6) G"(0.4) 0.33 0.53 0.14
rs13183458 C"(0.78) T"(0.22) 0.64 0.28 0.08
rs2938774 A"(0.62) G"(0.38) 0.38 0.49 0.13
rs17665158 C"(0.2) T"(0.8) 0.06 0.28 0.66
rs12515725 C"(0.62) G"(0.38) 0.4 0.44 0.17
rs1559051 A"(0.67) C"(0.33) 0.46 0.42 0.12
rs9688032 A"(0.27) T"(0.73) 0.06 0.42 0.52
rs12654448 C"(0.9) T"(0.1) 0.8 0.2 0
rs1421763 A"(0.25) G"(0.75) 0.07 0.35 0.58
SNP Allele$1 Allele$2 1/1$Freq 1/2$Freq 2/2$Freq X2 P-Value
rs11742567 0.66 0.34 0.43 0.45 0.12 0.026 0.872
rs7728604 0.62 0.38 0.41 0.44 0.16 3.691 0.055
rs1345588 0.14 0.86 0.02 0.24 0.74 0.266 0.606
rs17734503 0.88 0.12 0.79 0.19 0.02 3.711 0.063
rs11134527 0.27 0.73 0.08 0.39 0.53 0.066 0.797
rs10036727 0.48 0.52 0.22 0.53 0.25 2.469 0.116
rs3733975 0.74 0.26 0.55 0.38 0.07 0.026 0.872
rs4282339 0.2 0.8 0.04 0.32 0.64 0.047 0.828
rs11749001 0.85 0.15 0.73 0.25 0.02 0.053 0.818
rs12521041 0.75 0.25 0.56 0.38 0.07 0.094 0.759
rs297886 0.79 0.21 0.63 0.33 0.04 0.122 0.727
rs295994 0.55 0.45 0.31 0.48 0.21 0.515 0.473
rs13183458 0.74 0.26 0.57 0.34 0.09 4.411 0.244
rs2938774 0.57 0.43 0.35 0.46 0.2 1.622 0.208
rs17665158 0.22 0.78 0.07 0.3 0.63 4.008 0.045
rs12515725 0.55 0.45 0.3 0.51 0.2 0.548 0.459
rs1559051 0.7 0.3 0.5 0.41 0.1 0.821 0.365
rs9688032 0.33 0.67 0.12 0.43 0.45 1.169 0.28
rs12654448 0.91 0.09 0.83 0.16 0.01 0.532 0.501
rs1421763 0.22 0.78 0.05 0.35 0.6 0.064 0.8
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6.3.2 Statistical analysis 
 
Since there is significant conservation of neural pathways between vertebrate species 
(M. O. Parker, Brock, Walton, & Brennan, 2013) we  looked for associations between 
19 single nucleotide polymorphisms (SNPs) in the human SLIT3 gene and self-
reported smoking behavior. Two SNPs, rs12654448 and rs17734503 in high linkage 
disequilibrium (Figure 6.3) were associated with number of cigarettes smoked per day 
(p=0.00125 and p=0.00227; Table 6.6a).  We repeated the analysis on heavy smokers 
(>=20 cigarettes per day) to investigate whether effects were related to level of intake. 
Controlling for age and sex rs12654448 (P=0.008569) and rs17734503 (P=0.01837) 
were again associated with number of cigarettes smoked as was rs11742567 
(P=0.006145, (Table 6.6b). When adjusted for age, sex and cohort, the same SNPs 
remained significant: rs12654448 (p-value=0.0003397); rs17734503 (p-
value=0.0008575) and rs11742567 (p-value=0.004715) (Table 6.6d). rs11742567 was 
also associated with smoking cessation (Table 6.6d). No other SLIT3 polymorphisms 
were associated with initiation, persistent smoking or cessation (Supplementary 
Tables 6.7a&b). 
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Table 1A. Associations of SLIT3 SNPs with self-reported level of tobacco consumption. 
Regression coefficients, confidence intervals and p values from linear regression of cigarettes smoked 
per day (CPD) on minor allele count for smokers from COPD, asthma and general cohorts, adjusted for 
age, sex and cohort. β=regression coefficient, which represents the effect of each extra minor allele. 
SE=standard error of regression coefficient. Benjamini-Hochberg cut-off at q-value 0.1 = 0.01053. 
Table 1B. Associations of SLIT3 SNPs with tobacco consumption in heavy smokers (>=20 
cigs/day).  Adjusted for age, sex and cohort. (q-value 0.1 = 0.01579). Table 1C. Associations of 
SLIT3 SNPs in light smokers (<20 cigs/day). Adjusted for age, sex and cohort. (q-value 0.1 = 
0.00526). Table 1D. Associations analysis of slit3 SNPs with cessation. Logistic regression of 
current smokers vs ever smokers controlling for age, sex and cohort. OR: Odds ratio. >1 value 
indicates that the minor allele increases odds of persistent smoking relative to the major allele, SE: 
standard error, L95: lower limit of 95% confidence interval, U95: upper limit of 95% confidence 
interval. (q value 0.1 = 0.00526). For all panels, associations marked in red remained significant after 
adjustment for multiple comparisons using a Benjamin-Hochberg procedure to control the false 
discovery rate at 10%. 
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Supplementary table 5 & 6: Results of association analysis of slit3 SNPs on smoking initiation (5) 
and Persistent smoking (6). logistic regression of initiation vs non-initiation on additive genotype, 
controlling for age, sex and cohort. OR: Odds ratio. >1 value indicates that the minor allele increases 
odds of persistent smoking relative to the major allele, SE: standard error, L95: lower limit of 95% 
confidence interval, U95: upper limit of 95% confidence interval. Benjamini Hochberg cut off at 0.1 = 
0.00526. 
 
 
 
SNP OR SE L95 U95 P value
rs2938774 0.7253 0.1418 0.5493 0.9578 0.02357
rs11742567 1.328 0.1538 0.9825 1.796 0.06496
rs4282339 0.7277 0.1815 0.5099 1.039 0.07991
rs297886 1.328 0.176 0.9405 1.875 0.1071
rs9688032 1.269 0.1495 0.9467 1.701 0.111
rs7728604 1.198 0.1446 0.9024 1.591 0.2112
rs1345588 0.7788 0.2046 0.5215 1.163 0.2218
rs17734503 0.7362 0.2632 0.4395 1.233 0.2445
rs12515725 0.8612 0.1458 0.6471 1.146 0.3052
rs11749001 0.8698 0.1951 0.5933 1.275 0.4746
rs3733975 1.116 0.1641 0.8092 1.54 0.5029
rs12521041 1.116 0.1641 0.8092 1.54 0.5029
rs11134527 0.9212 0.155 0.6798 1.248 0.5964
rs12654448 0.8718 0.2654 0.5182 1.467 0.6052
rs1559051 0.9257 0.1575 0.6799 1.26 0.6241
rs17665158 0.9304 0.171 0.6654 1.301 0.673
rs1421763 0.9423 0.1704 0.6748 1.316 0.7271
rs295994 0.9732 0.1404 0.7391 1.281 0.8464
rs10036727 1.01 0.1522 0.7491 1.361 0.9503
SNP OR SE L95 U95 P value
rs11134527 1.428 0.1573 1.049 1.943 0.02359
rs12521041 0.6871 0.1736 0.489 0.9655 0.03061
rs11742567 0.7288 0.1547 0.5382 0.987 0.04089
rs3733975 0.7165 0.1712 0.5123 1.002 0.05146
rs17734503 0.6142 0.2631 0.3667 1.029 0.06398
rs1345588 0.6786 0.2145 0.4457 1.033 0.07068
rs17665158 1.338 0.163 0.9722 1.842 0.07393
rs12654448 0.6225 0.2671 0.3688 1.051 0.07597
rs2938774 1.232 0.1394 0.9373 1.619 0.1348
rs295994 1.214 0.1443 0.9147 1.61 0.1796
rs7728604 1.152 0.1434 0.8699 1.526 0.3232
rs1559051 1.115 0.1549 0.8231 1.511 0.4821
rs12515725 0.9108 0.1456 0.6846 1.212 0.521
rs297886 0.9342 0.1726 0.6661 1.31 0.6932
rs4282339 0.9391 0.19 0.6471 1.363 0.7411
rs10036727 0.9596 0.1516 0.713 1.292 0.7857
rs1421763 1.029 0.1671 0.7417 1.428 0.8633
rs9688032 1.013 0.1511 0.7531 1.362 0.9328
rs11749001 0.9943 0.1969 0.676 1.463 0.977
A 
B 
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6.3.3 Linkage disequilibrium & haplotype block analysis 
 
The LD analysis produced the plot seen in figure 6.3, with two main blocks of high 
LD. Regions are partitioned into segments of strong LD. This display shows lines to 
indicate transitions from one block to the next with frequency corresponding to the 
thickness of the line. The blocks of LD were calculated using the default algorithm 
(Gabriel et al., 2002). The level of LD between pairs of SNPs are represented by 
colors, with dark red indicating strong LD, through to white indicating little linkage 
(Barrett, Fry, Maller, & Daly, 2005). The first block encompassed the 3 SNPs 
rs3733975, rs12521041 and rs17665158. The second comprised of a larger block of 
SNPs including rs1559051, rs11749001 rs297886 and rs1421763 
 
Figure 6.3: Linkage disequilibrium plot constructed by haploview from genotyping data using default 
LD algorithm. Two LD blocks are shown, the first consisting of 3 SNPs rs3733975, rs12521041 and 
rs17665158. The second is comprised of a larger block of SNPs including rs1559051, rs11749001 
rs297886 and rs1421763. 
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6.4 Discussion 
 
 
The analysis presented in this chapter was successful in addressing the second 
aim of this thesis; namely to use genetic loci identified in the zebrafish behavioural 
paradigm to both reaffirm previous GWAS studies and inform further clinical studies. 
The first generation screen of mutants was able to identify a slit3 mutation in a line 
that clustered to the right arm of the. The gene had previously been identified, along 
with several others, as having an association with precessation NRT quitting success 
(Uhl, Drgon, Johnson, Ramoni, et al., 2010). This justified carrying out a SLIT3 SNP 
analysis on the COPD and asthma cohorts, chosen due to the participants having a 
heavy and light smoking histories respectively. In doing so 1 SNP (rs12654448) was 
found to show significance at the corrected threshold (p < 0.0027) with the number of 
cigarettes smoked per day in the COPD cohort. This SNP also showed an association 
in the asthma cohort, though this was not significant at the corrected alpha level (p = 
0.04). Interestingly, 9 SNPs reached significance in this cohort indicating that there 
was a likely ceiling effect in the COPD cohort masking possible effects. This is also 
indicative of rs12654448 being of particular importance due to not being affected by 
this ceiling effect. 
The rs12654448 SNP, located in an intronic region of the SLIT3 gene. This 
SNP was initially selected for inclusion in the genotyping analysis based on 
previously appearing in GWAS literature as a polymorphisms that was associated 
with a human disease phenotype. This SNP had previously showed association with 
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increase body-mass index in two studies (Y. J. Liu et al., 2008; Zhao et al., 2007) 
though this was not found to be replicable in a third study (Vogel et al., 2009).  
Variations in the SLIT3 gene may affect BMI due to alterations in dopamine 
signaling, which plays an important role in appetite control (Hardman, Herbert, 
Brunstrom, Munafo, & Rogers, 2012). Hormones from the gut, pancreas and fat stores 
influence dopamine signaling as a means of detecting nutritional status and regulating 
feeding behaviour (Clifton, 2000; Wise, 2006). It therefore seems plausible that 
abnormalities in the dopaminergic system contribute to over-eating and obesity with 
inappropriate cues to eat becoming as compelling as drug addictions. 
The SLIT3 SNPs rs12654448 and rs17734503 (in LD with rs12654448 and 
significant in general population cohort) and were reported to be associated with 
increased BMI with odds-ratios and confidence intervals of 1.150 (0.814 – 1.626) and 
1.126 (0.791 – 1.602) respectively. In this smoking study, the effect of rs17734503 
(4.5 fewer cigs/day) and rs12654448 (2.8 fewer cigs/day) was to reduce the average 
number of cigarettes smoked per day for those with at least 1 copy of the minor allele. 
As such, these two polymorphisms in the SLIT3 gene have been shown in this study 
and previous studies to be a modifier of the reward-motivated characteristics, 
smoking and obesity.  
These two SNPs are located in intron 32 and in LD with one another while 
also being in LD with a number of other SNPs. The marker rs12654448 was tagged as 
being in LD with the following SNPs: rs17734605, rs1432898, rs17666992, 
rs3749674, rs2278386, rs7700954, rs17667033, rs17734593, rs1059160, rs6887076 
and rs6555846. All of these SNPs are present in intron 32 of the SLIT3 gene. There 
were no SNPs in LD with rs17734503, however it is also present in intron 32 of the 
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SLIT3 gene. This raises the possibility of the SNPs being linked to variations in the 
32nd intron that effect translational or transcriptional processes, which in turn alters 
phenotype. The intron itself is roughly 318kb in length, which is very large and 
accounts for roughly 50% of the entire SLIT3 gene. These findings reaffirm a role for 
SLIT3 variation in effecting smoking behavior as well as identifying a number of new 
SNPs that could potentially act as markers when informing smoking cessation 
strategies. 
There were three common SNPs between the asthma and general population 
cohorts. The first SNP was rs7728604, previously implicated in Parkinson’s disease in 
GWAS studies (Fung et al., 2006; Simon-Sanchez et al., 2007). The SNP rs17665158 
falls within block 1 of the LD analysis while rs12515725 occurs in block 2. These two 
regions of the SLIT3 gene may be good targets for further haplotype analysis. 
There are also limitations to an analysis of this type. Primarily, the sample is 
of modest size from the perspective of a genetic association study and this results in 
the power being quite modest also. This lack of power led to a few promising 
associations being lost when the new significance threshold was calculated. These 
associations may have proven to have reached significance with a more adequate 
sample size. Also, since this was not a smoking trial in the first instance, smoking 
histories are not as detailed as they could be. Future work like this could really benefit 
from having a dedicated library of genomic DNA from a larger cohort of people with 
differing smoking histories. If more detailed information was available about smoking 
habits (social smoker, number of quit attempts etc.) there might be greater resolutions 
for picking up gene-behaviour interactions. 
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Chapter 7  
 
 
General Discussion 
 
 
A summary of the work covered in this thesis as well as ways in which the work can 
be explored further. 
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7.1 Thesis Summary 
 
The aim of this thesis from the outset was to firstly identify polymorphisms affecting 
nicotine reward by screening mutagenized fish using the conditioned place preference 
paradigm. The second aim was to use any information garnered from the model to 
inform a human study and determine whether genetic variations in human orthologues 
confer any variations in smoking behavior. Using a forward genetic screen two loss of 
function mutations in the slit3 gene that caused increased nicotine place preference in 
zebrafish were identified. The translational relevance was identified using focused 
SNP analysis in one cohort of current or previous heavy smokers, one of current or 
previous lighter smokers, and one of the general population. This is the first report of 
a novel human functional polymorphism, identified using a forward genetic screen of 
adult zebrafish to uncover loci affecting a complex human behavioral trait.  Taken 
together, these results provide preliminary evidence for a role for SLIT3 in regulating 
smoking behaviour, and may be a useful target when designing tailored treatments to 
aid permanent smoking cessation in patients.  
There are a number of ways in which the work can be continued, both in terms of 
SNP analysis on the families generated in the three-generation screen and in 
molecularly characterizing the slit3 mutants. 
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7.1.1 The CPP assay 
 
The first results chapter of this thesis explores the zebrafish conditioned place 
preference assay as a means of measuring drug-induced reward. It was decided that a 
‘biased’ CPP would be used in which the animal is allowed to explore the apparatus 
during the baseline, and the exemplar they least prefer is the one that the drug is 
administered in and the one they most prefer is where they receive saline. This 
allowed it to certain that in the future population screen, fish were going to be 
selected that showed a shift in preference from one compartment to the other when 
conditioned to nicotine. To minimise habituation responses being misinterpreted as 
drug induced CPP, any fish showing a preference exceeding 75% for either 
compartment was removed from the analysis. The assay was tested using different 
classes of drugs that included stimulants, opioids and general anaesthetics. The drugs 
that were tested were (p=0.02), caffeine (p=0.01), nicotine (p=0.01), the opioid 
compound fentanyl (p=0.01), and PCP (p=0.03. The aim was to assess the validity of 
CPP in fish as a means of assessing the reinforcing properties of compounds, 
particularly nicotine. All five of the compounds produced a reinforcing effect 
comparable with other animal models. This high degree of correlation between results 
found in zebrafish CPP and mammalian self-administration and/or CPP assays 
instilled confidence that the developed protocol was robust and sensitive enough to 
pick up genetic variations that may effect a zebrafish response to the reinforcing 
properties of nicotine. 
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7.1.2 Mutagenesis screen 
 
With the paradigm protocol established, progression to the 3-generation mutagenesis 
screen was possible. The subjects included in the experiment were all generated at the 
Sanger Institute, as part of the zebrafish mutation project.  Founder line males were 
chemically mutagenized, introducing a SNP roughly every 300kb in their germline 
stem cells. The resulting progeny were then exome sequenced and outcrossed to 
generate the F2 lines. The resulting fish contained a number of artificially generated 
markers including known gene breaking mutations in coding regions. The first 
generation screen gave a normal distribution with mean change in preference of 0.14. 
The top five centiles had a 0.6 change in nicotine preference, with the lowest five 
showing an aversion to nicotine (- 0.4). Four fish from a Humbog line (Obtained from 
Stephen C. Ekker) were included in the screen as a positive control. Humbog fish 
have a Gaba-B receptor 1.2 (gabbr1.2) knock-out that has previously been shown to 
alter sensitivity to nicotine (Petzold et al., 2009). The gabbr1.2 knockouts clustered at 
one end of the distribution, this demonstrated the assays ability to identify specific 
lines. The second generation showed a shift in preference for both low (mean = 0.17, 
p = 0.03) and high responders (mean = 0.05, p = 0.01) when compared with the 
previous generation, there was a large effect size when comparing the two groups 
(Cohen’s d = 0.89). The third generation screen showed the high responder line to 
have a mean of 0.21 compared with a population mean of 0.01 in the low responders. 
There was a large effect size (Cohen’s d = 1.64) indicating the difference in response 
to the rewarding effect of nicotine has been genetically maintained. The increase in 
effect size from the last generation indicates the two populations are becoming more 
genetically distinct with each generation. In the screened set of F3 fish a unique 
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strong or weak responding fish with siblings in the “average region” responding range 
could be homozygous mutant. Genotyping and establishing for which gene breaking 
mutations for which an outlying fish is homozygous might identify candidate 
recessive modifiers. 
 
7.1.3 Identification of dominant mutation in first generation screen 
 
Due to the nature of lines obtained from the Wellcome Sanger Trust, there remained 
the possibility of identifying knockout mutations of major effect that alter phenotype. 
The first generation screen identified a mutant line, which showed higher nicotine 
reinforcement than the population mean and clustered at the right of the distribution, 
as well as a line that clustered to the left arm of the distribution. The four individuals 
from this line were selected from an F3 generation containing a mixture of 
homozygous, heterozygous and wild type individuals suggesting the line contained a 
dominant mutation affecting the phenotype. Candidate genes from a list of known 
possible null mutations (obtained from The Wellcome Sanger Trust) were 
investigated in the QMhigh and QMlow lines. While no SNPs were shown to 
segregate in the QMlow line, in the QMhigh line a slit3 mutation segregated with the 
observed phenotype. An independent line with a nonsense mutation in a similar 
region of the slit3 gene was then acquired through the zebrafish mutation project and 
the same phenotype was observed indicating the slit3 mutation was causal as opposed 
to other linked artifacts in the lines genetic background. Quantitative PCR on embryos 
from a +/- incross of this slit3 line showed there to be an up-regulation of nAChR 
alpha 5, presenting multiple mechanism by which a slit3 knock-out may have and 
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affect on nicotine mediated reward processes. This chapter provided powerful 
evidence for mutagenesis screens of this type to be a useful translational model for 
investigating the genetic basis of human psychiatric disorders. 
 
7.1.4 Identification of SNPs affecting smoking rate  
 
As zebrafish are vertebrates with significant conservation of neural pathways thought 
to be important for drug-mediated reward (M. O. Parker et al., 2013) it was 
hypothesized that findings in fish could be used to predict loci in humans influencing 
smoking behavior. This hypothesis was tested on two cohorts of patients. The first 
cohort comprised of heavy smokers, with a diagnosis of chronic obstructive 
pulmonary disease (COPD) (n=272), and having amassed ≥15 pack-years. The second 
cohort comprised of lighter smokers (<15 pack years), with a diagnosis of asthma (n = 
293). The dependent variables were initiation (only for Cohort 2), persistent smoking 
(current vs ex) and the number of cigarettes smoked per day (cigs/day). One SNP 
(rs12654448), was found to be strongly related to number of cigarettes smoked per 
day in the COPD cohort. No other smoking-related behaviors tested were predicted by 
any of the SNP. In the asthma cohort, 10 SNP significantly predicted cigs/day. We 
next validated the association of variants at the SLIT3 locus with smoking behavior in 
one further cohort from the general UK population (without asthma or COPD; 
n=298). Four common SNPs between the asthma and general population cohorts were 
found, including rs7728604, rs7129099, rs17665158 and rs12515725. These were 
consistent in terms of the direction of effect between the cohorts. The SNP from the 
COPD cohort, rs12654448, significantly predicted smoking rate in the general 
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population, but not in the asthma cohort. However, in the asthma cohort, the SNP was 
significant at the uncorrected alpha level (p = 0.04). There was no SNP that predicted 
other smoking-related factors (persistent smoking and quitting).  
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7.2 Future directions 
 
This screen is shown to be capable of identifying subtle nicotine seeking behavioral 
phenotypes as well as showing nicotine reinforcement to be a heritable trait in 
zebrafish. A gene underlying nicotine reinforcement was identified using this method 
and furthermore, was used to inform a human study of smoking behaviors. This 
presents powerful evidence for mutagenesis screens of this type to be a useful 
translational model for investigating the genetic basis of human psychiatric disorders. 
Ultimately, more precise information about genetic influences on the ability to quit 
smoking from these and previous data sets will aid in constructing predictive genetic 
quit success scores that could be implemented in a personalized approach to smoking 
cessation treatment. On top of this, there are numerous ways in which this body of 
work can be continued both as a means of identifying more genomic regions 
associated with nicotine addiction as well as characterising the mechanisms by which 
slit3 affects nicotine mediated reward processes. 
 
7.2.1 Admixture mapping of high and low populations 
 
The first generation population screen was successful in identifying 1 gene of major 
effect, which also showed an association with smoking behavior in a human cohort. 
The selection screen continued for a further 2 generations, allowing the possibility of 
using additional genetic markers located in the genome to identify genomic regions 
being selected for in the context of the CPP paradigm.  
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Having demonstrated heritable variation, key loci can subsequently be 
identified using SNP based genome-association analysis of the families. As the 
mutation rate in the founder population is approximately 1 every 300 base pairs, the 
fish included in the screen carry a large number of unknown ENU-induced single 
nucleotide mutations (SNMs). The zebrafish genome is approximately 1.4Gb, so with 
a mutation rate of 1/300kb the founder fish will have had roughly 5000 mutations 
across the genome. Assuming even distribution of ENU-induced markers and an 
average chromosomal length of 100cM and 1 recombination event per chromosome, 
95% of the chromosomes in the F3 generation will have had at least 1 recombination 
event and contain regions of ENU-mutagenised fragments with an average of more 
than 20 ENU SNMs per fragment. As the founder fish were outcrossed to the 
mapping line with a high density of naturally occurring SNP markers, SNMs and 
outcross SNPs can then be used to identify genetic regions linked to specific 
phenotypes using the principles of disequilibrium mapping. 
 Now that the lines of distinct (high and low) phenotypes have been established 
the parental F3 fish (that were fin-clipped before the first generation screen) can be 
sequenced to identify ENU markers that can be used for genome association analysis 
of the families. Once linked regions are identified, high-density SNP mapping and 
sequencing can be used to fine map any linked alleles. There exists a 200,000 SNP 
array at the Sanger Institute that is available for fine mapping once this stage is 
reached. Using this strategy it will be possible to identify linked genes of major effect 
as well as more context specific alleles of reduced effect. It will also be possible to 
identify both ENU induced SNM as well as linked naturally occurring SNPs. 
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In reality though, this inbreeding strategy needs to be discussed more critically in 
terms of whether it will be a viable strategy going forward. Much of the positive shift 
might have been created by inclusion of slit3 heterozygotes. As such, it is likely that 
any other remaining genetic contributors will be relatively minor.  
It may be more sensible to focus on the identification of strong dominant 
modifiers. The data that is already present from the low responders may have 
interesting candidate genes that could be identified by correlating missense mutaions 
with behavior. Information on these missense genetic varients should be available 
from the Wellcome Sanger Trust. It is also worth noting that it is unlikely it will be 
possible to continue inbreeding as due to the indeterminate way sex is determined in 
fish you are bound to run into genetic bottlenecks, with all male or female skewed 
stocks. 
It would perhaps make more sense to screen further lines using the robust CPP 
assay designed here to determine loci with major effect on nicotine reward. Knock-
outs of major effect in fish provide a good candidate to investigate in humans. It 
seems unlikely that a total knock-out in a zebrafish that conveys a relatively minor 
effect will prove to show significant associations of self-reported nicotine intake rates 
in humans. As such, trying to tease out these small associations through repeated 
selective breeding seems a waste of resources as well as time in terms of impact and 
results. 
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7.2.2 Molecular characterization of slit3 zebrafish embryos 
 
There still remains further work that can be done to unravel mechanisms by 
which the slit3 may affect drug seeking. The qPCR results presented one possible 
mechanism in the up-regulation of chrna5, which may result in a greater number of 
presynaptic (α4β2)2α5 assemblies which show lower rates of desensitisation to 
nicotine as well as a higher permeability to Ca2+ than the typically more prevalent 
(α4β2)2α4. This could hypothetically leads to greater dopaminergic transmission. 
Alternatively, a nonsense mutation in the slit3 locus may lead to increased drug 
seeking behavior through a neurodevelopmental role affecting path-finding and circuit 
formation. A number of molecular experiments could help shed like on a mechanism 
underlying the change in nicotine seeking in fish and smoking behavior in humans.  
Fundamental to understanding the role of variations at the slit3 locus in 
affecting nicotine reward is to fully understand where the slit3 transcript is expressed 
in the brain. Slit3 is possibly involved in the repulsive action of the caudal midbrain 
that initiates the turning of growing fibres towards the rostral brain (Gates, Coupe, 
Torres, Fricker-Gates, & Dunnett, 2004; Holmes, Jones, & Greenfield, 1995); so you 
would expect to see a degree of expression in the midbrain. 
 It will also be possible to look at dopaminergic genes like drd2 and slc6a3 and 
compare expression levels in wildtype and slit3 knock-outs. While there was no 
significant change in expression levels shown when using qPCR analysis, more subtle 
differences that may be present that may be visualized using staining. For example, 
small changes in drd2 expression in regions such as the posterior tuberal nucleus 
(PTN) or the ventral and dorsal telencephalic nuclei (Vv and Vd) (Panula et al., 2010) 
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would impact upon zebrafish behavior in a CPP assay. Small changes in specific areas 
like the PTN may be masked when carrying out qPCR on whole empbryos. Also, due 
to pooling of embryo’s from heterozygous in crosses, effects can be masked due to 
varying phenotypes within a pooled sample. Staining techniques as well as individual 
geneotyping of embryo’s before carrying out RNA-Seq may provide a clearer picture 
as to what is occurring transcriptionally. 
 Similarly, while there was a significant increase in chrna5 mRNA expression 
in embryos derived from a slit3 +/- incross, it is difficult to determine what this 
change in expression means in relation to the phenotype without knowning how 
expression changes spatially. If the increase in chrna5 expression occurs 
predominantly in the PTN, it would give credence to the hypothesis that presynaptic 
(α4β2)2α5 assemblies on dopaminergic cells is giving rise to an increase in nicotine 
mediated reward. 
 The effect of a slit3 knockout on axon pathfinding can be investigated using 
antibody staining. Using tyrosine hydroxylase (TH) staining it would be possible to 
label dopaminergic cells bodies as well as their projections in the midbrain. In slit3 
knockout zebrafish, it may be possible to visualize mesodiencephalic dopaminergic 
axons aberrantly crossing the midline due to lesser prevalence of repulsive cues from 
the midline (Kawano et al., 2003; Marillat et al., 2002). A combination of all these 
techniques and experiments would provide a clearer picture of the mechanisms behind 
this altered nicotine seeking, as well as an insight into why variations at the SLIT3 
locus affect smoking behavior in humans. 
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7.2.3 Closing summary 
The aim of this study was to use forward genetic screening in zebrafish to identify 
loci affecting human smoking behavior. Two loss of function mutations were 
identified in the slit3 gene that caused increased nicotine place preference in 
zebrafish. The translational relevance was confirmed using focused SNP analysis in 
one cohort of current or previous heavy smokers, one of current or previous lighter 
smokers, and one of the general population. This is the first report of novel human 
functional polymorphisms, identified using a forward genetic screen of adult zebrafish 
to uncover loci affecting a complex human behavioral trait.  Taken together, these 
results provide preliminary evidence for a role for SLIT3 in regulating smoking 
behavior, and may be a useful target when designing tailored treatments to aid 
permanent smoking cessation in patients.   
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